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Summary 
 
NAMPT (nicotinamide phosphoribosyltransferase) is a universally expressed protein 
elevated in the serum and synovial fluid of rheumatoid arthritis (RA) sufferers. NAMPT 
is a rate-limiting enzyme in the biosynthesis of (nicotinamide adenine dinucleotide) 
NAD+, an essential cellular coenzyme, and has also been shown to exert cytokine-like 
activities as a mediator of innate immunity. However little is currently known of the role 
of NAMPT in cartilage metabolism. In this thesis, the role and regulation of NAMPT was 
studied in a variety of model systems. Addition of exogenous (e)NAMPT to fibroblasts in 
vitro increased MMP-3 release, an effect attenuated by APO866. In vivo studies in a 
murine arthritis model showed APO866 treatment reduced arthritis index, with a slight 
reduction in synovial hyperplasia, inflammatory infiltrate and cartilage degradation. In 
vivo imaging with MMP activatable fluorescent probes showed a reduction in MMP 
activity in APO866-treated animals compared with placebo. Analyses of archived tissue 
indicated that APO866 reduced MMP gene expression in affected limbs in a time and 
dose dependent manner. In a cartilage explant culture system, APO866 significantly 
attenuated cytokine-mediated proteoglycan (PG) depletion and MMP-2 and -9 release. 
This was associated with a dose-dependent loss of cell viability. These effects were 
reversed by co-incubation with NAD+ metabolites NMN and NA, suggesting that cell 
survival was highly NAD+-dependent, and that cytokine-induced MMP expression could 
be NAMPT independent. Finally, in vitro studies in RA synovial fibroblasts revealed that 
intracellular (i)NAMPT is upregulated by cytokine stimulation, with concurrent 
upregulation of MMPs -1 and -3. The data emphasise the pleiotropic function of NAMPT 
in health and disease, and suggest a role for extracellular (but not intracellular) NAMPT 
in cartilage catabolism. Finally, NAMPT inhibition is highlighted as a promising 
therapeutic strategy for RA. 
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Chapter 1: Introduction 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease 
characterised by the activation and proliferation of synovial tissue, which is associated 
with progressive destruction of synovial joint articular cartilage and bone. Current 
therapies are focused on targeting factors that contribute to the inflammatory milieu, such 
as tumour necrosis factor alpha (TNFα). However, these biologic therapies are not 
curative, and so new therapeutic targets are continually sought. One such target, 
NAMPT (nicotinamide phosphoribosyltransferase), is a pleiotropic protein that was first 
characterised in 1994 (Samal et al., 1994) and shown to be upregulated in RA patients 
(Otero et al., 2006, Nowell et al., 2006). Originally named pre B-cell colony enhancing 
factor (PBEF), it is also found in the literature under a number of alternative names, 
including NaPRTase and visfatin. The focus of the thesis is the role of NAMPT on 
articular cartilage catabolism in inflammatory arthritis. In this introductory chapter I 
describe the structure of the synovial joint in health and disease (i.e. rheumatoid arthritis), 
with a particular focus on articular cartilage and control of its turnover by matrix 
metalloproteinases (MMPs; section 1.2.4). I then discuss what is currently known about 
the structure and function of NAMPT, and its soluble inhibitor, APO866, and the potential 
of NAMPT inhibition as a therapy in the treatment of RA (section 1.4.5). Finally, I 
delineate the objectives of this study and the specific aims of each experimental chapter 
(section 1.5).  
1.1 The normal synovial joint 
Dysregulation of NAMPT has been associated with numerous pathological 
disorders, including sepsis (Jia et al., 2004), atherosclerosis (Chung et al., 2009) and 
acute lung injury (Ye et al., 2005). This thesis will focus on the role of NAMPT in 
inflammatory joint disease pathogenesis, specifically the processes that contribute to 
destruction of articular cartilage within the synovial joint. Before describing these 
processes in depth, the tissues and cells that comprise a normal, healthy joint are 
identified.  
1.1.1 Tissues of the normal joint 
A synovial, or diarthrodial joint, consists of highly specialised tissues of bone, 
articular cartilage, synovial tissue, adipose tissue (the infrapatellar fat pad), ligaments, 
menisci and tendons. They are enclosed within a fibrous tissue capsule and bathed in 
synovial fluid. Synovial joints achieve movement at the point of contact between two 
opposing articulating bony surfaces that are lined with a smooth, durable layer of articular 
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cartilage. This articular cartilage, together with the menisci, absorbs shock and reduces 
friction during movement (figure 1.1).  
 
Figure 1.1 the diarthrodial joint 
A schematic drawing of the structure of a healthy joint. The intimal layer of the synovium 
(shown in purple) is only 1-2 cells thick and remains separate from the cartilage and 
bone. The synovial fluid is clear of infiltrating cells, and cartilage provides a smooth 
articulating surface for the ends of the adjacent bones. Figure drawn from (Feldmann et 
al., 1996a). 
 
1.1.1.1 Synovial membrane 
The synovial membrane, also referred to as the synovium, lines the joint cavity. 
This membrane, normally 1-2 cells thick, produces synovial fluid, which lubricates the 
joint and provides nutrients for adjacent cartilage. The synovium contains a sub-intimal 
layer of fibrous or fatty tissue, and a thin intimal layer. The intimal layer is comprised of 
two cell types: fibroblasts and macrophages (MΦ). The synovium is highly vascular, with 
a dense network of small blood vessels beneath the intimal layer that provide nutrients 
for the synovium and adjacent cartilage (reviewed by Firestein et al., 2009). 
1.1.1.2 Articular cartilage 
The articulating joint surfaces are covered by hyaline-type cartilage. Articular 
cartilage is avascular with no lymphatic or nerve supply and contains only a single cell 
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type, the chondrocyte. Mature articular cartilage has a high matrix volume to cell ratio 
and is constantly being remodelled through the continuous synthesis and degradation of 
various extracellular matrix (ECM) components. The resident chondrocytes are pivotal 
regulators of these processes. Chondrocyte viability is therefore essential for adequate 
maintenance of the cartilage (Rowan, 2001). 
 Mature articular cartilage is both structurally and functionally heterogeneous. It 
consists of four distinct zones: i) superficial/tangential, ii) 
middle/transitional/intermediate, iii) deep/radial and iv) calcified cartilage. A tidemark 
separates the upper non-calcified tissue from the lower calcified cartilage. Beneath the 
calcified cartilage lies the subchondral bone plate. Each of the cartilage zones differs 
with respect to cell morphology and organisation, collagen fibre organisation and the 
biochemical composition of its ECM (figure 1.2; reviewed by Poole et al., 2001). 
Approximately 70-80% of articular cartilage consists of water (Rowan, 2001).  The 
remainder of the tissue consists primarily of an insoluble fibrous protein called collagen 
and a highly glycosylated aggregating proteoglycan (PG), known as aggrecan. Collagen 
comprises two thirds of the dry weight of articular cartilage, and each of the distinct 
cartilage zones differs considerably in its collagen content and fibril organisation (Eyre 
et al., 2006). Type II collagen is the predominant collagen throughout articular cartilage, 
although collagen types I, III, VI, IX, XI, XII and XIV are also present in smaller amounts 
(Eyre, 2002, Eyre et al., 2006). Type II collagen consists of three polypeptide a1(II) 
chains arranged into a triple helix. These molecules pack together side-by-side forming 
banded fibrils with a periodicity of 67 nm (Revenko et al., 1994). Collagen fibrils in 
articular cartilage are heterofibrils that contain, in addition to the dominant collagen II, 
also types XI and IX collagens (Gelse et al., 2003) Collagen fibrils give cartilage its tensile 
strength and entrap many soluble molecules such as PGs, retaining them within the ECM 
(Otero and Goldring, 2007).  
PGs are a family of glycosylated proteins that occur within the ECM, filling in the 
gaps of the collagen network, and occurring on cell surfaces. They are made up of a 
protein core with covalently linked, negatively charged, sulphated-glycosaminoglycans 
(s-GAGs). These are linear polysaccharide chains consisting of repeating disaccharide 
units (an amino sugar, N-acetylglucosamine or N-acetylgalactosamine, and an uronic 
acid sugar, glucuronic acid or iduronic acid). They include chondroitin sulphate, 
dermatan sulphate, keratan sulphate and heparan sulphate. As a family, the PGs vary 
considerably in terms of the size of their core proteins and the number and type of 
attached GAG chains. Although aggrecan is the principal PG of articular cartilage, the 
cartilage ECM comprises a number of other PGs, including decorin, biglycan, 
fibromodulin, perlecan, glypican and syndecan (reviewed by Knudson and Knudson, 
2001). 
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Aggrecan is a large aggregating PG with a core protein consisting of three 
globular domains (G1, G2 & G3). The interglobular domain between G2 and G3 carries 
distinct chondroitin- and keratan sulphate-rich regions that give the molecule its 
distinctive ‘bottlebrush’ ultrastructural appearance (Watanabe et al., 1998). Aggrecan 
monomers are attached to hyaluronic acid, another unsulphated GAG, at the G1 domain 
by special link proteins, generating supramolecular aggregates that are confined by the 
collagen network. The high negative charge of the s-GAG within these aggregates 
attracts water, providing articular cartilage its viscoelastic properties and the ability to 
resist compressive impact loads (reviewed by Poole et al., 2001). 
 
Figure 1.2 Zonal organisation of mature articular cartilage 
A diagrammatic representation of the general structure of human articular cartilage, 
showing i) typical histology, ii) cellular morphology and organisation and iii) ECM 
composition and organisation. SZP, superficial zone protein; HA, hyaluronan. Compiled 
from (Poole et al., 2001). 
 
 
1.1.1.3 Bone 
Bone is a hard, dense connective tissue that is comprised of approximately 70% 
hydroxyapatite, an inorganic mineral compound. It also consists of 22% organic material, 
mainly type I collagen, and 8% water. Bone maintenance depends on the balance 
between bone formation by mesenchymal-derived osteoblasts, and bone resorption by 
haematopoietic osteoclasts. This process is known as remodelling or bone turnover, and 
is essential for development and growth, regulation of calcium homeostasis and to repair 
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micro-damage caused by everyday stress. Sub-chondral bone is also highly 
vascularised, and provides a conduit for nutrients from circulation for deeper zones of 
cartilage. 
1.1.2 Cells of the normal synovial joint 
The joint contains a number of different cell types of both mesenchymal and 
haematopoietic lineage. Many of the cells that make up the synovial joint are derived 
from precursor cells from the joint interzone, a thin mesenchymal cell layer believed to 
be critical for joint and articular cartilage development (Pacifici et al., 2006). Cells of 
mesenchymal origin include the articular chondrocytes, fibroblast-like synoviocytes, 
osteoblasts and osteocytes that are present within bone, adipocytes of the infra-patellar 
fat pad, and fibrochondrocytes of the meniscus. Outside the joint capsule, myocytes, 
tenocytes, and ligamentous cells occur within the supporting tissues of the joint. Cells of 
haematopoietic lineage include the macrophage-like osteoclasts and synoviocytes that 
populate bone and synovium respectively (Bartok and Firestein, 2010). This overview 
will focus on the cell types primarily involved in the degradative processes in RA (i.e. 
synovial cells and articular chondrocytes). Their specific involvement in the disease 
process, and the co-involvement of other invading cell types, is discussed further in 
section 1.2.2. 
Fibroblast-like synoviocytes are non-vascular, non-epithelial cells that reside 
locally within both the intimal and sub-intimal layers of the synovium. They provide the 
joint cavity and the adjacent cartilage with nutritive plasma proteins and lubricating 
molecules such as hyaluronan, a long-chain sugar polymer that retains synovial fluid 
within the joint space (Edwards, 2000), and lubricin (superficial zone protein; SZP), which 
protects cartilage surfaces and inhibits synovial cell overgrowth (Rhee et al., 2005). 
Along with fibroblast-like synoviocytes, macrophage-like synoviocytes (MΦ) also 
comprise much of the intimal layer of the synovium. In normal tissue homeostasis, 
synovial MΦ are derived from CD34+ stem cells in the bone marrow, which differentiate 
into monocytes and circulate the peripheral blood. Upon entering specific tissues these 
monocytes differentiate further into different types of resident MΦ, including synovial MΦ. 
These mature cells remain localised within the synovial tissue until they senesce and die 
(Firestein et al., 2009). The monocyte/MΦ system is an integral part of the innate immune 
system, participating in the first-line response against infectious agents. They are 
responsible for removal of undesirable substances from the synovial fluid and contribute 
to the body’s homeostasis by scavenging debris generated by physiological or 
pathological processes (Kinne et al., 2007).  
Chondrocytes are the sole cell constituent of articular cartilage and are located 
within discrete lacunae within the cartilage ECM. Their size and morphology varies with 
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articular cartilage depth, ranging from small and discoidal at the articular surface to large 
and ovoid (i.e. hypertrophic) within the deep and calcified zones (see figure 1.2). The 
chondrocytes are responsible for the synthesis and turnover of the cartilage ECM. In 
each zone of the tissue, the chondrocytes synthesise and secrete unique matrix 
components (e.g. SZP in the surface zone and type X collagen in the calcified zone). 
Chondrocytes maintain a stable equilibrium between matrix synthesis and degradation 
in response to anti- and pro- inflammatory mediators. Anti-inflammatory mediators 
include transforming growth factor beta (TGFβ), whilst pro-inflammatory mediators 
include TNFα and interleukin (IL)-1 (Rowan, 2001). The latter are induced in response 
to mechanical stress, trauma or microbial insult (McInnes and Schett, 2007). If 
homeostasis is disrupted, then diseases of the tissue may occur.  
  
 11  
1.2 Rheumatoid arthritis (RA) 
Inflammatory arthritis is a term used to describe a number of conditions, including 
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic 
arthritis. Of these, RA is the most common, affecting approximately 1% of the world’s 
population and around 400,000 people within the UK. Onset generally occurs between 
the ages of 40-60, although it can potentially occur at any age. RA is most common in 
women, with 3-5 times more female sufferers compared to males (Walker, 2011). RA is 
a systemic, polyarticular autoimmune disease that causes chronic inflammation of the 
joints, leading to the progressive destruction of joint cartilage and bone. The condition 
was first described by Augustin Jacob Landré-Beauvais in 1800 (Landré-Beauvais, 
2001), and the name rheumatoid arthritis was coined by Sir Alfred Garrod in 1859 
(Garrod, 1892). In 1987 the American College of Rheumatology devised criteria for the 
classification of RA, based on symptoms ranging from morning stiffness and presence 
of rheumatoid factor in blood, to radiographic evidence of erosions and/or periarticular 
osteopenia (Arnett et al., 1988). However, these criteria were criticised for their lack of 
sensitivity, as diagnosis was largely based on late-stage features of disease. Therefore, 
in 2010, these criteria were superseded by a new classification system, which places 
more emphasis on serum markers and acute-phase reactants of disease (Aletaha et al., 
2010); see Table 1.1). The aetiology of the disease is largely unknown; however, it is 
thought to be multi-factorial, with genetic and environmental factors playing a role. 
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Table 1.1 Classification criteria for Rheumatoid Arthritis 
Criteria  Score 
A. Joint involvement  1 large joint 0 
 2-10 large joints 1 
 1-3 small joints (with or without involvement 
of large joints) 
2 
 4-10 small joints (with or without involvement 
of large joints) 
3 
 >10 joints (at least 1 small joint) 5 
   
B. Serology Negative RF and negative ACPA 0 
 Low-positive RF or low-positive ACPA 2 
 High-positive RF or high-positive ACPA 3 
   
C. Acute phase 
reactants 
Normal CRP and normal ESR 0 
 Abnormal CRP or abnormal ESR 1 
   
D. Duration of 
symptoms 
<6 weeks 0 
 ≥6 weeks 1 
Classification criteria for the diagnosis of RA, as defined by the American College of 
Rheumatology (ACR) in 2010. A total score of 6 or more out of the listed criteria suggests 
a positive diagnosis of RA.  RF, Rheumatoid factor; ACPA, anti-citrullinated protein 
antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. Adapted from 
(Aletaha et al., 2010) . 
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1.2.1 Pathogenesis of RA 
In RA the synovial intimal lining, normally only a thin layer of 1-2 cells, becomes 
thickened due to proliferation of macrophage-like and fibroblast-like synoviocytes. There 
is also a large degree of infiltration by inflammatory lymphocytes, macrophages and mast 
cells. A large number of neutrophils produced in the synovium rapidly transmigrate into 
the synovial fluid, which is produced in large quantities. All of these features contribute 
to significant joint swelling. Enhanced production of cytokines, along with autoantibodies 
such as rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA), maintain 
persistent chronic inflammation in RA tissue. Continuous inflammation of the synovium 
results in the growth of a large cellular mass called a pannus, derived from the Latin word 
meaning ‘cloth’, and the Greek word meaning ‘web’. This pannus covers and invades 
the articular cartilage and subchondral bone, causing erosions to occur through the 
secretion of catabolic mediators. This pannus formation is often described as a malignant 
mesenchymal transformation due to its aggressive and invasive behaviour (Burrage et 
al., 2006).  
Secretion of these catabolic mediators from the proliferating pannus leads to a 
progressive loss of matrix proteins within the articular cartilage. The large PG aggrecan 
is amongst the first components of the cartilage ECM to be degraded. Cleavage of 
aggrecan monomers by aggrecanases known as A disintegrin and metalloproteinases 
with thrombospondin motifs (ADAMTSs) results in the loss of its GAG binding domains 
(Fosang et al., 2008); section 1.2.4.2). These PGs lose their GAG chains, which are 
essential for water retention within the cartilage ECM. As a result, they lose their ability 
to retain water, leading to a progressive weakening of the collagen fibre network. Loss 
of PG mainly occurs within the superficial zone of cartilage, although there is evidence 
of PG loss throughout the cartilage matrix, progressing from the surface to the deep 
zones. This is eventually accompanied by the enzymatic and biomechanical destruction 
of collagen. In contrast to PGs, which can be readily replaced once the catabolic stimulus 
is removed, collagen is more difficult to replace (Karsdal et al., 2008;  Cawston and 
Young, 2010). All this results in a loss of tensile strength and increased friction of joints, 
leading to pain and decreased mobility in RA patients. The cells important in these 
processes are summarised in figure 1.3, and in the following sections.  
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Figure 1.3 Processes and cells involved in joint destruction in RA 
A diarthrodial joint, showing the appearance of a normal joint (left), compared with an 
inflamed diseased joint (right), Italicised writing indicates the processes involved in 
disease pathogenesis, whilst main cells associated with disease are also shown. Figure 
drawn from (Feldmann et al., 1996a).  
 
 
 1.2.2 Cells that propagate RA pathogenesis  
Fibroblast-like synoviocytes (FLS) play a major role in RA disease pathogenesis. 
In RA, fibroblast cells become hyperproductive and phenotypically distinct from normal 
fibroblasts, leading to chronic persistent inflammation (Buckley et al., 2001). At a 
morphological level, these cells are more rounded, with large pale nuclei and prominent 
nucleoli compared to non-activated cells (Pap et al., 2000). Fassbender first described 
this altered phenotype in 1983 (Fassbender, 1983). FLS have an aggressive phenotype, 
and are capable of attaching to the articular cartilage surface and invading the ECM (Pap 
et al., 2000). These cells are more commonly referred to in the literature as rheumatoid 
arthritis synovial fibroblasts (RASFs), therefore the term RASFs will be used for the 
duration of the thesis. RASFs can be activated through stimulation by a number of 
soluble molecules, including cytokines, chemokines, growth factors, and bacterial 
products. The latter stimulate RASFs via highly conserved innate immune receptor 
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systems such as Toll-receptors (TLRs). RASFs can also be activated through cell-cell 
interactions with CD4+ T cells and MΦ. These stimuli cause activation of signalling 
pathways, leading to the induction of pro-inflammatory molecules via transcription factors 
such as NF-κB and AP-1. RASFs also produce vascular endothelial growth factor 
(VEGF), which promotes vascularisation of the synovium, and chemo-attractant proteins 
such as CXC chemokine ligand (CXCL) 8 and chemokine (C-C motif) ligand (CCL) 2, 
which increase accumulation of inflammatory cells into the synovium. Finally, RASF can 
also produce factors such as CXCL16, which induce CD4+ T cells. Thus,  a exacerbatory 
cycle is established, contributing further to the inflammatory milieu (see (Müller-Ladner 
et al., 2007) and references therein).  
Activated synovial macrophages (MΦ) also contribute greatly to the inflammatory 
environment. In RA there is increased plasticity in this differentiation process. Within the 
tissue, pro-inflammatory cytokines and growth factors may direct the differentiation of 
precursor monocytic cells, causing increased numbers of activated synovial MΦ, and 
also differentiation into dendritic cells (DCs), which are the major antigen-presenting and 
antigen-priming cells of the immune system. Activated MΦ have a clear activation status; 
they produce increased levels of cytokines, growth factors and chemokines, in addition 
to major histocompatibility complex (MHC) II proteins, C-reactive protein (CRP) and also 
MMPs -2 and -9 (Kinne et al., 2007). In response to inflammatory stimuli, synovial MΦ 
can produce yet more effector molecules to activate other MΦ in an autocrine fashion. 
This process is initiated through stimulation of TLRs by bacterial/viral components. They 
also engage in various cell-cell interactions, mainly with T cells, RASFs, endothelial cells 
and natural killer (NK) cells. These interactions cause activation of neighbouring cells, 
thus further perpetuating numbers of inflammatory cells present within the joint (Kinne et 
al., 2007).   
In RA, proliferation of the synovium by RASFs and MΦ may eventually lead to 
pannus invasion of the neighbouring cartilage. Here, cells of the synovial pannus may 
produce excessive amounts of cartilage-degrading enzymes, causing dysregulation of 
cartilage homeostasis. This leads to substantial loss of PG within the superficial zone of 
cartilage, mainly at sites where the pannus has invaded the cartilage ECM. However, 
even in early stages of RA, PG loss can occur throughout the cartilage, indicating that 
chondrocytes themselves participate in degrading their own matrix (Otero and Goldring, 
2007). This gives rise to what is called ‘inside-out’ degradation by resident chondrocytes, 
which coincides with the ‘outside-in’ enzymatic degradation caused by synoviocytes, 
thus creating a bidirectional attack (McInnes and Schett, 2007). This is supported by 
studies that have shown that cartilage destruction can occur uncoupled to joint 
inflammation (van den Berg, 1998). Furthermore, cytokines induce chondrocytes to 
produce nitric oxide (NO), which induces apoptosis and therefore loss of cell viability, 
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which may hinder the resynthesis of degraded matrix components (Otero and Goldring, 
2007). All this contributes to gradual loss of the cartilage ECM within the RA joint.  
Although activated synoviocytes play a requisite role in synovial joint 
inflammation, T cells also play a major role in RA disease pathogenesis. T cell 
aggregates are observed in the synovial sub lining layer of 50-60% of RA patients (Tak 
and Bresnihan, 2000). T cells can activate RASFs and MΦ through receptor-ligand 
interactions, triggering transcription factors such as NF-κB and AP-1, which in turn lead 
to upregulation and release of cytokines, growth factors and chemokines (Raza et al., 
2005). Dendritic cells located near the intimal lining layer also play a pro-inflammatory 
and antigen-presenting role (Lutzky et al., 2007). B cells are also often observed in close 
contact with the inflamed synovial membrane, and can actively participate in the 
autoimmune process through interaction with T cells (Mauri and Ehrenstein, 2007). NK 
cells are also present within both the synovial lining layer and in the sub-synovial lining 
(Tak and Bresnihan, 2000). Mast cell subpopulations have been found to expand in RA 
synovial tissue, and may possibly be the main source of the disease-associated cytokine 
IL-17 within the RA synovium (Hueber et al., 2010). Finally, although not localised within 
the synovium, excessive numbers of neutrophils may be present within the synovial fluid. 
Collectively, these various cell types contribute to pro-inflammatory and pro-degradative 
processes (reviewed by Firestein et al., 2009). 
1.2.3 Cytokines that regulate destructive processes in RA  
Cytokines are low molecular weight proteins that act locally as intercellular 
mediators, with important roles in major biological processes. Cell surface receptor 
binding is the primary means by which cytokines mediate their effects upon cells. This 
ligand-induced activation is very efficient, meaning small quantities of cytokines can have 
extensive effects. During acute inflammation, cytokines play an immunomodulatory role, 
and are essential for resolving inflammation. However, in RA disturbance of the immune 
system leads to the persistence of cytokines within the sterile joint environment, 
promoting autoimmunity and driving chronic inflammation and tissue destruction 
(reviewed by Feghali and Wright, 1997). In the context of RA, cytokines are traditionally 
sub divided into those with pro-inflammatory effects and those with anti-inflammatory 
effects (Feldmann et al., 1996b); however, the situation is clearly more complex, as 
different cytokines can exert different effects depending upon their local 
microenvironment. Cytokines are implicated in each phase of disease pathogenesis in 
inflammatory joint diseases, from the promotion of autoimmunity in the pre articular 
phase (Raza et al., 2005), to the maintenance of chronic synovial inflammation, and 
eventually the destruction of the adjacent joint (McInnes and Schett, 2007). These 
processes are summarised in figure 1.4. 
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Numerous studies in vitro and in vivo suggest that the major cytokines involved 
in these processes are interleukin 1 beta (IL-1β) and TNFα, produced mainly by 
fibroblast- and macrophage-like synoviocytes (McInnes and Schett, 2007). In a systemic 
murine arthritis model, anti-TNFα treatment showed great efficacy shortly after disease 
onset, but had little effect in established disease. Anti-IL-1β ameliorated both early and 
full-blown disease (Joosten et al., 1996). This review will therefore explore these 
cytokines in depth, although other cytokines that are relevant to the RA disease process 
will also be discussed. 
 
 
 
 
Figure 1.4 Cytokine interactions involved in cartilage destruction in RA 
Synoviocytes activated by cytokines such as IL-1 and IL-17. The upregulation of pro-
inflammatory cytokines produced within the synovium and chondrocytes leads to an 
upregulation of cartilage-degrading enzymes, leading to matrix degradation. 
Chondrocyte death is another feature of cartilage damage, preventing replenishment of 
the degraded ECM. TH17, T-helper type 17 cells; IL, Interleukin; TNFα, Tumour necrosis 
factor alpha; PG, proteoglycan; ADAMTS, a disintegrin metalloproteinases with 
thrombospondin motifs; MMPs, matrix metalloproteinases. Figure adapted from McInnes 
and Schett (2007). 
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Members of the IL-1 family of cytokines are pivotal in early and late stages of 
disease. This superfamily consists of 11 proteins, the most notable being IL-1α, IL-1β 
and IL-1 receptor antagonist (IL-1ra) (Dunn et al., 2001). The two isoforms IL-1α and IL-
1β share low protein homology, but have comparable function and similar binding 
capacity to receptors. Produced predominantly by synovial MΦ, IL-1 is significantly 
elevated in the synovial fluid of RA patients compared to osteoarthritis (OA) patients 
(approximately 100 pg/ml and 30 pg/ml, respectively; (Westacott et al., 1990). It has long 
been established that IL-1 levels correlate with disease severity in RA patients (Eastgate 
et al., 1988). IL-1 promotes joint degradation by stimulating the production of MMPs and 
the inflammatory mediator Prostaglandin E2 (PGE2). Furthermore, it also inhibits the 
synthesis of new matrix proteins in cartilage through upregulation of NO (Järvinen et al., 
1995).  
Formally known as cachectin, TNFα is the best-known member of the TNF 
superfamily, a large group of cytokines involved in systemic inflammation. In contrast to 
IL-1β, TNFα levels are not elevated in the synovial fluid of RA patients compared to OA 
patients (Westacott et al., 1990). However, patients with early disease do exhibit high 
TNFα levels within synovial tissue samples, suggesting a role in disease onset (Tak and 
Bresnihan, 2000). Like IL-1β, TNFα stimulates pro-inflammatory cytokine release and 
PGE2 production, and is also involved in chemokine induction and release, attracting 
leukocytes into the inflamed synovium (Brennan and McInnes, 2008). 
The IL-6 family of cytokines are a group of pleiotropic regulators that use 
glycoprotein (gp)130 as a signal transducer. Members of the IL-6 family include 
leukemia-inhibitory factor (LIF), Oncostatin M (OSM), IL-11 and ciliary neurotrophic 
factor (CNTF) (Kishimoto et al., 1995). IL-6 is one of most highly elevated cytokines in 
RA, especially during acute disease (Houssiau et al., 1988). IL-6 cytokines facilitate the 
maturation and activation of B and T cells, MΦ, chondrocytes and osteoclasts (Brennan 
and McInnes, 2008). Along with TGFβ, they promote the differentiation of precursor cells 
into TH17 cells, a key cell subset in inflammatory arthritis (McInnes and Schett, 2007). 
Also of vital importance in RA pathogenesis is the IL-2 cytokine family, in 
particular IL-15. Produced by cells lining the synovium, it stimulates T cells to bind to MΦ 
and induce cytokine production, thus creating a self-perpetuating pro-inflammatory loop 
(Kinne et al., 2007). IL-17 is produced very early in the disease process by Th17 cells. It 
performs many functions, enhancing RASF cytokine and MMP release and leukocyte 
cytokine production, as well as downregulating GAG synthesis by chondrocytes 
(McInnes and Schett, 2007). 
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1.2.4 Proteinases involved in joint destruction in RA 
Proteinases are essential for the completion of a range of biological processes, 
including development and apoptosis. Cytokines and growth factors stimulate the 
production of proteinases involved in normal ECM turnover. These proteolytic enzymes 
play major roles in the development of tissue lesions in RA, and are essential to pannus 
formation and invasion. Enzymes can be divided into two main categories: the 
intracellular proteinases, including aspartic, cysteine and threonine proteinases (refer to 
(Rengel et al., 2007) and references therein), and the extracellular proteinases, including 
serine and metalloproteinases (figure 1.5). Of these, the metalloproteinases are the most 
extensively investigated.  These enzymes can be further sub-categorised into MMPs, A 
disintegrin and metalloproteinases (ADAMs; including those with additional 
thrombospondin motifs), serralysins, astracins and pappalysins (Rengel et al., 2007). Of 
these, MMPs and ADAMs, particularly those with additional thrombospondin motifs (see 
section 1.2.4.2), are considered to be the main enzymes responsible for the degradation 
of collagens and aggrecan, the large aggregating PG of cartilage (Firestein et al., 2009). 
 
 
Figure 1.5 Classification of proteinases involved in ECM turnover  
Schematic diagram showing the various classes of proteinases involved in ECM 
turnover. Compiled from (Rengel et al., 2007). 
 
 
1.2.4.1 Matrix metalloproteinases 
The MMPs are a group of zinc-dependent enzymes that collectively degrade all 
the components of the ECM. These proteins can be membrane bound or secreted 
extracellularly. The MMP family consists of collagenases, gelatinases, stromelysins and 
matrilisins, as summarised in Table 1.2. Although diverse in structure and biological 
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function, they all contain three shared domains; including a propeptide domain, a 
catalytic domain and hemopexin domain.  
In healthy tissue, the proteolytic activities of MMPs are rigorously controlled to 
avoid inappropriate degradation of proteins. Firstly, MMPs are controlled at the 
transcriptional level, by the stimulating effects of cytokines and growth factors, which 
promote signalling cascades that lead to the transcription of MMPs (Nagase and 
Woessner, 1999). The production of MMPs as inactive proproteins (zymogens) is 
another important mechanism of regulation. The propeptide domain contains a “cysteine 
switch”, which keeps the catalytic domain inactive. Most MMPs are secreted from cells 
as inactive proproteins. Upon proteolytic removal of the cysteine residue, the catalytic 
domain is activated and MMPs are able to bind to and modify their substrates (Visse and 
Nagase, 2003). This proteolysis is often localised to pericellular pockets close to the cell 
membrane, limiting MMP activity to distinct regions (Firestein et al., 2009).  
Finally, MMPs are also regulated by natural endogenous inhibitors known as 
tissue inhibitors of metalloproteinases (TIMPs). Like MMPs, expression of TIMPs is 
regulated during development and tissue remodelling. Four TIMPs have been identified 
in vertebrates, though only three are associated with the cartilage ECM (Table 1.2). All 
TIMPs inhibit all types of MMPs tested, with the exception of TIMP-1, which fails to inhibit 
MT1-MMP. TIMPs bind to MMPs in a 1:1 stoichiometry in order to exert their inhibitory 
effects (Visse and Nagase, 2003). In addition, TIMP-3 has been shown to inhibit ADAMs 
and ADAMTSs. In healthy tissue, a balance is maintained between MMPs and TIMPs, 
and thus matrix synthesis and degradation. Within the healthy joint, proteinases such as 
MMPs are involved in the catabolic aspect of normal tissue remodelling (Goldring, 2003). 
However, in RA an excess of MMP enzymes drives progressive joint damage. High 
levels of MMPs -1, -3, -8, and -9 are found in the synovial fluid of RA patients (Yoshihara 
et al., 2000, Tchetverikov et al., 2004). In particular, levels of MMPs -1 and -3 in the sera 
of RA patients correlate with disease activity (Green et al., 2003). 
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Table 1.2 MMPs and TIMPs in ECM degradation 
 Name ECM Substrates/target Cell source/localisation Inducers 
 
 
MMP-1  
Interstitial 
collagenase-1 
Collagens I-III, VII, X; gelatins; 
aggrecan; link protein; entactin; 
tenascin; perlecan 
Fibroblasts; synovial cells; 
chondrocytes; MΦ, endothelial cells 
Cytokines and growth factors (IL-1β, TNFα, VEGF); 
Chemical agents (LPS, EMMPRIN); Physical factors 
(heat shock, Ultra-violet rays 
MMP-8  
collagenase-2 
Collagens I-III; gelatins; aggrecan; link 
protein 
Neutrophils, chondrocytes TNFα; TPA; IL-1β  
MMP-13 
collagenase-3 
Collagens I-IV, IX, X, XIV; aggrecan; 
Fn; tenascin 
Chondrocytes; MΦ; fibroblasts,  bFGF; TNFα; TGFβ 
Gelatinases MMP-2  
gelatinase A 
Gelatins; collagens IV, V, VII, XI; 
laminin; fibronectin; elastin; aggrecan; 
link protein 
Fibroblasts; chondrocytes; mesangial 
cells; MΦ, endothelial cells 
TGFβ; concanavalin A; EMMPRIN 
MMP-9  
gelatinase B 
Gelatins; collagens III, IV, V; 
aggrecan; elastin; entactin; link protein 
Neutrophils; MΦ; chondrocytes; 
osteoclasts; trophoblasts; T 
lymphocytes 
IL-1β; TNFα; EGF; TGFβ; TPA 
Stromelysins MMP-3  
stromelysin-1 
Aggrecan; decorin; gelatins; 
fibronectin; laminin; collagens III, IV, 
IX, X 
Synovial cells; chondrocytes; fibroblasts IL-1β; TNFα; EGF; LPS; concanavalin A; EMMPRIN 
MMP-10  
stromelysin-2 
Aggrecan; fibronectin; laminin; 
collagens III, IV, V; link protein 
T lymphocytes TPA; A23187; TGFβ; EGF 
Matrilysins MMP-7  
matrilysin 1 
Aggrecans; gelatins; fibronectin; 
laminin; elastin; entactin; collagen IV; 
tenascin; link protein 
Chondrocytes; MΦ, mesangial cells; 
gland cells 
IL-1β; TNFα; EGF; TPA; LPS 
Membrane-type 
MMPs 
MMP-14  
MT1-MMP 
Collagens I-III; gelatins; aggrecan; 
fibronectin; laminin; fibrin;  
Chondrocytes; fibroblasts; synovial cells Concanavalin A; TPA; bFGF; TNFα; IL-1α 
Metalloprot-
einase inhibitors 
TIMP-1 MMPs (except MT-MMPs) Connective tissue cells; Fibroblasts; MΦ IL-1; IL-6; IL-11; TPA; TGFβ; TNFα; retinoic acid; LPS 
TIMP-2 MMPs Connective tissue cells; MΦ Progesterone, TGFβ, IGF-1, OSM 
TIMP-3 MMPs; ADAMs; ADAMTSs Fibroblasts; synovial cells  
Classes of MMPs and MMP inhibitors associated with ECM degradation. MMPs highly expressed in RA are indicated in bold. bFGF, basic fibroblast 
growth factor; EGF, epidermal growth factor; TGF, transforming growth factor; EMMPRIN, extracellular matrix metalloproteinase inducer; TPA, 12-O-
tetradecanoylphorbol-13-acetate (compiled from Firestein et al., 2009).
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1.2.4.2 ADAMs 
ADAMs are similar to MMPs, but also contain a unique disintegrin domain 
(Firestein et al., 2009). In particular, the ADAMTSs, which contain additional 
thrombospondin motifs, are significantly upregulated in RA. Pathologically relevant, 
ADAMTS-5 is expressed in the RA synovium. ADAMTS5 mainly degrades aggrecan, 
which along with type II collagen is a principle component of cartilage. (Vankemmelbeke 
et al., 2001). In contrast, ADAMTS4 can also cleave a number of other PGs including 
fibromodulin and decorin (Verma and Dalal, 2011).
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1.2.5 Rheumatoid arthritis therapeutics 
Inflammatory conditions like RA are a huge socioeconomic burden on society. As 
a consequence of the pain and disability caused by RA, the overall cost to the UK 
economy due to productivity losses is almost £8 billion annually, and NHS expenditure 
totals nearly £700 million per year (National Rheumatoid Arthritis Society, 2010). RA can 
be a devastating condition with a major impact on sufferers and their families. However, 
modern treatments have vastly improved disease prognosis. The costs of disease can 
be lowered with earlier intervention, which may slow the progression of disease and 
reduce the extent of joint damage. In newly diagnosed patients, a combination of drugs 
are administered as soon as possible; ideally within three months of onset of persistent 
symptoms. There are currently four distinct types of anti-rheumatic therapies available: 
NSAIDs, glucocorticoids, DMARDs and biologics.  
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin have also been 
used extensively as anti-inflammatory, antipyretic and analgesic agents. These drugs 
work by blocking the synthesis of prostaglandins, through inhibition of the enzymes 
involved in prostaglandin biosynthesis, Cyclooxygenase (COX)-1 and -2. Although 
widely used and highly beneficial, some patients can be at risk of developing 
gastrointestinal ulcerations. This is because whilst COX-2 expression is increased during 
inflammation, COX-1 is a constitutively expressed isoform essential for tissues not 
directly involved in inflammation, such as the gastroduodenal mucosa (Firestein et al., 
2009). 
Glucocorticoids such as the corticosteroid hormone cortisone have been in use 
since the 1950s. They work by acting on the glucocorticoid receptor, regulating the 
transcription of a variety of target genes, such as certain classes of cytokines. These 
treatments are considered some of the most effective anti-inflammatory and 
immunosuppressive substances around. However, they are associated with a wide array 
of potentially serious side effects, such as growth retardation and osteoporosis and so 
careful administration and monitoring is essential (Firestein et al., 2009).  
Although the above therapies are effective, first line of treatment is usually a 
combination of disease-modifying anti-rheumatic drugs (DMARDs) (NICE, 2009). Of 
these, methotrexate (MTX) is one of the most frequently used since its introduction over 
50 years ago. DMARDs not only decrease pain and inflammation, they also reduce or 
prevent joint damage. MTX is typically administered alone or in combination with other 
DMARDs such as sulfasalazine and hydroxychloroquine (Choy et al., 2005). 
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More recently, increased knowledge of the critical effector pathways in disease 
has led to the development of biologic DMARDs. The most widely-used biologic is 
infliximab, a chimeric antibody specific for human TNF. Many patients with RA respond 
well to anti-TNFα treatment, with substantially reduced signs and symptoms of disease. 
Since the development of Infliximab, attention has turned to the utility of other pro-
inflammatory cytokines as therapeutic targets. Some of these are summarised in Table 
1.3. Many of these biologics fall within two categories: antibodies or antagonistic 
proteins. Pharmaceutical companies continually develop new compounds, and screen 
them for promising activity against a particular biological target that may be important in 
disease. Despite early success with these biologic therapies, further challenges remain. 
Blockade of TNF is not curative, and not every patient is responsive to treatment. A 
recent meta-analysis showed that even the most efficacious biologic, certolizumab, only 
yielded a 20% improvement in ACR score (see Table 1.1) in 60% of patients (Mandema 
et al., 2011). It is thought patients with higher TNF levels in synovium prior to treatment 
generally respond better to anti-TNF therapies (Wijbrandts et al., 2008). Treatment safety 
is another concern, as the targeted cytokines also have essential roles in 
immunomodulation. For example, TNFα regulates host defences against mycobacterial 
infection (Bellofiore et al., 2009); therefore patients may be susceptible to new onset 
tuberculosis, or even reactivation of latent tuberculosis, as well as infection from other 
opportunistic pathogens (Rubbert-Roth, 2012).  
For the reasons stated above, new pharmacological targets are continually being 
sought. In addition to therapies that target cytokines, a range of other possible targets 
have been explored, ranging from broad-spectrum B cell inhibitors, to specific inhibitors 
of proteolytic enzymes such as MMPs (Table 1.3). Despite early promise, MMP inhibitors 
have not been very successful, due to lack of efficacy and adverse side effects due to 
the inappropriate inhibition of MMPs not involved in disease processes. Clinical 
evaluation of these drugs is difficult and expensive, and large-scale trials have been 
terminated at great cost (Close, 2001).  
Recently attention has returned to small molecule drugs as possible therapeutics 
for RA. Small molecule inhibitors are relatively cheap and easy to manufacture. These 
drugs can also be administered orally, compared to many biologics that need to be 
administered by injection or infusion (Sheridan, 2008). There is a vast array of potential 
inhibitors in the pipeline, including tyrosine kinase inhibitor CP-690550 (Tofacitinib 
citrate) and the extracellular signal-regulated kinase (ERK) inhibitor ARRY-162 
(Waldburger and Firestein, 2009).  If successful, small molecules could be used alone 
or in conjunction with the current mainstays of RA treatment.   
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Table 1.3 Targeted biologics for treatment of RA 
Type Agent(s) Advantages Disadvantages Stage of development 
Anti-
cytokine 
antibodies 
TNFα Infliximab; 
Adalimumab 
Validated clinical target; 70% 
efficacy 
Infection risk; risk of 
increased malignancy 
Widespread use 
 IL-1 AMG 108 (anti IL-
1β) 
Plausible bioactivity; 
particular role in ECM 
degradation 
Infection risk; limited efficacy 
in clinical trials 
Licensed 
 IL-6 receptor Tocilizumab  Plausible bioactivity; good 
efficacy 
May affect anti-inflammatory 
actions of IL-6 
Licensed 
 IL-15 AMG 714 Bioactivity in vitro; trends to 
efficacy 
Possible disruption of host 
antiviral responses 
Phase II clinical trials1 
 IL-17 LY2439821 Plausible bioactivity; 
important role in rodent 
autoimmunity 
Human biology requires 
clarification 
Phase II clinical trials2 
Soluble 
receptors 
TNFα Etanercept  Validated clinical target Infection risk Licensed 
 IL-1 Anakinra (IL-1RA),  Plausible bioactivity; 
particular role in ECM 
degradation 
Infection risk; cannot be 
used with TNF antagonists 
Licensed 
 IL-6 Soluble gp130 Efficacy in patients refractory 
to anti-TNF treatment 
Infection risk Pre-clinical phase 
Cell-
targeted 
B cells Rituximab Enduring clinical response; Intravenous only; possible 
immune toxicity 
Licensed 
 T cells Abatement Good efficacy; delays 
progression of structural 
damage 
Cannot be used with TNF 
antagonists 
Licensed 
Signalling 
inhibitor 
p38α  VX-745, BIRB 796 Promising target; well-
tolerated 
Limited efficacy Phase I/II clinical trials3 
MMP 
inhibitors 
Collagenase 
inhibitor  
Ro32-3555 Good results in animal models Limited efficacy; adverse 
effects  
Clinical trials 
terminated 
Selected targeted biologics trialled and tested for the possible treatment of rheumatoid arthritis. IL-1RA, Interleukin 1 receptor antagonist; ECM, 
extracellular matrix. 1Clinical Trial Identifier NCT00433875 2Identifier NCT00966875 3Identifier NCT00303563. Information compiled from Firestein et 
al., 2009; Brennan and McInnes, 2008; clinicaltrials.gov 
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1.3 NAMPT 
NAMPT has received a great deal of attention in recent years as a potential target 
for the treatment of cancer (Holen et al., 2008), with the small-molecule NAMPT inhibitor 
APO866 exhibiting anti-angiogenic (inhibition of blood vessel growth) and anti-
tumorigenic properties both in vitro (Wosikowski et al., 2002, Hasmann and Schemainda, 
2003) and in vivo (Drevs et al., 2003), More recently, APO866 has been used to 
investigate the role of this protein in chronic disease progression in a murine arthritis 
model (Busso et al., 2008). This study suggested that NAMPT inhibition might have 
potential as a viable option for the treatment of RA. The next part of this chapter will 
provide a historical perspective of this protein. 
1.3.1 Discovery of NAMPT 
B-cell lymphogenesis within bone marrow cells is a tightly regulated process that 
requires several regulatory elements for each stage of activation, proliferation and 
differentiation. The early steps of B-cell development are controlled by IL-7, which acts 
synergistically with stem cell factor (SCF).  Billips et al (1992) discovered that in addition 
to these two factors, pre-B-cell formation is dependent on the presence of S17 stromal 
cells, suggesting that a stromal-cell-derived molecule is involved in this early 
developmental step (Billips et al., 1992). Subsequent studies revealed that an 
uncharacterised cytokine was responsible (Dorshkind et al., 1992). In an attempt to 
discover new factors involved in the earliest events in B-cell development, Samal and 
colleagues (1994) screened activated human peripheral blood lymphocytes with a 
degenerate oligonucleotide probe designed to detect sequences similar to those present 
at the signal peptidase processing sites of numerous cytokines, including granulocyte 
macrophage-colony-stimulating factor (GM-CSF), IL-2, IL-1β, IL-6 and IL-3 (Samal et al., 
1994). Clones with sequence homology or complements to the probe were isolated. 
From this screen, a novel cytokine-like gene was isolated and designated the name 
PBEF. Although PBEF alone did not enhance pre B cell formation in COS 7 cells, when 
added in conjunction with both IL-7 and SCF it caused a synergistic increase in pre-B 
cell colony formation (Samal et al., 1994).  
The PBEF cDNA contained only one open reading frame of 1,470 bp (base pairs) 
encoding a polypeptide of 52 kDa (Samal et al., 1994). PBEF cDNA, as its encoded 
protein, shared no homology with any sequences present in the GenBank, EMBL or 
Swiss Protein databases at either the nucleotide or amino acid level, indicating the 
discovery of a novel factor. The presence of numerous message destabilising sequences 
(recognition signals for mRNA degradation processes) on the 3’ untranslated region of 
the mRNA suggested that PBEF was a cytokine-like molecule. Through northern blot 
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analysis, three mRNA transcripts of 2.0, 2.4 and 4.0 kb were detected in human tissues, 
with the 2.4 kb transcript predominating (Samal et al., 1994). These transcripts are 
thought to arise due to alternative splicing of exons, or alternative polyadenylation sites. 
Recent annotation of the mRNA sequence suggests that there may be as many as 19 
different mRNA variants of human PBEF, including 14 alternatively spliced variants and 
five unspliced forms. However, many of these variants have yet to be validated 
experimentally, and the physiological relevance of the variants is currently unknown. 
Current information on PBEF splice variants can be found using NCBI AceView (Thierry-
Mieg and Thierry-Mieg, 2006). 
Through northern blot analyses, PBEF was found to be expressed within the 
human heart, brain, placenta, lungs, liver, skeletal muscle, kidney and the pancreas 
(Samal et al., 1994). PBEF message is ubiquitously expressed in all tissues, with 
maximal expression occurring within the liver, muscle tissue (Samal et al., 1994) and 
immune cells (Friebe et al., 2011).  The coding sequence of the PBEF gene is highly 
conserved, with orthologs found in prokaryotes (Martin et al., 2001) and also eukaryotes 
ranging from fish to Xenopus (Fujiki et al., 2000). Amino acid sequence alignment has 
revealed that the canine PBEF protein sequence is 96% identical to its human 
counterpart (McGlothlin et al., 2005), suggesting that the gene is evolutionarily highly 
conserved. 
1.3.2 NAMPT and disease 
It is clear from the literature that NAMPT is a ubiquitously expressed pleiotropic 
protein that is important for life. Attempts to create NAMPT knockouts in mice result in 
early embryonic lethality at embryonic day 10.5 (E10.5; (Fukuhara et al., 2005, 
Ognjanovic and Bryant-Greenwood, 2002), suggesting an essential role in cell 
metabolism. In normal tissues, NAMPT is very highly expressed in the liver, adipose 
tissue and peripheral blood leukocytes (summarised in figure 1.6). If NAMPT is 
expressed relative to the organ’s metabolic activity, it is possible that organs that require 
NAMPT start to develop around E10.5; and therefore homozygous knockout embryos 
are not viable and are thus expelled. In contrast, NAMPT shows very low expression in 
brain tissue (Samal et al., 1994), suggesting that brain development is not affected by 
NAMPT deletion. NAMPT is constitutively expressed in human foetal membranes during 
pregnancy; however,  it is overexpressed in the placenta during infection-induced pre-
term labour (Ognjanovic and Bryant-Greenwood, 2002). Since its initial discovery, 
dysregulation of NAMPT has been continually implicated in a number of human diseases 
and conditions (summarised in figure 1.6).  
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Figure 1.6 Expression and distribution of NAMPT in the human body 
A) NAMPT is ubiquitously expressed in all tissues, though it is preferentially expressed 
in circulating leukocytes and the liver. Coloured boxes denote expression levels of 
NAMPT in cells and tissues, ranging from low (yellow) to very high (red). B) Pathological 
conditions where elevated NAMPT levels have been reported in the organ tissues and/or 
peripheral blood of patients. PCOS, Polycystic Ovary Syndrome.  
 
Otero and colleagues (2006) published the first study linking NAMPT to RA, a 
chronic inflammatory syndrome characterised by swelling and stiffness of the joints. They 
investigated plasma levels of numerous adipokines in patients with RA and compared 
them with healthy controls, including leptin, adiponectin, NAMPT (called visfatin) and 
resistin. They reported a marked increase in levels of leptin, adiponectin and NAMPT in 
patients with RA, indicating NAMPT as one of the biomarkers of the disease (Otero et 
al., 2006). At the same time, Nowell et al (2006) found that levels of NAMPT were also 
elevated in the serum and synovial fluid of RA patients. Analysis of human RA synovial 
tissue confirmed that NAMPT was immunolocalised within the synovial membrane, 
adipose tissue and the subintimal lining of the synovial joint. Additionally, NAMPT was 
shown to be upregulated in fibroblast-like synoviocytes treated with IL-6 and its soluble 
receptor sIL-6R. Subsequently, RT-PCR analysis revealed that NAMPT regulation by IL-
6 trans-signalling could by blocked by the inclusion of a STAT-3 inhibitor peptide. Based 
on these in vitro observations, wild type and IL-6 deficient mice were induced with 
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antigen-induced arthritis (AIA). Induction of AIA resulted in a 4-fold increase in NAMPT 
expression in wild-type mice, whilst little or no change was observed IL-6 deficient mice. 
Synovial STAT-1/3 activity was also impaired in the latter. This work demonstrated that 
STAT-3-dependent IL-6 trans-signalling regulates NAMPT expression, and that NAMPT 
is actively expressed during RA (Nowell et al., 2006). 
Brentano and colleagues (2007) reported that increased levels of NAMPT in 
serum and synovial fluid were significantly correlated with the degree of inflammation 
and clinical disease severity in patients with RA. In RASFs, NAMPT was induced by TLR 
ligands and cytokines characteristically present in the joints of RA patients, including IL-
1β, TNFα, TLR-4 ligand LPS, and TLR-2 ligand bLP (Brentano et al., 2007). The addition 
of NAMPT itself to RASFs activated NF-κB and AP-1, and induced IL-6 and CXCL8 
protein, and NAMPT stimulation of RA monocytes caused an upregulation of IL-6 and 
TNFα. Similarly, Gosset et al (2008) found that IL-1β stimulated NAMPT synthesis in 
human articular chondrocytes. This was associated with excessive release of the 
catabolic mediator PGE2, which in turn triggered the expression of MMPs and ADAMTSs; 
(Gosset et al., 2008).  
NAMPT gene expression is elevated in synovial tissues, peripheral blood 
mononuclear cells (PBMC) and peripheral blood granulocytes (PBG) in patients with RA 
(Matsui et al., 2008). NAMPT is often described as an adipokine, a protein mediator 
secreted by fat cells (section 1.3.5). Rho and colleagues (2009) explored the effects of 
NAMPT, along with other adipokines, on radiographic joint damage in patients with RA. 
They compared serum concentrations of RA patients and non-diseased controls, and 
determined associations between adipokines and body mass index (BMI), CRP, IL-6 and 
TNFα and radiographic joint damage. They found that NAMPT levels were significantly 
higher in RA patients than controls, even after adjusting for BMI and inflammation. In 
addition to this, NAMPT concentrations were significantly and positively associated with 
the degree of radiological joint damage (Rho et al., 2009) suggesting that NAMPT is 
actively involved in degradative processes in RA. 
Mesko and colleagues (2010) studied a database of 400 genes associated with 
RA, inflammatory bowel disease (IBD) and psoriasis. They identified 53 genes expressed 
in peripheral blood, which differed significantly between diseased and healthy 
individuals. Of these genes, NAMPT was identified as one of five genes that discriminate 
between samples from healthy controls and patients with chronic inflammatory diseases; 
highlighting NAMPT as a universal marker of chronic inflammation (Mesko et al., 2010). 
These data, combined with observations within our group, establish NAMPT as a pro-
inflammatory and pro-degradative mediator of joint inflammation in RA. However, the 
possible mechanisms by which NAMPT exerts these effects are as yet to be resolved. 
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1.3.3 Cytokine-like properties of NAMPT 
Ognjanovic and colleagues (2001) performed in silico analysis of the PBEF 
nucleotide sequence, combined with primer extension analyses of RNA extracted from 
a human amniotic epithelial cell line. They discovered that the gene for PBEF spans a 
length of 34.7 kb on the long arm of chromosome 7, and incorporates 11 exons and 10 
introns, which encode 491 amino acids (Ognjanovic et al., 2001). The PBEF gene has 
both proximal and distal promoters upstream of the translation initiation codon, 
suggesting that the gene may be differentially expressed in different tissues. The 1.4 kb 
proximal promoter is GC1 rich (60% GC), with a particularly G+C rich segment spanning 
the first 500 bp upstream of the major transcription initiation site. This segment contains 
several transcription initiation sites for numerous regulatory elements including NF 
(nuclear factor)-1 and AP (activator protein)-1. In contrast, the 1.6 kb distal promoter has 
more AT bases (60% AT), and several canonical TATA and CAAT boxes about 2 kb 
upstream from the transcription initiation site. The distal promoter shares many 
regulatory elements with the proximal promoter, including an NF-κB binding site, a 
regulatory element associated with inflammation (figure 1.7) (Ognjanovic et al., 2001).  
Since these initial studies, evidence of more functions of PBEF have been 
uncovered. Jia and colleagues (2004) found that PBEF is expressed in neutrophils and 
monocytes in response to inflammatory stimuli such as LPS, TNFα and IL-1β stimulation. 
Neutrophils have a key role in normal immune homeostasis, and are constitutively 
apoptotic cells with a limited lifespan of 5-6 hours in vivo. However, in response to 
inflammatory stimuli apoptosis is delayed. Blocking PBEF translation with an antisense 
oligonucleotide blocked inhibition of apoptosis in activated neutrophils, suggesting a 
requisite role for PBEF in the delayed neutrophil apoptosis observed in clinical and 
experimental sepsis (Jia et al., 2004).  
Ye and colleagues (2005) discovered that the PBEF gene is polymorphic, 
detecting two single-nucleotide polymorphisms (SNPs). The T-1001G SNP was found 
within in the proximal promoter region, and the C-1543T SNP was found in the distal 
promoter (Ye et al., 2005). Since this observation, yet more SNPs have been uncovered 
in the PBEF gene. According to the dbSNP NCBI database (Sherry et al., 2001), there 
are currently 620 reported SNPs in the human PBEF gene, although the functional 
consequences of many of these SNPs are currently unknown. This polymorphic nature, 
coupled with the presence of transcription factor binding sites within promoter regions, 
                                               
1 Referring to amino acid base content. G= Guanine, T= Thymine, C= Cytosine, A= 
Adenine 
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are characteristics PBEF shares with many innate immunity genes (Lazarus et al., 2002). 
These data suggest a role for PBEF in innate and adaptive immunity, functioning as a 
secreted cytokine. A number of pathways have been implicated in these processes. 
Studies in CD14+ monocytes suggested that PBEF upregulates a number of cytokines 
through p38 and MEK1 pathways (Moschen et al., 2007). PBEF also exhibits angiogenic 
actions in vascular endothelial cells via the activation of ERK 1/2 (Kim et al., 2007). 
Similar findings have been observed in human umbilical vein endothelial cells (HUVECs), 
with PBEF-mediated upregulation of VEGF dependent on the mitogen-activated protein 
kinase (MAPK)/ERK, phosphatidylinositol 3-kinase (PI3K)/Akt, and VEGF/VEGF type-II 
receptor (VEGFR2) signalling cascades (Adya et al., 2008). PBEF was also found to 
activate NF-κB and AP-1 signalling pathways in fibroblasts (Brentano et al., 2007). 
Finally, extracellular PBEF was found to block macrophage apoptosis through activation 
of an IL-6/STAT3 signalling pathway (Li et al., 2008b). This body of evidence suggests 
that PBEF plays an active role in numerous signalling pathways.   
Despite this evidence, two early observations have raised questions about this 
putative cytokine-like role. Firstly, the 5’ flanking region of the gene lacks the classical 
sequence motif GPuGPuTTPyCAPy2 (Ognjanovic et al., 2001). This sequence, found in 
many haematopoietic cytokines including IL-2, IL-3, C-SF (colony-stimulating factor) and 
GM-CSF, may be important for the coordinated activation of these factors (Zhang et al., 
2011). However, the chemokine CXCL8 also lacks this sequence, so it may not be a 
prerequisite for all cytokines (Nemeth et al., 2000). Secondly, PBEF mRNA transcripts 
do not contain cytokine-specific secretion sequences, as predicted using von Heijne’s (-
3,-1) principle (von Heijne, 1986). This suggests it is not secreted in the same manner 
as other cytokines. Despite these observations PBEF appears to exert cytokine-like 
activity in response to pro-inflammatory mediators. Using FLAG-tagged versions of 
PBEF in conjunction with FLAG-tagged intracellular and extracellular control proteins 
(Dhfr-FLAG and Ppl-FLAG respectively), Revollo et al (2007) showed that PBEF is 
actively secreted from adipocytes, and not merely released as a result of cell lysis or 
death. The addition of brefeldin A (an inhibitor of Golgi-ER mediated protein secretion) 
had no effect on PBEF levels in cell culture supernatants, indicating that PBEF release 
is not mediated by an ER-Golgi-dependent pathway (Revollo et al., 2007b). Studies in 
3T3-L1 preadipocytes reinforced these findings, and also ruled out release of PBEF 
through microvesicle secretion (Tanaka et al., 2007). All these data suggest that PBEF 
is released from cells through a non-classical secretory pathway, as originally 
determined by Samal and colleagues (1994) with von Heijne’s principle (Samal et al., 
                                               
2 G= Guanine, T= Thymine, C= Cytosine, A= Adenine, Pu= Purine base, Py= Pyrimidine 
base 
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1994, von Heijne, 1986). To date, PBEF has been detected in the culture medium of 
numerous cell types, including lymphocytes (Samal et al., 1994), neutrophils (Jia et al., 
2004), HepG2 cells (Garten et al., 2009), and murine 3T3-L1 adipocytes (Tanaka et al., 
2007, Revollo et al., 2007b). 
 
 
 
Figure 1.7 Genomic organisation of NAMPT/PBEF/Visfatin 
A simplified schematic representation of proximal and distal promoters upstream of the 
NAMPT gene, showing a selection of regulatory elements present. Adapted from (Luk et 
al., 2008). 
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1.3.4 Enzymatic activity of NAMPT 
As studies into its cytokine-like properties continued, another vital function of 
PBEF was being uncovered. In 2001, Martin and colleagues were attempting to identify 
a factor that enabled some bacterial species to grow in the absence of nicotinamide 
adenine dinucleotide (NAD+). NAD+ is a coenzyme found in all living cells that plays a 
pivotal role in a variety of biochemical and biological processes. In mammals, 
intracellular NAD+ is mainly synthesised via three distinct metabolic pathways (figure 
1.8). In many bacterial species, NAD+ is synthesised via the de novo pathway, which 
involves the essential amino acid tryptophan. In addition to this, NAD+ can also be 
synthesised either by nicotinic acid (NA) or nicotinamide (NAm) via two analogous 
pathways known as the salvage pathways, the former of which is also referred to as the 
“Preiss-Handler” pathway (Martin et al., 2001). More recently, nicotinamide riboside (NR) 
was identified as an additional NAD+ precursor in eukaryotes (Bieganowski and Brenner, 
2004). 
 
 
Figure 1.8 The mammalian NAD+ biosynthesis pathways 
QPRT, quinolinic acid phosphoribosyltransferase; NAPRT, nicotinic acid 
phosphoribosyltransferase; NaMN, nicotinic acid mononucleotide; NMNAT, 
Nicotinamide mononucleotide adenylyltransferase; NAMPT, nicotinamide 
phosphoribosyltransferase; NMN, nicotinamide mononucleotide; NAD, nicotinamide 
adenine dinucleotide; SIRT1, Silent mating type information regulation 2 homolog1. 
Adapted from (Imai and Kiess, 2009). 
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Although the de novo pathway is the predominant pathway for NAD+ biosynthesis 
in bacteria, some species can use NAm as a precursor for NAD+, and are thus classified 
as NAD+-independent. Through cloning, sequence analysis and characterisation of a 
plasmid-encoded gene, Martin and colleagues (2001) characterised a gene in 
Haemophilus ducreyi that could confer NAD+-independence when transformed into 
NAD+-dependent species, allowing them to utilise NAm as a precursor for NAD+. The 
gene, designated nadV, shared significant homology with the human PBEF sequence, 
in addition to other previously unidentified genes in NAD+-independent bacterial species 
(Martin et al., 2001). 
Previously, little was known about the enzyme involved in the conversion of NAm, 
which had been designated nicotinamide mononucleotide pyrophosphorylase (Dietrich 
et al., 1966, Powanda et al., 1969). On the basis of the work by Martin et al (2001), 
Rongvaux and colleagues (2002) hypothesised that murine PBEF is a NAMPT which 
incorporates NAm and 5-phosphoribosyl-1-pyrophosphate (PRPP) to produce 
nicotinamide mononucleotide (NMN). To test this, they measured the formation of 
radioactive NMN in mouse liver cytoplasmic extracts containing [14C]NAm as a substrate. 
They detected high levels of NAMPT enzymatic activity, which was strongly abrogated 
by the addition of an anti-PBEF polyclonal antibody. The role of NAMPT was further 
confirmed by cloning the murine PBEF gene into nadV-deficient NAD+-dependent 
Pasteurellaceae. Bacteria containing the cloned gene acquired the ability to grow in the 
presence of NAm, indicating that the gene allowed the utilisation of NAm as a precursor 
for NAD+ biosynthesis (Rongvaux et al., 2002). In the same study, splenic T cells were 
stimulated in vitro and cell extracts and culture supernatants were analysed for PBEF 
protein levels by enzyme-linked immunosorbent assay (ELISA). In contrast to expected 
findings, PBEF was not actively secreted upon cellular activation, remaining as a 
cytoplasmic protein (Rongvaux et al., 2002). This suggests that in T-cells, release of 
PBEF upon activation-induced cell death is the mechanism for homeostatic control of 
lymphocyte responses (Rongvaux et al., 2002). The Human Genome Organisation Gene 
Nomenclature Committee (HGNC) has since approved Nicotinamide 
phosphoribosyltransferase (NAMPT) as the official gene name for PBEF. Therefore for 
the duration of this thesis PBEF will be referred to as NAMPT. This enzymatic role for 
NAMPT occurs intracellularly, and so intracellular NAMPT is often referred to as 
iNAMPT. The proposed NAMPT signalling molecule is often referred to as extracellular 
(e)NAMPT (Imai, 2009).  
Revollo et al (2004) explored the enzymatic role of iNAMPT further by studying 
its kinetics in NAD+ biosynthesis, along with nicotinamide mononucleotide 
adenylyltransferase (NMNAT), which directly synthesises iNAMPT product NMN into 
NAD+ (figure 1.8). Using murine his-tagged recombinant proteins, they reconstituted the 
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NAD+ biosynthesis pathway and developed an enzyme-coupled fluorometric assay in 
vitro (Revollo et al., 2007b). The group discovered that iNAMPT, not NMNAT, was the 
rate-limiting enzyme in the pathway. They also found that no NAD+ was generated in the 
absence of iNAMPT substrates Nam or PRPP, confirming that the NAMPT pathway is 
the predominant pathway in most mammalian tissues (Revollo et al., 2004). The few 
exceptions to this are the brain and the liver, which primarily synthesise NAD+ via the de 
novo pathway (Bogan and Brenner, 2008).   
Following on from this work, Van der Veer (2005) found that vascular smooth 
muscle cells (SMCs) overexpressing iNAMPT had a significantly higher intracellular 
NAD+ content and enhanced cell survival when compared to control cells, providing 
further evidence that iNAMPT is a regulator of NAD+-dependent reactions in cells (Van 
Der Veer et al., 2005). Furthermore, NAD`+-dependent histone deacetylates (HDACs, 
also known as sirtuins) were required for SMC maturation, suggesting that NAD+ levels 
are a key determinant of SMC behaviour (Van Der Veer et al., 2005).  
1.3.5 Insulin mimetic activity of NAMPT 
In 2005 yet another function of NAMPT was proposed. Fukuhara and colleagues 
detected a cDNA fragment that was more abundantly expressed in visceral fat than 
subcutaneous fat (Fukuhara et al., 2005). Sequencing revealed that this fragment 
corresponded to the NAMPT gene. Further analysis revealed that the NAMPT protein 
was secreted by visceral fat in humans and mice. The authors named it visfatin (a name 
still commonly used throughout the scientific literature) and described it as an adipokine, 
a protein mediator secreted by fat cells. From two female patients they found that levels 
of NAMPT/visfatin were predominantly higher in visceral fat compared to subcutaneous 
fat. They also reported that high doses of NAMPT/visfatin lowered plasma glucose levels 
in both insulin-resistant and insulin-deficient mice. Finally, they claimed that NAMPT had 
insulin mimetic effects, engaging and activating insulin signalling through the insulin 
receptor (IR), but in a manner distinct from insulin (Fukuhara et al., 2005).  
These findings had a high impact, prompting increased interest in NAMPT and 
its implications in metabolic syndrome. They also raised the possibility that NAMPT could 
be a useful target for the development of drug therapies for diabetes. Chen et al (2006) 
reported elevated plasma levels of NAMPT in patients with Type 2 diabetes mellitus, 
suggesting a role in the pathogenesis of this condition (Chen et al., 2006). Xie and 
colleagues (2007) also reported insulin mimetic effects of NAMPT in cultured 
osteoclasts, resulting in increased glucose uptake in these cells (Xie et al., 2007).  
However, other groups failed to replicate these findings and started to dispute the 
integrity of the research. Berndt and colleagues (2005) could find no evidence that 
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NAMPT was predominantly expressed in visceral fat compared to subcutaneous fat, in 
some cases finding greater amounts of NAMPT in the latter (Berndt et al., 2005). They 
also failed to observe a correlation between NAMPT plasma concentrations and 
parameters of insulin sensitivity (Berndt et al., 2005). Upon investigation of the laboratory 
by the Committee for Research Integrity (CRI), it was recommended that the entire paper 
should be retracted, although the authors continue to stand by their observations 
(Fukuhara et al., 2007).  
1.3.6 Crystal structure of NAMPT  
In 2006 the three dimensional structure of mammalian NAMPT was resolved 
individually by different groups. The crystal structure of murine NAMPT was elucidated 
by Wang and colleagues, alone and in combination with its substrate NMN (Wang et al., 
2006). Meanwhile Kim et al (2006) resolved the crystal structure of rat NAMPT (Kim et 
al., 2006). Both groups reported that the NAMPT monomer consists of 491 residues that 
form 22 -strands and 15 -helices arranged into three structural domains (figure 1.9). 
Analyses of human and murine NAMPT 3D structures were performed by Khan et al 
(2006), who showed that NAMPT protein has a low sequence identity with other 
phosphoribosyltransferase enzymes. However, its tertiary structure is similar to nicotinic 
acid phosphoribosyltransferase (NAPRT) from Thermoplasma acidophilum, the enzyme 
that catalyses the conversion of NA into nicotinic acid mononucleotide (NaMN). NAMPT 
protein also shares some common features with Mycobacterium tuberculosis quinolinic 
acid phosphoribosyltransferase (QPRT), which converts quinolinic acid to NaMN. On the 
basis of these similarities, NAMPT has been designated a type II 
phosphoribosyltransferase. However, there are important conformational differences 
between the three enzymes. NAMPT is the largest of the three, constituting 100 more 
amino acid residues than NAPRT, with QPRT being smaller still. There are also notable 
differences in the composition of their residues, which impact greatly on both the 
structure and orientation of their active sites (Khan et al., 2006).  
NAMPT is homodimeric in solution, with its product NMN bound near the top of 
the central β-sheet in domain B. Two active sites lie at the interface of the dimer, 
suggesting that dimerisation is required for catalytic activity of the NAMPT enzyme. 
Revollo et al (2007) confirmed this by showing that mutation of Ser199 and Ser200 
residues, essential for symmetrical dimer formation, decreased NAMPT enzymatic 
activity (Revollo et al., 2007b). NAMPT contains an acidic residue that specifies Nam as 
a substrate, excluding alternative negatively charged substrates. NAMPT was also 
shown to undergo autophosphorylation of histidine residues, hydrolysing adenosine 
triphosphate (ATP) to increase its enzymatic activity. This autophosphorylation is thought 
to enhance enzymatic activity through the generation of additional negative charge, 
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which may promote cleavage of pyrophosphate from PRPP, enhancing the formation of 
NMN. Mutation of the residue His247, an important residue in autophosphorylation, 
either significantly decreases or abolishes NAMPT enzymatic activity (Wang et al., 
2006).  
 
 
 
 
 
Figure 1.9 Crystal structure of PBEF/NAMPT/Visfatin 
A) A schematic ribbon diagram of the overall fold of the PBEF monomer. The first domain 
in shown in blue, and the second domain is in green. B) The PBEF dimer, with the second 
monomer shown in pale blue and green. Two APO866 (PBEF inhibitor) molecules are 
shown in red. Taken from (Kim et al., 2006).  
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1.4 APO866 
Due to its association with the degree of disease inflammation and clinical 
disease activity (Rho et al., 2009), NAMPT has been identified as a possible therapeutic 
target for the development of new RA drugs (Brentano et al., 2007). Preliminary studies 
have demonstrated that suppressing NAMPT with a highly specific small molecule 
inhibitor named APO866 limits the effects of RA in a murine collagen-induced arthritis 
model. This effect was seen when treatment was administered before the appearance 
of arthritis, and also in established disease (Busso et al., 2008). In fact,  in vivo studies 
indicated that APO866 had comparable efficacy to  anti-TNF treatment (Busso et al., 
2008) and Nowell et al; unpublished). Therefore the last part of this review will provide a 
historical perspective on APO866, including its interactions with NAMPT and the findings 
of work involving this molecule. 
1.4.1 Discovery of APO866 
Angiogenesis is the process involving the growth of new blood vessels from pre-
existing vessels. In normal tissues this is a vital process in growth, development and 
wound healing. However, excessive angiogenesis is associated with tumour formation. 
In 2003 researchers working for Fujisawa Deutschland GMBH developed a number of 
different compounds with the aim of inhibiting/reducing angiogenesis. One such 
compound was (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl) acrylamide, 
which was designated FK866 (Beidermann et al., 2003).  Since its development this 
compound has been in the possession of a number of different pharmaceutical 
companies. In 2005 the Fujisawa Pharmaceutical Co., Ltd merged with Yamanouchi 
Pharmaceutical Co., Ltd to form Astellas Pharma GmbH. In October 2005 Swiss 
biopharmaceutical company Apoxis SA acquired exclusive worldwide development and 
marketing rights to the drug and renamed it APO866, although it is still often referred to 
in some literature by its former names FK866 and WK175 (Apoxis, 2005). Finally, in 2007 
Apoxis was acquired by TopoTarget, which has continued to initiate clinical studies of 
APO866 in order to understand its biologic effects. 
1.4.2 Assigning in vitro functionality of APO866 
Wosikowski et al (2002) published the first study of APO866 in vitro. In a screen 
of novel anti-tumour agents, they discovered that APO866 had distinct characteristics to 
conventional chemotherapies: it induced apoptosis in cells, with no DNA-damaging 
effects which can lead to genomic instability and generation of resistant tumour 
phenotypes (Wosikowski et al., 2002). They stimulated a human monocytic cell line 
(THP-1) with APO866 for four days, and found that this agent caused a time and dose-
dependent decrease in cell metabolic activity, as determined by a cell proliferation assay. 
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They also observed a concurrent increase in the proportion of apoptotic cells. They 
discovered that it exerted these effects by interfering with NAD+ biosynthesis, resulting 
in decreased cellular NAD+ content (Wosikowski et al., 2002). Prolonged incubation of 
cells with APO866 altered mitochondrial membrane potential. This disruption of 
mitochondrial function led to activation of caspase 3, which is a crucial event in the final 
degradation phase of apoptosis. These data suggest that depletion of intracellular NAD 
+ is a trigger that initiates the apoptotic cascade, resulting in an anti-tumour effect 
(Wosikowski et al., 2002).  
In 2003 Hasmann and Schemainda explored the pro-apoptotic effects of APO866 
further in human liver carcinoma (HepG2) cells. Like Wosikowski et al (2002), they 
observed that APO866 decreased metabolic activity and cell number, whilst increasing 
the proportion of non-viable cells. These effects were observed along with a concurrent 
decrease in intracellular NAD+. They sought to determine which NAD+ biosynthesis 
pathway APO866 was involved in, using radiolabelled NAD+ precursors Nam and NA. 
APO866 caused rapid inhibition of Nam-mediated NAD+ production, with no discernible 
effect on NA-mediated NAD+ levels. Additionally, no accumulation of radiolabelled NMN 
was observed; suggesting that NAMPT and not the downstream enzyme NMNAT was 
the target for APO866 (Hasmann and Schemainda, 2003).  
1.4.3 Molecular basis of APO866 inhibition of NAMPT activity 
In 2006 groups working on the crystal structure of NAMPT co-crystallised it with 
APO866, as well as its reaction product NMN, in order to determine the molecular basis 
of NAMPT enzymatic activity and inhibition (Kim et al., 2006, Khan et al., 2006). NAMPT 
is a dimer in solution, and is only active in this dimeric form. APO666 is tightly bound in 
a tunnel at the interface of this dimer. It competes directly with Nam, and therefore acts 
as a competitive inhibitor of NAMPT activity (figure 1.10). This inhibition is highly specific 
to NAMPT, as the structurally similar NAPRT does not contain a tunnel at its dimer 
surface, which is the molecular basis for APO866 inhibition. Mutations of the NAMPT 
binding site abolished inhibition by APO866 (Khan et al., 2006). 
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Figure 1.10 The molecular basis of NAMPT inhibition by APO866 
A) Ribbon diagram of the NAMPT dimer (in cyan and gold) co-crystallised with NMN 
(shown in green and red). B) Interaction of NAMPT dimer with APO866 (shown in black). 
Images adapted from (Hasmann and Schemainda, 2003). 
 
 
1.4.4 Assessing impact of APO866 in vivo  
Once the anti-tumour effects of APO866 were established, Drevs and colleagues 
(2003) set out to investigate the anti-tumour, anti-metastatic and anti-angiogenic potency 
of this agent in a murine renal cell carcinoma model (RENCA) (Drevs et al., 2003). This 
was achieved by inoculating mice with RENCA tumour cells to initiate tumour growth, 
before treating orally with various doses of APO866. Mice were sacrificed on day 21 and 
analysed for primary tumour weight and volume, lung metastases and tumour vessel 
density. It was found that doses of ≥10 mg/kg showed significant anti-tumour and non-
significant anti-metastatic activity on RENCA primary tumours, with all doses resulting in 
anti-angiogenic activity (Drevs et al., 2003). In a subsequent study the metabolic effects 
of APO866 were investigated in a mouse mammary carcinoma model in vivo.  Groups 
of mice were given two different dosages of the drug, administered by intra-peritoneal 
(i.p.) injection. The lower dosage treatment resulted in retarded tumour growth compared 
to controls, whilst the higher dose also caused reduced mammary carcinoma tumour 
radiation sensitivity. Histological annexin staining of APO866-treated tumours also 
showed evidence of apoptosis compared with controls (Muruganandham et al., 2005).  
Although most interest in APO866 is focused on its potential as an anti-cancer 
agent, it is now emerging that APO866 may also be useful in inflammatory and 
autoimmune diseases. Busso et al found that APO866 treatment reduced intracellular 
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NAD+ levels and pro-inflammatory cytokine secretion by inflammatory cells in vitro. In 
vivo, animals with collagen-induced arthritis (CIA) were treated with APO866 by i.p. 
Injection, resulting in reduced disease severity, comparable to anti-TNFα drug 
etanercept. They observed that APO866 caused a reduction in circulating TNFα levels 
during endotoxemia in mice (Busso et al., 2008). In light of these findings, the Nowell 
research group have further investigated the in vivo efficacy of APO866 in CIA animals 
with the use of osmotic minipumps. Early findings suggest that APO866 ameliorates 
disease in treated animals in a time and dose-dependent manner. 
1.4.5 Clinical studies involving APO866 
Preclinical studies in rats and monkeys showed that lymphocytes are most 
sensitive to APO866, resulting in lymphocytopenia and reticulocytopenia (Holen et al., 
2002). Following on from these findings Holen et al (2008) carried out an open-label 
Phase I clinical trial (Holen et al., 2008). Patients with solid tumour malignancies were 
given escalating doses of APO866 as continuous 96 hour infusions. The group aimed to 
determine dose-limiting toxicities of APO866, in addition to its pharmacokinetics, efficacy 
and effect on VEGF levels. VEGF is an important signalling protein in vasculogenesis 
and angiogenesis, which can contribute to disease when over expressed by providing a 
blood supply to solid tumours.  APO866 was generally well tolerated, although some 
patients suffered from a drop in platelet levels, but recovered quickly at the end of the 
study. Plasma VEGF levels appeared to drop, but due to the small sample size this effect 
was not significant. None-the-less, a few patients showed improvement. Although 
APO866 has potential as a single agent, it may work best if administered in combination 
with other anti-tumour agents (Holen et al., 2008). TopoTarget subsequently initiated a 
Phase II study to determine the efficacy and safety of 3 cycles of APO866 for the 
treatment of advanced cutaneous melanoma (Topotarget, 2009b), as well as a Phase 
I/II study for the treatment of B-Chronic Lymphocytic Leukaemia (B-CLL) (Topotarget, 
2009a). These studies have recently been completed, and a third Phase II study on 
APO866 in cutaneous T cell lymphoma (CTCL) is currently underway (Topotarget, 2011).  
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1.5 Summary and Thesis aims 
NAMPT is a relatively newly characterised pleiotropic protein. Since its discovery 
in 1994 it has been implicated in a variety of important cellular processes, and has 
garnered increased interest in the last decade for its role in NAD+ biosynthesis, and its 
association with a host of diseases, including inflammatory arthritis.  
The overall hypothesis of this thesis is as follows: 
Overexpression of NAMPT in the synovial joint propagates cartilage 
destruction during inflammatory arthritis. 
It is anticipated that the results of this thesis will further our knowledge of the role 
of NAMPT in the disease pathology of RA and may lead to the development of novel 
therapeutics aimed at suppressing its activity in driving pathology. In addition, this 
knowledge may potentially be applied to other chronic conditions such as inflammatory 
bowel disease or chronic kidney disease. The specific aims of the individual experimental 
chapters are outlined below: 
 To determine the effect of exogenous (e)NAMPT on catabolic proteinases in vitro.  
 To determine the effect of NAMPT inhibition on catabolic proteinases in vivo.  
 To determine the effect of iNAMPT inhibition on articular cartilage ex vivo.  
 To investigate how intracellular (i)NAMPT is regulated in RASFs in vitro. 
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Chapter 2: Materials and methods 
2.1 Cell and tissue culture experiments  
Unless otherwise stated, all cell and tissue culture reagents were purchased from 
Gibco, Life Technologies Ltd. In chapter 3, the human recombinant extracellular NAMPT 
(eNAMPT) used was purchased from Enzo Life Sciences Ltd, Exeter, UK. The 
lyophilised protein was reconstituted in sterile phosphate-buffered saline (PBS) to 
produce a stock solution which was aliquoted and stored at -20°C, as recommended by 
the manufacturer. All cytokines used throughout this thesis were purchased from R&D 
Systems, Abingdon UK (Cat no: 201-LB, 210-TA, 295-OM; IL-1β, TNFα and OSM, 
respectively). Lyophilised cytokines were reconstituted in sterile PBS containing 0.1% 
bovine serum albumin (BSA) to a stock concentration of 10 μg/ml, and were aliquoted 
and stored at -20°C until required. Cytokines were used at working concentrations 
ranging from 1-20 ng/ml, depending on the model system. Concentrations of 1-10 ng/ml 
of cytokine were typically applied to monolayer cultures of RASFs (Brentano et al., 2007, 
Niederer et al., 2011) and chondrocytes (Gosset et al., 2008, Hong et al., 2011). In 
cartilage ex vivo culture (section 2.1.5), cytokine concentrations up to 20 ng/ml were 
used, as per previously published work (Sondergaard et al., 2006, Karsdal et al., 2008). 
NAMPT inhibitor APO866 (provided by TopoTarget A/S, Denmark) was stored in a 10 
mg/ml solution in 60% propylene glycol. For each stimulation assay, APO866 was diluted 
to a working concentration in Dulbecco's modiﬁed Eagle's medium (DMEM) prior to use. 
Concentrations ranging from 0.01 nM to 100 nM were used, as previously described 
(Busso et al., 2008, Nahimana et al., 2009). Beta NMN and NA (both available from 
Sigma-Aldrich Ltd, Dorset, UK) were dissolved in deionised water (dH2O) at a stock 
concentration of 10 mg/ml, aliquoted and stored at -20°C until required. These NAD+ 
precursors were used at a working concentration of 100 μM, as this is within the range 
of concentrations typically applied to cells in previous studies (Busso et al., 2008, Van 
Gool et al., 2009). 
2.1.1 Monolayer tissue culture  
2.1.1.1 Cell passage 
All cells used in this thesis were cultured as monolayers, in medium 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), and 100 U/100 μg 
per ml Penicillin-Streptomycin (Penstrep). For cell passage, culture medium was 
removed and cells were washed twice in 10 ml sterile PBS, in order to remove residual 
FBS that may inhibit trypsinisation. PBS was aspirated, and 0.25% Trypsin-
ethylenediaminetetraacetic acid (EDTA) was added. Cells were incubated at 37°C for 5-
10 minutes with frequent agitation until all cells had been seen to detach from the flask 
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under an inverted microscope. Trypsin activity was quenched by the addition of an equal 
volume of fresh culture medium with 10% FBS. The cell suspension was centrifuged at 
400 x g for 5 minutes, and the resulting pellet was resuspended in fresh culture medium. 
Cells were seeded at a density of approximately 3x104 cells/ml and incubated in new 
culture flasks at a volume of 15 ml in a T75 flask, and 30 ml in a T175 flask. Cells were 
then grown at 37°C in a humidified atmosphere containing 5% CO2. Culture medium was 
changed twice weekly.   
2.1.1.2 Freezing and resuscitating cells 
Prior to freezing, cells were washed twice in PBS and trypsinised as described in 
the previous section. A small (<100 μl) aliquot of cell suspension was taken for 
determination of cell number. A series of dilutions of the cell aliquot (1:5, 1:10, 1:20) were 
made, and a 10 μl aliquot of cell suspension was pipetted onto a bright line 
haemocytometer and covered with a clean glass coverslip (Sigma-Aldrich Ltd, Dorset, 
UK). The cells were counted in 5 grids (figure 2.1) and the total number of cells in the 
sample was calculated as follows: 
Number of cells= average grid count x 104 x dilution x total volume 
If cell numbers exceeded 50 per grid, then a more diluted cell suspension was 
used, until an appropriate count was obtained. The remaining cell suspension was 
centrifuged at 400 x g for 5 minutes. The cell pellet was reconstituted in FBS containing 
10% dimethyl sulfoxide (DMSO; Sigma-Aldrich Ltd, Dorset, UK) as a cryoprotectant, at 
a concentration of 3x104 cells/ml according to European Collection of Cell Culture 
(ECACC) recommendations. Cell suspensions were mixed thoroughly and aliquoted into 
1 ml Cryo™ cryovials (Greiner Bio-One Ltd, UK). Vials were labelled and stored at -80°C 
in a “Mr. Frosty” freezing container to gently cool at 1°C per minute (Nalgene, Thermo 
Fisher Scientific, Denmark) overnight, before being transferred into liquid nitrogen (LN2) 
dewars for long-term storage. 
To revive frozen cell stocks, 5 ml of fresh culture medium with 10% FBS was 
prepared, sterilised with a 0.22 μm filter, and pre-warmed in a 37°C water bath. Cryovials 
of cells were carefully removed from LN2 storage. Vials were sprayed with 70% (v/v) 
ethanol and opened partially under sterile laminar flow in a Class II cabinet to permit the 
release of pressure caused by excess LN2. Vials were resealed and thawed rapidly in a 
37°C water bath until only a few ice crystals remained. The thawed suspension of cells 
was quickly added to the pre-warmed culture medium. Cells were counted, before being 
transferred to a T25 tissue culture flask. Cells were maintained in culture as described in 
section 2.1.1.1, and used as needed. 
 
 45 
 
 
Figure 2.1 Haemocytometer grid for cell counts 
Shaded regions show where cells are counted. Cells positioned on the right hand or 
bottom boundary lines were also counted. 
 
2.1.2 Human primary cells and cell lines 
Human RA joint cells, namely articular chondrocytes and synovial fibroblasts, 
were extracted from an elbow joint, acquired with ethical approval from an RA patient 
undergoing joint replacement surgery. The joint was stored at 4°C in sterile DMEM 
culture medium prior to digestion. Dissection equipment was sterilised prior to use by 
autoclaving at 121°C for 30 minutes. The entire chondrocyte extraction procedure was 
carried out in a Class II Safety cabinet. Throughout the dissection procedure, equipment 
was routinely sterilised by exposure to alcohol flame.  
2.1.2.1 Human primary articular chondrocytes (HACs)  
Cartilage was removed from the entire articulating surface of the elbow joint using 
a sterile scalpel, and finely diced to enable efficient dissociation of chondrocytes from 
the cartilage ECM. Cartilage shavings were placed into a sterile tube containing 
chondrocyte-specific culture medium comprising DMEM supplemented with the 
following: 100 U/100 μg per ml Penstrep, 10% (v/v) FBS, 100 mM HEPES, 1 mM sodium 
pyruvate (all from Gibco, Life Technologies Ltd, Paisley, UK), 0.1 mM ascorbic acid, and 
5 mM glucose (both Sigma-Aldrich, Dorset, UK).  
Once all the articular cartilage was harvested, the medium was removed and 
replaced with chondrocyte culture medium containing 5% FBS and 70 units/ml pronase 
from Streptomyces griseus (Roche Diagnostics Ltd, West Sussex, UK). Articular 
cartilage was incubated in the pronase solution with gentle agitation for 1 hour at 37°C, 
 46 
5% CO2. Pronase medium was then removed and replaced with chondrocyte culture 
medium containing 5% FBS and 300 units/ml collagenase Type I from Clostridium 
histolyticum (Gibco, Life Technologies Ltd, Paisley, UK). Collagenase digestion was 
carried out for 3 hours at 37°C 5% CO2, with gentle agitation. Prior to the digestion 
procedure, both pronase and collagenase solutions were sterilised by filtration with a 
0.22 μm Millex-GP syringe driven filter (Millipore Ltd, Watford, UK). The resulting 
suspension was passed through a 40 μm cell strainer (BD Biosciences, Oxford, UK) to 
remove any undigested material. An equal volume of serum-free DMEM plus 
supplements was added to quench the collagenase, and the suspension was centrifuged 
at 400 x g for 5 minutes. The supernatant was aspirated, and the cell pellet was 
reconstituted in 1 ml serum-free DMEM. A 100 μl aliquot of cell suspension was taken to 
determine cell number (see section 2.1.12). Finally, chondrocytes were seeded onto 
tissue culture plates at a seeding density of 6000 cells/cm2, and cell stimulations were 
performed as described in section 5.2.1. 
2.1.2.2 Human RA synovial fibroblasts 
Under sterile conditions, synovial tissue was finely diced to maximise its surface 
area for digestion. Tissue was added to a sterile tube containing a 1:1 mixture of DMEM 
and Nutrient Mixture F-12 (DMEM:F-12) containing 100U/100 μg/ml Penstrep, 5% heat-
inactivated FBS, and 1 mg/ml Collagenase Type I. The tissue was digested in the 
collagenase solution at 37°C, 5% CO2 with mechanical agitation, for 2 hours, or until the 
synovial tissue was fully digested. The resulting suspension was passed through a cell 
strainer to remove any undigested material. This filtrate was centrifuged at 400 x g for 5 
minutes, and the resulting pellet was washed once in DMEM:F-12, and centrifuged once 
more. Finally, the washed pellet was resuspended in 5 ml DMEM:F-12 containing 10% 
FBS and transferred to a T25 tissue culture flask. Cells were cultured overnight, and non-
adherent cells were removed by changing the culture medium. Medium was changed 
twice weekly until confluence was achieved. In order to produce a uniform cell 
population, primary cells (passage 0) were passaged and used at passage 3 and 
beyond. This was to ensure a homogeneous population free of contaminating 
macrophage-like synoviocytes, and also to expand the number of proliferating cells 
(Neumann et al., 2010). Passage was carried out when cells reached 80% confluency 
(see section 2.1.1.1). Cell stimulations were performed as described in section 6.2. 
2.1.2.3 Human foetal foreskin fibroblasts 
Two sources of human foetal foreskin fibroblasts (HFFF2) were used for in vitro 
experiments. One batch was obtained in-house, whilst another batch was purchased 
from ECACC. At time of purchase, the cells were at passage 14, and used up to (but not 
exceeding) passage 20.  Cells were seeded at a density of 3x104 cells/ml, and cultured 
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in a monolayer in tissue culture flasks containing DMEM supplemented with 10% FBS, 
and 100 U/100 μg per ml Penstrep. Cells were grown in a humidified atmosphere, at 
37°C, 5% CO2, and culture medium was changed twice weekly. Cells were cultured and 
passaged (section 2.1.1.1). For stimulation assays, cells were trypsinised and passaged 
onto 6-well tissue culture plates. Refer to section 3.2 for details of individual experiments 
using HFFF2 cells. 
2.1.3 ELISA of culture supernatants 
Tissue culture supernatants were thawed and analysed for the presence of 
natural MMP-1, MMP-3, TIMP-1, CCL2 and CXCL8 released from cells using an ELISA 
(figure 2.2). Commercial kits were purchased from R&D Systems, Abingdon UK and 
performed as per manufacturer’s instructions. The general ELISA protocol is described 
below, and details of individual assays given in Table 2.1. 
Firstly, the capture antibody supplied within the kit was reconstituted with 1 ml 
sterile PBS to make a stock solution. This stock was subsequently diluted further to a 
suitable working concentration recommended by the protocol, and 100 μl of capture 
antibody was added to each individual well of a 96-well Immulon 4HBX flat-bottomed 
microtitre plate (Fisher Scientific, UK). The plate was sealed and incubated overnight at 
4°C. Wells were aspirated and washed three times with a wash buffer solution containing 
0.05% Tween® 20 (Sigma-Aldrich Ltd, Dorset, UK) in PBS, ensuring complete removal 
of liquid at each step for good ELISA performance. This was achieved by forcefully 
blotting plates onto tissue paper. The plate was then blocked for 1 hour with the addition 
of 200 μl 5% BSA (Affymetrix Ltd, High Wycombe, UK) in PBS. The aspiration/wash step 
was repeated before the addition of 100 μl of the samples to be tested, or serial dilutions 
of the standard provided. Samples and standards were diluted in a reagent diluent 
consisting of 1% BSA in PBS. Samples and standards were plated in duplicate. The plate 
was sealed and incubated 2 hours at room temperature. The aspiration/wash step was 
repeated, and 100 μl of the provided detection antibody (diluted to a working 
concentration in reagent diluent) was added to wells, and the plate was incubated for a 
further 2 hours. After another wash step, 100 μl of a working dilution of streptavidin-
horseradish peroxidase (HRP; diluted in reagent diluent) was added to each well. The 
plate was covered and incubated for 20 minutes at room temperature, away from direct 
light. Finally, the plate was aspirated and washed again, before the addition of 100 μl 
SureBlue TMB (3,3’,5,5’-tetramethylbenzidine) Microwell Peroxidase (Insight 
Biotechnology Ltd, UK) for 20 minutes, or until a sufficient colorimetric change had 
occurred. The reaction was terminated by the addition of 50 μl of a stop solution 
containing 1M sulphuric acid (H2SO4). The plate was read in a microplate reader set to 
450 nm with a wavelength correction of 540 nm. The standard values were used to 
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generate a line of best fit, which was used to extrapolate protein titres in culture 
supernatants.  
 
 
Figure 2.2 Enzyme-linked immunosorbent assay (ELISA)  
The ELISA technique is used to quantify the amount of a protein of interest within a 
sample/solution. Firstly, the protein (antigen) in solution is affixed to the surface of the 
plate by a capture antibody, and then a specific detection antibody is applied over the 
surface, which binds with the standard/sample. Then, streptavidin attached to the 
enzyme horseradish peroxidase (HRP) is applied. Finally a TMB solution (a substrate for 
HRP) is applied, which results in a colorimetric change upon cleavage of the substrate 
by HRP. Between each step, the plate is washed with a mild detergent solution (e.g. 
PBS-TWEEN®) to remove any unbound proteins. 
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Table 2.1 Antibody concentrations and standards for human ELISA assays 
ELISA assay Capture antibody Top standard 
concentration 
Detection antibody 
Human MMP-1 
Cat no: DY901 
Goat anti-human 
MMP-1 (Working 
solution: 2 μg/ml) 
10,000 pg/ml Biotinylated goat anti-
human MMP-1 (100 ng/ml) 
Human MMP-3 
Cat no: DY513 
Goat anti-human 
MMP-3  
(0.8 μg/ml) 
2,000 pg/ml Biotinylated goat anti-
human MMP-3 (100 ng/ml) 
 
Human TIMP-1  
Cat no: DY970 
Mouse anti-
human TIMP-1  
(2 μg/ml)  
2,000 pg/ml Biotinylated goat anti-
human TIMP-1 (50 ng/ml) 
Human 
CCL2/MCP-1 
Cat no: DY279 
Mouse anti-
human CCL2  
(1 μg/ml) 
1,000 pg/ml Biotinylated goat anti-
human CCL2 (100 ng/ml) 
Human 
CXCL8/IL-8 Cat 
no: DY208 
Mouse anti-
human CXCL8  
(4 μg/ml)  
2,000 pg/ml Biotinylated goat anti-
human CXCL8 (20 ng/ml) 
 
2.1.4 Quantification of NAD+ 
NAD+ was quantified using both an in-house assay and a commercial kit, both 
based upon previously published NAD+ cycling assays (Hinz et al., 1973, Szabo, 1996, 
Ying et al., 2001). In essence they are based on the ability of NADH (the reduced form 
of NAD+) to reduce thiazolyl blue tetrazolium bromide (MTT) to purple-coloured 
formazan. This results in a change in absorbance that can be detected 
spectrophotometrically. The resulting absorbance readings are proportional to NAD+ 
levels within the sample (figure 2.3).  
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Figure 2.3 Principles of in-house NAD+ detection assay  
Samples extracted from actively-dividing human RASFs were tested for intracellular 
NAD+ using a colourimetric detection assay. NAD+ is rapidly reduced to form NADH by 
enzymatic cycling with alcohol dehydrogenase. In turn, NADH reduces MTT to purple-
coloured formazan through the intermediation of electron carrier phenazine 
methosulfate.  
2.1.4.1 In-house NAD+ assay  
All reagents for the in-house assay, unless otherwise stated, were purchased 
from Sigma-Aldrich Ltd. Firstly, medium was aspirated from cell monolayer cultures on 
6-well plates, and cells were washed once in PBS. Cells were then treated with 750 μl 
0.5 N ice-cold perchloric acid (HClO4), to rapidly extract the metabolites of interest, and 
scraped at 4°C with a cell scraper. The solution was subsequently neutralised by the 
addition of 120 μl 3 M KOH/125 mM Gly-Gly buffer, pH 7.4. The cell solutions were mixed 
by pipetting and transferred to 1.5 ml microcentrifuge tubes. The mixtures were 
centrifuged at 10,000 x g for 2 minutes at 4°C. Finally, supernatants were collected and 
stored at -20°C for use in the NAD+ cycling assay. 
For the cycling assay, 25 μl of each sample was added in duplicate to a flat-
bottomed 96-well plate. A standard solution of NAD+ was prepared and diluted serially 
from a top standard of 30 μg/ml to 0.47 μg/ml and plated in duplicate. A cycling buffer 
(100 μl per reaction) was prepared fresh immediately prior to each assay, and consisted 
of the following: 0.1 mM MTT, 0.9 mM phenazine methosulfate, 13 units/ml alcohol 
dehydrogenase, 100 mM nicotinamide and 5.7% (v/v) ethanol in 61 nM Gly-Gly buffer. 
Nicotinamide was added to ensure complete recovery of the pyridine nucleotides within 
the extracts (Zerez et al., 1987), whilst the other components were needed for cycling to 
occur (figure 2.3). Upon addition of the cycling buffer, plates were covered and incubated 
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at room temperature for 10 minutes, and absorbance was read at OD595nm. Standard OD 
values were plotted on a Michaelis menton non-linear regression curve using GraphPad 
Prism version 4.0a, and sample NAD+ values were extrapolated from the curve. 
2.1.4.2 Commercial NAD+ assay 
Intracellular NAD+ levels were also quantified with a commercially-available 
NAD/NADH Assay Kit (Abcam®, Cambridge UK). The kit was used as per 
manufacturer’s instructions. Firstly, cells were scraped and a small aliquot of the resulting 
suspension was taken to obtain a cell count, whilst the rest of the cell suspension was 
pelleted at 400 x g for 5 minutes. The supernatant was removed and 1 ml of ice- cold 
PBS was added, and cells were pelleted again at 400 x g for 5 minutes at 4°C. The PBS 
was removed and replaced with 400 μl of NAD/NADH extraction buffer and cells were 
extracted by two freeze/thaw cycles (20 minutes on dry ice, then 10 minutes at room 
temperature). Extractions were vortexed for 10 seconds and then centrifuged at 20,000 
x g for 5 minutes. The supernatants were transferred to 10 kDa molecular weight cut-off 
filters (Millipore Ltd, Watford, UK) and centrifuged at 20,000 x g until the buffer had 
passed through the filters. Finally, samples were kept on ice and assayed immediately. 
For the assay, 10 μl of a 1 nmol/μl standard was diluted with 990 μl NADH/NAD 
extraction buffer to generate a 10 pmol/μl standard NADH. Varying quantities of the 
standard were added in duplicate to wells of a 96-well plate, and diluted further with 
extraction buffer to generate 0, 20, 40, 60, 80 and 100 pmol/well standards. To detect 
total NADt (total NADH and NAD+), 50 μl of extracted samples were transferred into the 
96-well plate in duplicate. To detect NADH, an additional 200 μl of extracted samples 
were heated to 60°C for 30 minutes to decompose NAD+, before cooling on ice. These 
NAD+ decomposed samples were transferred to the 96-well plate in duplicate along with 
NADt extracted samples.  
Once standards and samples were plated, a NAD+ cycling mix was prepared with 
100 μl cycling buffer mix and 2 μl NAD+ cycling enzyme mix per reaction, and 100 μl was 
added to each well. Wells were mixed and the plate incubated at room temperature for 
5 minutes to convert NAD+ to NADH, before adding 10 μl NADH developer into each 
well. The reaction continued to develop for 1-4 hours before the absorbance was read at 
an optical density of 450 nm in a FLUOstar Optima plate reader (BMG Labtech Ltd, 
Aylesbury, UK). Once the plate was read, sample readings were applied to a NADH 
standard curve and amounts of NADt and NADH in the samples were calculated. The 
concentration of NAD+ was determined as follows: 
NAD+ = Total NADH - NADH.  
NAD+ yields were normalised to cell count and expressed as pmol/106 cells. 
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2.1.5 Bovine tissue culture 
2.1.5.1 Bovine articular cartilage preparation and culture 
Articular cartilage was obtained from the metacarpophalangeal 
/metatarsophalangeal (MCP/MTP; hock) joints of freshly slaughtered 7-day old calves 
from F. Drury and Sons Ltd (Swindon, UK). Immature bovine cartilage was used for all 
ex vivo culture studies, as it is thicker and easier to harvest than articular cartilage from 
mature joints, and has a greater abundance of chondrocytes (Stockwell, 1971). In 
preparation for tissue culture, hocks were cleaned thoroughly with tap water, soap and 
a brush, and sprayed with 70% ethanol and microSol 3+ (Anachem Ltd, UK). Skin was 
removed using a non-sterile number 3 scalpel handle with number 10 surgical blade. A 
chainmail glove was worn on the other hand to safeguard against injury whilst cutting the 
tissue. Once skin was removed, both ends of the hind limb were covered with sterile 
rubber gloves or foil and the surface sprayed once again with 70% ethanol and microSol 
3+. Once the joints had been prepared for dissection under sterile conditions, all further 
work was carried out in a Class I tissue culture cabinet using aseptic technique. All 
utensils used for cartilage extraction were sterilised prior to use by autoclaving at 121°C 
for 30 minutes. To obtain full-depth cartilage explants of a consistent size and weight (76 
± 1.8 mg), articular cartilage cores were taken using a 6 mm biopsy punch. The explants 
were released from the subchondral bone with the aid of a scalpel, ensuring that the 
cores contained the full-depth of cartilage, including the basal calcified cartilage tissue. 
Throughout the procedure scalpel blades and other surgical utensils were routinely 
washed in 70% ethanol, followed by a wash in sterile PBS, to reduce the risk of 
contamination. Cartilage explants were weighed and then immersed in prepared culture 
medium consisting of DMEM supplemented with 100 U/100 μg/ml Penstrep, and 50 
μg/ml gentamicin (all from Gibco, Life Technologies Ltd, Paisley, UK). For each 
experiment, three explants were rapidly fixed in 4% paraformaldehyde solution to serve 
as time zero (T0) experimental controls, and processed for histology (see section 2.3.1). 
Full-depth cartilage explants were pre-incubated in culture medium containing 
5% heat-inactivated FBS (Gibco Life Technologies Ltd, Paisley, UK) at 37°C in 5% CO2 
for 72 hours to enable the cartilage to equilibrate prior to ex vivo culture. During this 
period, media were refreshed every 24 hours. Cartilage explants were then washed twice 
in sterile PBS, weighed individually and aseptically, before culturing in experimental 
medium (figure 2.4). Each explant was placed individually into a well of a 48-well plate. 
Unless otherwise stated, three explants were used for each experimental condition 
(n=3). Cultures were maintained for the required number of days, with medium change 
every 48 hours, including culture medium supplemented with IL-1ß. This continual 
cytokine assault was carried out to mimic the chronic inflammatory environment within 
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the RA joint, comparable to that performed in related studies (Sondergaard et al., 2006, 
Karsdal et al., 2008, Wang et al., 2009a). Tissue was processed for papain digestion 
(see below) or histology (section 2.3.1), and culture media were collected and stored at 
-20°C until required.  
Cartilage was papain digested for dimethylmethylene blue (DMMB) analysis 
(refer to section 2.1.5.2) using the following method. Cartilage was placed into a stock 
buffer (0.05 M sodium acetate, 0.025 M Na2EDTA, pH 5.6) containing 5 mM Cysteine-
HCl and 1 unit of papain suspension from papaya latex per ml of buffer (all reagents 
purchased from Sigma-Aldrich). 1 ml of buffer was used per 100 mg cartilage to be 
digested. Cartilage samples in buffer were then incubated at 65°C for 18 hours, with 
occasional mixing. Once digestion was completed, samples were boiled for 15 minutes, 
and then left to cool at room temperature. Finally, samples were stored at -20°C until 
needed.   
 
Figure 2.4 Cartilage explants in ex vivo culture system  
Cartilage explants taken from the bovine MCP/MTP joint using a biopsy punch were 
prepared for ex vivo culture in supplemented medium. Both cartilage and explant 
supernatants were analysed to assess cartilage integrity. 
 
2.1.5.2 DMMB assay 
A colorimetric assay was used to quantify levels of s-GAG in culture supernatants 
and cartilage extracts as described previously (Farndale et al., 1986). Within the cartilage 
ECM, degradative enzymes such as MMPs and ADAMTSs can cleave PGs such as 
aggrecan resulting in a loss of s-GAG (refer to section 1.2.4) which is detectable in the 
culture supernatant of explant cultures (figure 2.5). The DMMB assay is based on the 
ability of s-GAGs to bind to 1,9-dimethylmethylene blue, which results in a shift in its 
absorption spectrum. Total GAG remaining in the tissue was also analysed using the 
DMMB assay, following papain extraction (section 2.1.5.1). 
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A solution of 1,9-dimethylmethylene blue was prepared by dissolving 32 mg 
DMMB in 20 ml absolute ethanol overnight, and making up to 2 L with 59 ml 1M NaOH, 
7 ml 98% formic acid and MilliQ water. The solution was stirred and the absorbance 
readings at 525 nm and 592 nm were checked. Absorbance readings of 0.3 and 1.4 
respectively suggested that the dye was sufficiently dissolved and the solution was 
stored at room temperature ready for use. Standard curve solutions were prepared fresh 
for each set of assays using Chondroitin Sulphate C from shark cartilage (Sigma-Aldrich 
Ltd, Dorset, UK). Solutions of 0, 10, 20, 30 and 40 μg/ml in DMEM were prepared and 
40 μl plated in triplicate into wells of a flat-bottomed 96-well microtitre plate (Nunc, 
Thermo Scientific, UK). Samples were plated in duplicate at a volume of 40 μl at 1:10 
and 1:100 dilutions respectively. Using a multi-channel pipette, 200 μl of DMMB solution 
was added to all wells and plates were read immediately at 525 nm using the FLUOstar 
Omega microplate reader (BMG Labtech Ltd, Aylesbury, UK). From the standard curve 
the concentrations of total s-GAG in μg/ml were determined, and values were 
subsequently adjusted for explant wet weight (μg/ml per mg of cartilage). Samples 
outside the dynamic range (i.e. greater than 40 μg/ml) were adjusted for concentration 
accordingly and re-analysed.   
Figure 2.5 Principles of DMMB s-GAG detection assay  
Sulphated GAGs are cleaved from the aggrecan core protein by matrix-degrading 
enzymes such as MMPs and ADAMTSs, and released from the cartilage ECM into the 
surrounding culture media. The amount of s-GAG release can be detected using DMMB, 
a heterochromatic dye that rapidly changes colour upon binding to s-GAG. HA, 
hyaluronan; LP, link protein; KS, keratan sulphate; CS, chondroitin sulphate; G1, 2, 3, 
globular domains. 
S 
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2.1.5.3 Gelatin zymography 
Explant culture supernatants from ex vivo studies were analysed for MMP 
expression and activity using gelatin zymography (figure 2.6). The technique used was 
based upon a protocol devised by Leber and colleagues (Leber and Balkwill, 1997). 
Firstly, a 7.5% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) resolving gel 
containing 1 mg/ml gelatin was prepared (Table 2.2). Commercially-available premixed 
buffers were used whenever possible for ease of use and consistency. The gel mixture 
was mixed by pipetting to avoid the addition of oxygen (which inhibits the polymerisation 
process), before casting in a Bio-Rad mini-PROTEAN casting system (Bio-Rad 
Laboratories Ltd, Hertfordshire, UK). The resolving gel was overlaid with dH20, to ensure 
the interface between the stacking and resolving gels was smooth and level. Once the 
resolving gel had set, the water was poured away and a stacking gel (prepared as in 
Table 2.3) was overlaid and set using a 10-well comb insert to enable sample loading. 
This facilitates stacking of the samples and ensures they run evenly down the resolving 
gel (Schagger, 2006). 
 
 
Figure 2.6 Principles of gelatin zymography  
Samples are loaded onto an SDS-PAGE gel and proteins within the samples are 
separated on the basis of size by running through a resolving gel containing gelatin. Gels 
are washed in detergent to remove SDS, thus allowing enzyme renaturation, and a 
digestion buffer containing CaCl2 activates enzymes in the gel, enabling them to digest 
the gelatin embedded within the gel. Staining the gelatin with coomassie blue reveals 
areas of zymogen activity.  
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Table 2.2 Reagents and suppliers for 10 ml 7.5% gelatin SDS-PAGE resolving gel.  
Ingredient Volume  Supplier 
Acrylamide/bis-acrylamide 40% solution 
(cat no: A7168) 
1.875 ml Sigma-Aldrich Ltd, Dorset, 
UK 
4x Protogel resolving buffer (1.5 M Tris-
HCl, 0.4% (w/v) SDS, pH 8.8) (cat no: EC-
892) 
2.5 ml National Diagnostics UK, 
Yorkshire, UK 
dH2O 5.515 ml n/a 
50 mg/ml solution Type B gelatin from  
bovine skin, dissolved in dH2O (cat no: 
G9382) 
200 μl  Sigma-Aldrich Ltd, Dorset, 
UK 
10% Ammonium persulphate (APS), 
dissolved in dH2O (cat no: A3678) 
100 μl  Sigma-Aldrich Ltd, Dorset, 
UK 
N,N,N′,N′-Tetramethylethylenediamine 
(Temed) (cat no: T9381) 
10 μl Sigma-Aldrich Ltd, Dorset, 
UK 
 
Table 2.3 Reagents and suppliers for 5 ml 4% SDS-PAGE stacking gel 
Ingredient Volume Supplier 
Acrylamide/bis-acrylamide 40% solution  0.65 ml Sigma-Aldrich Ltd, Dorset, 
UK 
Protogel stacking buffer (0.5 M Tris-HCl, 
0.4% (w/v) SDS, pH 6.8 (cat no: EC-893) 
1.25 ml National Diagnostics UK, 
Yorkshire, UK 
dH2O 3.05 ml n/a 
10% Ammonium persulphate (APS)  25 μl Sigma-Aldrich Ltd, Dorset, 
UK 
N,N,N′,N′-Tetramethylethylenediamine 
(Temed) 
5 μl Sigma-Aldrich Ltd, Dorset, 
UK 
 
Cast gels were placed into the Mini-PROTEAN tetra electrophoresis module 
along with a 1X solution of running buffer comprising 25 mM Tris, 192 mM glycine, 0.1% 
(w/v) SDS, pH 8.3. Explant culture supernatants were thawed, and 10 μl of each sample 
was mixed with 5 μl of a non-reducing sample buffer containing 0.5 M Tris-HCl, 10% (v/v) 
glycerol, 10% SDS and 0.05% (w/v) bromophenol Blue (all from Sigma-Aldrich Ltd, 
Dorset, UK). The resulting mixtures were carefully loaded into wells of the stacking gel. 
The gels were run at 150 V and 20 mA per gel for 2 hours, or until the dye front had run 
to the bottom of the gel.  
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Gels were carefully removed from between the glass casting plates, and washed 
three times in 2.5% Triton X-100 solution (Sigma-Aldrich Ltd, Dorset, UK) for 15 minutes, 
to ensure the complete exchange of SDS with Triton X-100. Gels were then incubated 
for 18 hours at 37°C in a digestion buffer containing 100 mM CaCl2. Following this, gels 
were washed briefly in dH2O and stained for 1 hour in a solution containing 10% acetic 
acid, 45% methanol (Fisher Scientific) and 0.25% (w/v) Coomassie Brilliant Blue R (Cat 
no: B0149; Sigma-Aldrich). Finally, gels were destained in a solution of 10% acetic acid 
and 45% methanol, until clear bands were visible on a blue background (figure 2.7).  
Gels were scanned using the Kodak FX Pro Imaging system. UV epi-illumination 
images were taken against a white background, captured using an exposure time of 1 
second, F-stop 2.51. Images were analysed using the Carestream Molecular Imaging 
software v 5.3.2 (Carestream Health UK Ltd, Herts, UK). Band boundaries incorporated 
regions of pro and active MMP-2 or MMP-9. Background was corrected, and identified 
bands were quantified for net intensity. 
 
Figure 2.7 A representative gelatin zymogram  
A lane from a zymogram demonstrating a typical banding pattern revealed following 
digestion and staining of gelatin gels. The bands detected and their molecular weights 
are shown. Red squares indicate regions of interest used to determine total MMP-9 and 
MMP-2.  
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2.1.5.4 Histological assessment of PG depletion 
Fixed articular cartilage explants were placed into tissue processing/embedding 
cassettes (Simport Scientific, QC, Canada), sandwiched between foam pads to secure 
them within their cassettes, and processed overnight for histology (section 2.3.1). Full-
depth serial sections (7 μm thick) were cut so that all zones of the articular cartilage were 
evident, and stained with Safranin O/Fast green. 
Bovine cartilage explant sections were digitally scanned and examined for the 
degree of Safranin O staining retention. A percentage of PG loss was estimated from the 
proportion of Safranin O to Fast Green. Explant sections with full retention of Safranin O 
staining and no visible Fast Green staining were scored 0 % PG loss. Conversely, 
sections exhibiting no visible Safranin O staining were deemed to have complete (100%) 
PG loss (figure 2.8). Explant images were also analysed using the Leica QWin V3 digital 
processing software (Leica Microsystems Ltd, Bucks, UK). A macro program was 
designed to automatically detect regions of the image containing Safranin O staining 
(figure 2.9). The proportion of staining in the entire image was calculated as a 
percentage, and from this, PG loss was determined.  
 
 
Figure 2.8 Histological assessment of proteoglycan depletion  
Representative cartilage histological sections stained with Safranin O/Fast Green, 
exhibiting 0%, 50% and 100% proteoglycan loss. The rectangle indicates the region the 
of explant section studied for qualitative analysis, Scale bars indicate 500 μm. 
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Figure 2.9 Digital assessment of PG loss  
Imaging software was used to highlight regions containing staining of a certain hue (i), 
and the proportion of staining was determined within a defined region of interest (ii). 
Regions containing sub-chondral bone were excluded from the analyses. 
2.1.6 Cell viability assays 
In this thesis, two methods of determining cell viability were performed: the MTT 
assay and the LDH assay (see below). The MTT assay is a well-established technique 
that is widely used to analyse cell viability in monolayer culture (Cree et al., 2011). 
However, this method requires that all cells are lysed in order to quantify cytotoxicity, 
making it unsuitable for monitoring explant cell viability over time. Cell viability was 
therefore monitored in explants using the commercially-available LDH membrane 
integrity assay. In contrast to the MTT assay, the LDH assay measures leakage of 
components into the culture medium, making it applicable to longitudinal analyses of cell 
viability.  
2.1.6.1 MTT cell viability assay 
The MTT assay is based on the ability of mitochondrial dehydrogenase within 
living cells to cleave the tetrazolium rings of pale yellow thiazolyl blue tetrazolium 
bromide (MTT), to form purple formazan crystals (see figure 2.10). These crystals, 
impermeable to cell membranes, accumulate within healthy cells. Lysing cells with the 
addition of a detergent causes release and subsequent solubilisation of the formazan 
product. This colorimetric change can be used to determine the proportion of surviving 
cells within a culture dish. 
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Figure 2.10 The MTT viability assay  
Cells in a tissue culture dish convert pale yellow MTT into purple formazan crystals that 
accumulate within the cytoplasm. Non-viable cells do not create and accumulate 
formazan. Lysing the cells liberates the crystals, and the resulting formazan product is 
reflective of the proportion of viable cells within the culture dish. 
 
 
For the MTT assay, medium was removed from monolayer culture and replaced 
with 500 μl DMEM containing 1 mg/ml thiazolyl blue tetrazolium bromide (MTT; Cat no 
M2128; Sigma UK). Cells were incubated for 4 hours at 37°C, 5% CO2 to allow the MTT 
to be incorporated into cells and converted to formazan. Medium was removed and 
tissue culture plates were blotted onto tissue to remove excess MTT solution. Cells were 
lysed by the addition of 500 μl DMSO to each well. The resulting solutions were mixed 
thoroughly and added in duplicate to a flat-bottomed 96-well microtitre plate (100 μl per 
well) and the plate was read at 540/570 nm. A 100 μl aliquot of DMSO served as a blank 
control. Every OD value obtained was calculated relative to an untreated control well.  
2.1.6.2 LDH membrane integrity assay 
Cell viability is often defined based on the integrity of the cell membrane; 
therefore the measurement of leakage of components from the cytoplasm into the 
surrounding culture medium is a widely-accepted method for estimating viability. The 
CytoTox-ONE™ Homogenous Membrane integrity assay (Cat no: G7890; Promega UK, 
Southampton, UK) is a well-established method for measuring the release of LDH from 
damaged cells within the cartilage ECM. LDH is readily released from chondrocytes 
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(Peters et al., 2011), and its enzymatic activity is such that its conversion of lactate to 
pyruvate can be easily coupled with the generation of a fluorescent product called 
resofurin (figure 2.11). This technique has been successfully applied to cartilage explants 
in previous studies (Ailland et al., 2003, Hoffler et al., 2006, Devkota and Weinhold, 
2010). 
The assay was performed as per manufacturer’s instructions. Prior to the assay, 
explant culture supernatants to be tested were thawed and equilibrated to room 
temperature. A reagent mix was prepared by the addition of 11 ml of a supplied assay 
buffer to a lyophilised substrate mix. The resulting CytoTox-ONE™ reagent mix was left 
to equilibrate to room temperature. Test samples (100 μl per well) were added in 
duplicate to wells of an opaque-walled 96-well plate. In addition to test samples, the 
following controls were added in triplicate:  a medium control (containing DMEM:F12 
only) and a maximum LDH release control. For explants, maximum LDH control samples 
were made by the addition of a lysis solution (9% (w/v) Triton™ X-100 in dH2O) to 
explants in culture medium. Explants were incubated for 48 hours, before supernatants 
were removed and stored at -20°C for use in the LDH assay. For LDH analyses of cell 
monolayer cultures, the lysis solution was added to cells and left for 5 minutes, or until 
all cells had been lysed and had released the maximal potential amount of LDH into the 
surrounding culture medium.  
Once all controls and samples had been plated, an equal volume of CytoTox-
ONE™ reagent mix was added to each well, and the plate was protected from light and 
left to shake at 500 rpm for 10 minutes at room temperature. At the end of the incubation 
period, 50 μl of a supplied stop solution was added to each well, as recommended within 
the protocol to ensure consistency. Finally, fluorescence was measured using a 
FLUOstar Optima fluorescent plate reader (BMG Labtech Ltd, Aylesbury, UK) with 
excitation wavelength 560 nm and an emission wavelength of 590 nm. The average 
fluorescence values (rfu) of the background (culture medium) were subtracted from all 
the fluorescence values of the experimental and maximum LDH wells. From the resulting 
fluorescence readings, the percent cytotoxicity for each given treatment was determined 
as follows: 
Percent cytoxicity = 100 x (Experimental sample / Maximum LDH release) 
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Figure 2.11 Principles of LDH membrane integrity assay  
Schematic demonstrating how LDH released from damaged/leaky cells reacts with the 
substrates lactate, NAD+ and resazurin in the presence of the oxidoreductase enzyme 
diaphorase. The generation of the fluorescent product resofurin is proportional to the 
amount of LDH.  
 
 
2.2 In vivo experiments 
2.2.1 Collagen-induced arthritis 
Experimental arthritis was performed in accordance with the Home Office 
approved project licence (PPL-30/2361). Aged 7-8 week old DBA-1 mice were 
immunised intradermally (i.d.) at day 0 with 100 μl 1 mg/ml of type II collagen from chick 
sternal cartilage (Sigma-Aldrich Ltd, Dorset, UK) dissolved overnight in 10 mM acetic 
acid and emulsified in Freund’s complete adjuvant (FCA). FCA was made by grinding 
100 mg Mycobacterium Tuberculosis H37Ra (BD Biosciences, Oxford, UK) to a fine 
powder using a pestle and mortar, and mixing with a 10 ml vial of Freund’s incomplete 
adjuvant (Sigma-Aldrich Ltd, Dorset, UK). Once prepared, 2.5 ml of the FCA was 
combined with 2.5 ml of the dissolved collagen and mixed until an emulsion was formed. 
Once induced, the immune response to collagen was boosted 21 days later (day 21) with 
a second intradermal injection of type II collagen in FCA. If no clinical signs of arthritis 
were observed by day 25, animals were each given a single intra-peritoneal (i.p.) 
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injection of 20 g LPS dissolved in 100 l of PBS to potentiate the onset of disease 
(Caccese et al., 1992), as outlined in the project licence. Experiments were performed 
using 3-10 mice per study. Limbs were removed for analyses and either placed in fixative 
(for use in histology), or snap-frozen on dry ice and stored at -80oC (for use in quantitative 
PCR). In one experiment blood was taken for sera analyses (see section 2.2.1.4). 
2.2.1.1 Clinical score and paw diameter 
Animals were observed at least twice a week from day 21 for the development or 
arthritis. Arthritis was scored in each animal in a blinded manner using an established 
subjective clinical score: 0, normal; 1, mild/moderate erythema and swelling; 2, severe 
erythema and swelling affecting entire paw or joint; 3, up to three joints affected by 
arthritis; 4, greater than three joints affected by arthritis; 5, deformed paw or joint with 
ankylosis. Each paw was graded 0-5 and the total score for each mouse determined to 
give the clinical score. Any animal with a paw score of 5 in any one paw or a combined 
clinical score exceeding 14 was removed from the experiment and humanely killed, as 
outlined within the project licence. Hind paw ankle swelling was measured using a 
modified POCO 2T spring caliper gauge (Kroeplin Längenmesstechnik, Germany). In 
addition to clinical score and paw diameter, individual weights of the animals were 
monitored. Animals exhibiting >20% weight loss in two consecutive weigh-ins (compared 
to weight at the onset of arthritis) were removed from the experiment and humanely 
sacrificed.  
2.2.1.2 Radiology 
High power x-ray images of hind and front paws were carried out using a Kodak 
FX Pro in vivo imaging system and Kodak Molecular Imaging software. Images were 
captured using an exposure time of 60 seconds at 35KVP, f-stop 4, Field of view (FOV) 
80 mm. Radiological damage was scored in each limb in a blinded manner, based on a 
comprehensive scoring system validated by both a clinical Rheumatologist and an 
Orthopaedic Registrar (Smale et al, unpublished). In the forefoot, 2nd-4th proximal 
interphalangeal joints (PIPs) were scored for visible soft tissue swelling, based on the 
ratio of soft tissue to bone (scored 0-2 per joint, figure 2.12A[i]). The 1st-5th MCPs were 
assessed for erosion, osteopenia and periosteal reaction, and each scored 0 (no 
evidence) or 1 (evidence) for each parameter (figure 2.12A[ii]). The base of the 1st 
metatarsal in the hind paw (figure 2.12A[iii]) and the 5th metatarsal in the fore paw (figure 
2.13B[i]) were scored for erosion, osteopenia and periosteal reaction, with each 
parameter scoring 0 (no evidence) or 1 (evidence). In the midfoot the 2nd distal tarsal 
(hind paw, figure 2.12A[iv]) or the 3rd distal tarsal (front paw, figure 2.12B[ii]) were scored 
for joint space loss and osteopenia, with each parameter scoring 0 (no evidence) or 1 
(evidence). Finally, in the hindfoot hind paws were scored for joint space loss between 
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the fibulare and 4th and 5th distal tarsals and intermedium and centrale (figure 2.12A[v]). 
The front paws were scored similarly for joint space loss between the radial epiphysis 
and fused radiale and intermedium (figure 2.12B[iii]). The bones surrounding each of 
these joint lines were also scored for osteopenia. Each parameter was scored 0 (no 
evidence) or 1 (evidence). The maximum total radiology score obtainable with the above 
system is 30 and 28 for hind and front paws, respectively. 
 
 
Figure 2.12 High power radiographic images 
X-ray of a hind paw (A) and a front paw (B) from an arthritic animal, with the main features 
used for scoring indicated. A: [i] Proximal interphalangeal joints, showing how the extent 
of soft tissue swelling is determined; [ii] The 4th metacarpophalangeal joint; [iii] The base 
of the 1st metatarsal; [iv] The 2nd distal tarsal and [v] The loss of joint space between the 
fibulare and 4th and 5th distal tarsals and intermedium and centrale. B: [i] The base of the 
5th metatarsal; [ii] The 3rd distal tarsal; [iii] Radial epiphysis and fused radiale and 
intermedium. 
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2.2.1.3 Histopathology 
The bases of the hind limbs were slit with a scalpel blade prior to tissue 
processing, to aid in the penetration of fixative. Limbs were then placed in tissue 
processing/embedding cassettes (Simport Scientific, QC, Canada), fixed in neutral 
formal buffered saline (NFBS) and decalcified with formic acid at 4˚C for 48 hours. An X-
ray was performed on joints as in section 2.2.1.2 to determine whether tissue was 
completely decalcified. Tissue was then processed as described in section 2.3.1 before 
processing the tissue overnight. Mid-coronal serial sections (7 μm thickness) were 
sectioned and stained with Safranin-O/Fast Green (section 2.3.1). 
Histology sections were scored according to an adaptation of an established 
scoring method (Nowell et al., 2003). Firstly, inflammatory cells within the synovial tissue 
were scored as follows: 0, normal adipose tissue with no inflammatory infiltrate; 1, focal 
inflammatory infiltrate and adiposity hardly affected; 2, random inflammatory infiltrate 
equalling adiposity; 3, inflammatory infiltrate dominating the tissue; 4, substantial 
infiltrate with severe loss of adiposity; 5, ablation of adiposity due to infiltrate (figure 
2.13A). Secondly, synovial exudate was scored as follows: 0, normal; 1, evidence of 
inflammatory cells in space; 2, moderate numbers of inflammatory cells in space, 
possibly evidence of fibrin deposits; 3, substantial numbers of inflammatory cells with 
large fibrin deposits (figure 2.13B). Finally, articular cartilage/subchondral bone erosion 
was scored as follows: 0, no cartilage erosion and retention of Safranin O staining; 1, 
some loss of Safranin O staining from superficial zone of cartilage; 2, substantial loss of 
Safranin O staining and some erosion; 3, extensive loss of Safranin O staining with 
severe erosion (figure 2.13C). Forefoot histology (comprising the MCP joints) and 
mid/hindfoot histology (including the bones of the midfoot) were scored separately, and 
the mean scores calculated for each parameter. The maximum total histology score 
available is 11. 
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Figure 2.13 Histology scoring system  
A) Representative Scanscope images of hind paw histological sections, showing the 
progression of infiltrate score from 0-5. Forefoot and hindfoot regions were scored 
separately. B) High power images of joints of the midfoot, showing progress of extent of 
synovial exudate, from 0-3. [i] joint space; [ii] cartilage; [ii] sub-chondral bone; [iv] 
evidence of synovial exudate in the joint space. C) High power images demonstrating 
the progression of joint erosion from 0-3. [v] proteoglycan loss from cartilage; [vi] 
evidence of cartilage erosion. 
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2.2.1.4 Serum analysis 
Sera samples taken from mice were tested by ELISA for the presence of 
collagen type II (CII)-specific IgG2a, a marker of the antibody response to 
collagen. All blood sampling was taken when animals were sedated under 
anaesthetic nose cone. Approximately 100 μl of blood was taken from mice by 
removing less than 5mm of the tail tip using a sterile surgical scalpel blade. If 
blood was to be retaken, the blood clot formed from the previous tail tip bleed was 
removed. Blood was collected using a Microvette® CB 300 capillary tube 
(Sarstedt Ltd, Leicester, UK). Blood collected in capillary tubes was left at room 
temperature to clot and centrifuged for 10,000 x g for 5 minutes, or until the serum 
was separated from the plasma. Sera were aliquoted into sterile 1.5 ml 
microcentrifuge tubes and stored at -70°C until needed. 
An ELISA was carried out as in section 2.1.3, with the following 
modifications. A 96-well Immulon 4HBX flat-bottomed microtitre plate (Fisher 
Scientific, UK) was coated with 5 g/ml solution of chick type II collagen (dissolved 
in acetic acid) in PBS overnight at 4ºC, and blocked with 5% (w/v) bovine serum 
albumin (BSA) in PBS at room temperature for 1 hour. Mouse serum was diluted 
in 1% (w/v) BSA in PBS serially diluted down the plate (dilution range: 1:20 to 
1:2560), and incubated for 2 hours at room temperature. CII-IgG2a was detected 
with 0.25 µg/ml biotin-conjugated rat anti-mouse IgG2a (Southern Biotech, 
Alabama, US) in 1% (w/v) BSA in PBS and incubated for 2 hours at room 
temperature followed by Ready to Use Streptavidin-HRP (Vector Laboratories 
Ltd, Peterborough, UK) for 30 minutes and SureBlue™ TMB (Insight 
Biotechnology Ltd, UK). The substrate reaction was stopped with 2M H2SO4 and 
when a colorimetric change was detected, absorbances were read at OD450nm 
using a FLUOstar Optima plate reader (BMG Labtech Ltd, Aylesbury, UK).  
2.2.2 In vivo imaging with MMPSense fluorescent probes  
To monitor MMP activity in vivo, animals with established disease were 
injected with protease activatable fluorescent in vivo imaging agents; 
MMPSense680 or MMPSense750. MMPSense680 works by enzymatic cleavage 
of the peptide fluor from its quencher, resulting in fluorescence (figure 2.14). 
MMPSense750 FAST is similar, but contains a pharmacokinetic modifier 
designed to effect rapid accumulation and activation in target tissues (figure 2.14) 
which, according to the manufacturer, confers an improved pharmacokinetic 
profile and earlier imaging time points than MMPSense680 (Groves et al., 2010). 
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The MMPSense agents (Perkin Elmer, MA) are activated by a number of MMPs 
including MMP-2, -3, -9 and -13 (see figure 2.15 for activation profiles).  
 
 
Figure 2.14 MMPSense680 and MMPSense750 FAST probe activation 
 Schematic showing how MMPSense probes are activated. MMPSense680 
consists of a poly-L-lysine backbone to which methoxy polyethylene glycols 
(mPEGs) are attached for reduced immunogenicity and increased half-life. The 
peptide sequence (GPLGVRGKC) used to link the autoquenched fluorochromes 
(pink circles) to the backbone molecule is cleaved by a panel of MMPs, resulting 
in the activation of fluorochromes (orange circles). MMPSense750 is activated in 
a similar fashion, but cleavage specificity is conferred by the peptide sequence 
PLGVR. The backbone contains an unspecified pharmacokinetic modifier (PKM) 
and has a lower molecular weight than MMPSense680, allowing MMPSense750 
FAST to rapidly accumulate and fluoresce in tissue.
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Figure 2.15 Biochemical profile of the activatable MMPSense agents 
Fold activation of A) MMPSense680 and B) MMPSense750 FAST fluorescence 
produced as a result of cleavage by different MMPs in vitro. Fold activation was 
determined by dividing the fluorescence released after complete cleavage with 
the enzyme to the fluorescence of the probe only. Images adapted from (Kossodo 
et al., 2010) and (Groves et al., 2010). 
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2.2.2.1 Preparation and administration of fluorescent probes  
The MMPSense680 preparation comprised a solution of 20 nmol in 1.5 ml PBS. 
MMPSense750 FAST was delivered in a dry solid form, and was reconstituted with PBS 
to make a 7 nM solution. Upon reconstitution the vial was protected from light and stored 
at 4°C until further use, for up to 10 days. 
The imaging agents were left to equilibrate at room temperature prior to use. In 
preparation for i.v. injections, animals were placed in a warming chamber at 37°C for 15-
20 minutes to dilate the tail veins. Mice were then anaesthetised using the inhalational 
agent isoflurane, and were placed in a restraining device whilst under anaesthetic nose 
cone. Once the imaging agent was ready, it was loaded into a Monoject™ 29 gauge 
Insulin syringe (Covidien, MA). These syringes were used to ensure less of the probe 
solution was lost within the syringe (i.e. less “dead space”). Animals were injected i.v. 
with 2 nmol of the probe solution, the recommended dose for an adult (~25 gram) mouse. 
Immediately post-injection, the mice were placed back into the warming chamber until 
they had recovered from the anaesthesia and showed no signs of distress. 
2.2.2.2 MMPSense680 imaging and region of interest analysis 
For MMPSense680 imaging, mice were anaesthetised and imaged in the prone 
position, 24 hours post-injection using the Kodak FX Pro in vivo Imaging system. Animals 
were imaged every 24 hours thereafter until the experimental end-point. Fluorescent 
images were captured using an exposure time of 30 seconds at excitation 630 nm, 
emission 700 nm, f-stop 4. Radiographic images of the animals were captured using an 
exposure time of 30 seconds at 35KVP, f-stop 4, and field of view 11.7 cm.  
Analysis of MMPSense680 fluorescent images was carried out using KODAK 
software version 5.0.0.40 (Carestream Health UK Ltd, Herts, UK). The fluorescent signal 
was converted to a pseudocolour scale and overlaid onto the radiographic image (figure 
2.16). Regions of interest (i.e. areas showing high levels of fluorescent intensity) were 
highlighted using a free form region of interest (ROI) analysis tool (figure 2.16), and the 
net intensity of fluorescence was calculated for all individual limbs using the Kodak 
Molecular Imaging software. The net intensity is the sum of the background-subtracted 
pixel values within the ROI. This parameter was chosen for ROI analyses because it was 
the only parameter that corrected for ROI area size, allowing the signal intensity of front 
paws to be compared alongside hind paws.   
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Figure 2.16 ROI analysis with the Kodak molecular imaging software  
Panel showing an X-ray image of a hind paw, and its corresponding fluorescence image. 
Areas of high fluorescence were isolated with a free-form tool (blue line) and analysed 
for net fluorescence intensity. A pseudocolour overlay image could be obtained to 
visualise localisation and intensity of fluorescence. 
 
 
2.2.2.3 MMPSense750 FAST imaging and region of interest analysis  
For imaging MMPSense750 FAST, mice were anaesthetised and imaged in the 
prone position using the Xenogen IVIS 200 (Caliper Life Sciences, Runcorn, UK). This 
machine was used, to accommodate the emission and excitation filters required for the 
MMPSense750 imaging probe. Animals were imaged every 24 hours thereafter until the 
experimental end-point. Fluorescent images were captured using an exposure time of 1 
second at excitation 750 nm, emission 810 nm, f-stop 1, field of view 13.2 cm.  
Analysis of fluorescent images obtained was carried out using Living Image® 
2.50.2 software (Caliper Life Sciences Ltd, Cheshire, UK). Rectangular ROIs of a fixed 
dimension (front paws: w=1.1 x h=1.1 cm, hind paws: w= 1.9 x h=1.1 cm) were selected 
and fluorescent efficiency quantified for each ROI. Fluorescence efficiency is a display 
of the fluorescence emission range normalised to the incident excitation intensity. This 
eliminates the variable excitation light from the measurement, enabling a more 
quantitative comparison of fluorescence signal.  
2.2.3 Subcutaneous administration of APO866 via minipump  
In this study, animals were treated with APO866 by continual infusion by osmotic 
minipump 20 days post disease initiation. Preliminary studies within the group showed 
that the APO866 applied in this manner up to 0.08 mg/kg/h was a well-tolerated dose 
with no adverse effects on mice (figure 2.17). The range of doses chosen was based on 
the maximum tolerated dose in humans (0.126 mg/m2/h) (Holen et al., 2008). The 
  72 
equivalent dose in mice was calculated as 0.04 mg/kg/h, determined using an 
established dose translation formula (Reagan-Shaw et al., 2008). Alzet 1002 mini-
osmotic pumps (Durect Corp, CA) were chosen for APO866 administration, as they 
allowed for a continuous infusion of APO866 at a rate of 0.25 μl/h for up to 14 days (figure 
2.18).  
2.2.3.1 Minipump Filling and Priming 
Preparation of minipumps was carried out in a Class II tissue culture cabinet 
under aseptic conditions. The APO866 treatment solution was prepared by mixing 64 l 
APO866 with 36 l sterile saline per animal, vortexing well and loading 100 l of the 
resulting solution into each minipump using a blunt-tipped 27 gauge filling tube (supplied 
with the minipump), ensuring that no air bubbles were introduced into the reservoir.  The 
vehicle treatment solution (propylene glycol in saline) was prepared and loaded the same 
way. The minipump flow moderators were replaced and the filled pumps were primed in 
saline at 37 °C overnight to allow them to begin operation prior to implantation.   
2.2.3.2 Minipump implantation 
Pre-primed minipumps were implanted subcutaneously posterior to the scapulae 
of experimental animals. Implantation was carried out under complete aseptic conditions 
with autoclaved dissection instruments, including scissors, two hemostats and fine 
forceps. For subcutaneous placement, mice under anaesthesia were shaved and the 
implantation site was sterilised with povidone-iodine solution. Using fine scissors, a small 
incision was made in the skin between the scapulae, and a hemostat was used to spread 
the subcutaneous connective tissues apart, forming a small pocket. The pump was 
inserted into the pocket with the flow moderator pointing away from the incision. The skin 
incision was then closed up using fine forceps, hemostats and three to four sutures. All 
instruments were sprayed with 70% ethanol between procedures. Animals were placed 
into a warming chamber onto vet bedding immediately after the implantation procedure, 
and observed regularly to ensure sufficient recovery from the procedure.  
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Figure 2.17 CIA clinical scores from preliminary minipump studies  
In a previous study by Mari Nowell, DBA-1 mice (n=4 animals per group) were treated 
prior to the onset of disease with minipumps containing 0-0.08 mg/kg/h APO866. Data 
points represent the mean combined clinical scores of animals in each treatment group. 
T=treatment initiation at 20 days post induction.  
 
Figure 2.18 Cross section of an osmotic minipump  
Image taken from the Alzet® resources web page 
(http://www.alzet.com/resources/index.html). 
Semipermeable  
membrane 
Osmotic layer 
Impermeable 
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Flow moderator 
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2.3 General Tissue processing methods 
2.3.1 Histology  
2.3.1.1 Processing into wax 
Unless otherwise stated, all stains and reagents used for histological analyses 
were purchased from Sigma-Aldrich Ltd, Dorset, UK. Tissue was processed into wax 
using a Thermo Shandon Citadel 2000. This machine dehydrates samples by 
transferring them through baths of progressively more concentrated ethanol, followed by 
replacement with xylene, before impregnation in paraffin wax at 60°C to facilitate 
sectioning. Tissue was embedded in paraffin blocks, using a Shandon Histocenter, and 
7 μm sections taken using a Surgipath Microtome. Sections were mounted onto 
HistoBond® adhesion slides (VWR International Ltd, West Sussex, UK), and excess wax 
removed by overnight incubation at 60°C.   
2.3.1.2 Safranin-O Fast Green section staining 
Mounted sections were dewaxed in xylene and rehydrated through a descending 
gradient of industrial methylated spirits (100%, 90%, 70% IMS) to water. Tissue sections 
were then stained in 0.02% (w/v) aqueous fast green for 3 minutes, washed briefly in 1% 
(v/v) acetic acid and stained in 0.1% (w/v) aqueous Safranin O for 5 minutes. Sections 
were then dehydrated and mounted with coverslips using DPX mountant (Sigma-Aldrich 
Ltd, Dorset, UK). Slides were scanned using an Aperio Scanscope CS system and 
images acquired using ImageScope imaging software.  
2.3.2 Real-time quantitative PCR analyses 
2.3.2.1 Ribonucleic acid (RNA) preparation 
Whole joint RNA was prepared from murine front paws by grinding under liquid 
nitrogen using a pestle and mortar. The ground tissue was rapidly transferred to cooled 
microcentrifuge tubes and kept on dry ice. For each individual paw, 1 ml of TRI Reagent 
was added to the tissue and each mixture transferred to a Qiashredder (Qiagen Ltd, 
West Sussex, UK) and centrifuged for 17,000 x g for 2 minutes to filter out any insoluble 
debris and reduce the viscosity of the homogenate. For cell monolayer cultures, cells 
were lysed directly on the tissue culture plates by the addition of TRI reagent (1 ml per 
10 cm2 of plate surface area). All cell/tissue homogenates were transferred to 1.5 ml 
microcentrifuge tubes for RNA extraction.  
RNA was extracted from cell/tissue homogenates as recommended in the TRI 
Reagent manufacturer’s protocol. Firstly, each homogenate was incubated at room 
temperature for 5 minutes for the complete dissociation of nucleoprotein complexes. 
Then 0.2 ml of chloroform was added to each 1 ml sample, tubes were shaken for 15 
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seconds and incubated at room temperature for a further 3 minutes. For phase 
separation, the samples were centrifuged at 12,000 x g for 15 minutes at 2-8°C. 
Centrifugation caused samples to separate into three distinct phases: a lower red, 
phenol-chloroform phase, an interphase, and a colourless upper aqueous phase. The 
RNA-containing aqueous phase was transferred to a fresh tube, and mixed with 0.5 ml 
of isopropyl alcohol to precipitate the RNA. Samples were incubated for 10 minutes at 
room temperature before centrifugation at 12,000 x g for 10 minutes at 2-8°C. The RNA 
pellets were then washed by adding 1 ml of 75% ethanol and centrifuged at 7500 x g for 
5 minutes at 2-8°C. The pellets were air-dried and each re-dissolved in 20 μl of RNase-
free water. Finally, samples were heated to 55°C for 10 minutes to ensure the complete 
dissolution of RNA. RNA concentration was determined by measurement of the optical 
density at 260 and 280 nm using a NanoDrop-1000 spectrophotometer (Fisher Thermo, 
USA). A selection of samples was run in an Agilent 2100 Bioanalyzer (Agilent 
Technologies Ltd, Berkshire, UK), for quantification and quality control of the extracted 
RNA samples.  
Total RNA from each sample was DNase-treated using RQ1 RNase-Free DNase 
(Promega UK, Southampton, UK). A digestion reaction was set up for each sample 
containing 3 μg total RNA, RQ1 RNase-free DNase 10X reaction buffer, and RQ1 
RNase-Free DNase (1 unit/g of total RNA), to a total volume of 10 μl. Sample tubes 
were incubated at 37˚C for 30 minutes, before the addition of 1 l of RQ1 DNase Stop 
solution to terminate the reaction, followed by incubation at 65˚C for 10 minutes to 
inactivate the DNase enzyme. DNase-treated RNA was immediately reverse transcribed 
into cDNA, or stored at -80°C until needed. 
2.3.2.2 Complementary DNA (cDNA) synthesis 
DNase-treated RNA samples were reverse transcribed into cDNA using a 
Precision nanoScript™ Reverse Transcription kit (PrimerDesign Ltd, Southampton, UK).  
For each sample, 2 μg of RNA template was added to a sterile RNase-free 
microcentrifuge tube along with 1 μl of a 1:1 mixture of Oligo-dT and random nonamer 
primers, and RNase/DNase-free water to a final volume of 10 μl. This priming strategy 
was used for optimum cDNA yield (Primerdesign, 2011). Samples were heated to 65˚C 
for 5 minutes to melt the secondary structure within the template and allow primers to 
anneal, and then immediately cooled in an ice water bath to prevent secondary structures 
reforming. Next, a reaction mix containing the following components was added to each 
of the annealed primer/templates: 2 μl nanoScript 10X buffer, 1 μl 10 mM dNTP mix, 2 
μl 100 mM DTT, 4 μl RNase/DNase-free water and 1 μl nanoScript RT enzyme (enzyme 
units not disclosed). A separate reaction tube was set up containing an additional 1 μl of 
water in place of the nanoScript enzyme as a “minus RT” control.  Samples were mixed 
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by briefly vortexing followed by a pulse spin, and incubated at room temperature for 5 
minutes before incubating at 55˚C for 20 minutes for the reverse transcription reaction to 
occur. Finally, the reaction was heat inactivated by incubation at 75˚C for 15 minutes. 
The cDNA samples were stored at -20°C until further use. 
2.3.2.3 Primer design and synthesis 
Most primer assays used in quantitative real-time polymerase chain reactions 
(qPCR) were SYBR green based detection assays; with the exception of murine MMP-
3 and MMP-13, which were TaqMan® primer/probed based assays (purchased from 
Applied Biosystems). Details of murine and human primers used in this thesis are listed 
in Tables 2.4 and 2.5, respectively. With the exception of SIRT1, all SYBR green primer 
assays were designed and synthesised by Primerdesign Ltd, and upon arrival were 
reconstituted with RNase/DNase-free water and stored at -80°C. The SIRT1 gene was 
designed in- house by the following method. Firstly, the target gene was studied in the 
ENSEMBL genome browser (http://www.ensembl.org/index.html) for details of 
alternative transcripts/splice variants. Primers were targeted specifically against the 
gene of interest, and when possible primers were designed to span exon-exon junctions, 
to avoid amplification of contaminating genomic DNA in cDNA samples. Primers were 
designed using open-source software, Primer3 version 0.4.0. (http://frodo.wi.mit.edu/). 
The source sequence for the gene of interest was pasted into the input box, and square 
brackets were used to highlight preferred regions for the primers to target. Primer product 
sizes were limited to 50-150 bases in length, as shorter amplicons allow for faster more 
efficient reactions, and increased consistency of results (Rozen and Skaletsky, 2000). 
The Primer3 search was run and the output contained numerous forward and reverse 
primer pairs. Candidate primer pairs were entered into Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), to check the specificity of primers 
against a library of genomic DNA sequences. Finally, the Sigma-Aldrich DNA Calculator 
(http://www.sigma-genosys.com/calc/DNACalc.asp) was used to determine if the chosen 
primers were likely to form secondary structures, or 3’ self-complementary primer-
dimers. Custom oligonucleotides were purchased from Sigma-Aldrich UK and were 
reconstituted in RNase/DNase-free water to a stock concentration of 100 μM. From this 
stock, aliquots containing a mixture of forward and reverse primers (6 μM each) were 
made ready for use in qPCR reactions. 
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Table 2.4 Gene names and sequences of murine primers used in real-time PCR reactions 
Primer and 
primer type 
Gene name Gene symbol Sequence accession 
number 
Primer Sequences Amplicon 
length 
MMP-1a 
(SYBR 
green) 
Mus musculus matrix 
metallo-peptidase 1a 
(Interstitial collagenase 1) 
Mmp1a NM_032006 Sense-
TAAACTACACACCATATTT
GCCAAA 
Antisense-
CAATATCGCCTTCCTCCTC
AAA 
123 
MMP-3 
(TaqMan®) 
Mus musculus matrix 
metallo-peptidase 3 
(Stromelysin) 
Mmp3 NM_010809 Not disclosed N.D. 
MMP-9 
(SYBR 
green) 
Mus musculus matrix 
metallo-peptidase 9 (type 
IV collagenase) 
Mmp9 NM_013599 Sense-
TGATGCTATTGCTGAGATC
CAG 
Antisense-
CCTGTAATGGGCTTCCTCT
ATG 
92 
MMP-13 
(TaqMan®) 
Mus musculus matrix 
metallo-peptidase 13 
(Interstitial collagenase 3) 
Mmp13 NM_008607 Not disclosed N.D. 
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Table 2.5 Gene names and sequences of human primers used in real-time PCR reactions 
Primer Gene name Gene symbol Sequence 
accession 
number 
Primer sequences Amplicon 
length 
NAPRT Homo sapiens nicotinate 
phosphoribosyltransferase 
NAPRT1 NM_145201 Sense- GTGGTGCTGTCCGAGAGG 
Antisense- 
GGAAAAGTGAGTGATTCGTGTTG 
111 
NAMPT Homo sapiens nicotinamide 
phosphoribosyltransferase 
NAMPT NM_005746 Sense- TTCCCACTACTCCAGCCTAAG 
Antisense- 
TTTGTGTAAAGGGCAGGTTAATAAA 
94 
IDO Homo sapiens indoleamine 2,3-
dioxygenase 
IDO1 NM_002164 Sense-CAGTCCGTGAGTTTGTCCTTT 
Antisense- 
CAGGAATCAGGATGTACTTAGTCA 
129 
QPRT Homo sapiens quinolinate 
phosphoribosyltransferase 
QPRT NM_014298 Sense- CCCCAGCCCTTGATTTCTCC 
Antisense- 
GGTGTCATCCTCTTCCGGTTTA 
93 
MMP-1 Homo sapiens matrix metallopeptidase 
1 (interstitial collagenase) 
MMP1 NM_002421 Sense- 
GCACTGAGAAAGAAGACAAAGG 
Antisense- 
CTAAGTCCACATCTTGCTCTTG 
127 
MMP-3 Homo sapiens matrix metallopeptidase 
3 (Stromelysin 1, progelatinase) 
MMP3 NM_002422 Sense-
ATCATGAACAATGGACAAAGGATAC 
Antisense- 
AGTGTTGGCTGAGTGAAAGAG 
101 
 SIRT1 Homo sapiens sirtuin 1, transcript 
variant 1 
SIRT1 NM_012238 Sense- CCGGATTTGAAGAATGTTGG 
Antisense- 
AGCGCCATGGAAAATGTAAC 
174 
  79 
2.3.2.4 qPCR 
qPCR was performed with the ABI Prism 7900HT instrument (Applied 
Biosystems, Life Technologies Ltd, Paisley, UK). Each qPCR reaction consisted of the 
following: 1 μl primer or primer/probe mix (working concentration 300 nM in a 20 μl 
reaction), 10 l PrimerDesign 2X PrecisionTM Mastermix (PrimerDesign Ltd, 
Southampton, UK), 4 μl RNase/DNase-free water and 5 μl (5 ng/ μl) cDNA template. Of 
this mix, 15 μl was pipetted into each well of a MicroAmp® Optical 96-well Reaction Plate 
(Applied Biosystems, Life Technologies Ltd, Paisley, UK) according to the plate set up. 
Finally, 5 μl of cDNA diluted to a concentration of 5 ng/ml (based on the concentration of 
RNA used in the reaction) was added to wells according to the experimental plate set 
up. The plate was sealed using MicroAmp® adhesion film and centrifuged at 12,000 x g 
for 1 minute to bring contents to the bottom of the wells. The plate was placed into the 
7900HT Fast Real-Time PCR System and Sequence Detection System Software (SDS 
version 2.3; Applied Biosystems) was used to set the required cycling conditions and 
detectors for each reaction plate.  
All reactions were performed under the following cycling conditions: an enzyme 
activation step at 95˚C for 10 minutes, followed by 50 cycles of 95˚C for 15 seconds 
(denaturation step) and 60˚C for 60 seconds (data collection step). As SYBR green binds 
non-specifically to all double-stranded DNA sequences, an additional dissociation step 
analysis was performed to determine the specificity of the primers and detect the 
presence of any primer dimers. This involved heating samples to 95˚C for 15 seconds, 
cooling to 65˚C for 15 seconds, before a slow ramp to 95˚C. At a specific melting point 
(Tm), the amplicons dissociated causing the release of the SYBR green fluorophore. The 
resulting change in fluorescence was plotted as a derivative dissociation curve of rate of 
change as a function of temperature (for example see figure 2.19). Fluorogenic data 
were collected through the FAM and SYBR channels for TaqMan® and SYBR green 
probes respectively. Assays were performed in duplicate, and the following control wells 
were included: -RT control (wells where the equivalent concentration is added minus the 
reverse transcription step) and a –cDNA control (wells where the cDNA is replaced with 
RNase/DNase-free water). 
Upon completion of the real-time PCR run, the resulting data were saved as a 
.SDS file. For SYBR green runs, the SDS v2.3 software was used to determine the 
threshold value (CT) from the resulting amplification plots of the different primers.  The 
CT value is the fractional cycle number at which the fluorescence passes the threshold. 
The threshold level was set to be above the baseline, but sufficiently low to be within the 
exponential growth region of the amplification curve.  For TaqMan® reactions, RQ 
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Manager Version 1.2.1 was used to set the thresholds and determine CT values of 
TaqMan® primer/probe amplification plots. Once the CT values for both, the reference 
gene(s) and gene(s) of interest, had been determined, the resulting data were exported 
as a Microsoft Excel spreadsheet (.xls) file for further analysis (see section 2.3.2.6). 
 
 
 
Figure 2.19 Dissociation curve of SYBR green amplicon  
Using SDS v2.3 software, a dissociation curve of change in fluorescence (expressed as 
a derivative) was plotted against temperature. In this graph the specific primer product 
has a Tm of 82.5°C. A second smaller peak has a Tm of 75°C characteristic of a primer 
dimer. Any samples containing primer dimers were omitted from the analysis, as they 
were likely to contain low copy numbers of the target gene. If primer dimer formation 
proved a persistent problem, then redesigning the primer was necessary. Image adapted 
from SDS software output. 
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2.3.2.5 Reference gene selection 
For accurate gene quantification, it is essential to normalise qPCR data to a 
reference gene that is unaffected by experimental conditions. Reference gene 
expression levels are likely to vary between tissue origin, as well as between healthy and 
diseased tissue (Vandesompele et al., 2002). For this reason, prior to performing qPCR 
experiments, candidate reference genes were tested for their suitability for each given 
experimental scenario. This was achieved using geNorm™ reference gene selection kits 
(Primerdesign Ltd, Southampton, UK), comprising of a panel of candidate reference 
gene primers which can be tested for expression stability on a selection of cDNA 
samples. A mouse geNorm™ kit was used to determine the most stably expressed 
reference gene in cDNA samples from murine paws, whilst the equivalent human 
geNorm™ kit was used to determine the best candidate reference gene for real-time 
PCR reactions using human chondrocyte and RASF cDNA samples.  
For each geNorm analysis, a random assortment of six cDNA samples and six 
candidate reference targets were assessed. The cDNA samples chosen were randomly 
selected samples from cells or tissues subject to different experimental treatments. The 
analyses were carried out as outlined in the manufacturer’s protocol. Firstly, the 
lyophilised primer and probe mixes were each reconstituted in 220 μl RNase- free water. 
Next, each re-suspended primer was used to create a real-time PCR master mix as 
follows (per one reaction): 1 μl primer/probe (creating a working concentration of 300 nM 
per 20 μl reaction); 10 μl PrimerDesign 2X Precision™ Mastermix; 4 μl RNase- free 
water.  The following cycling conditions were applied: enzyme activation (95˚C for 10 
minutes), followed by 50 cycles of 95˚C for 15 seconds, 50˚C for 30 seconds and 72˚C 
for 15 seconds. All geNorm kits were primer/probe based assays, so an additional 
dissociation step was not required. Upon completion of the real-time PCR run, the 
resulting data were saved as .SDS files. RQ Manager Version 1.2.1 was used to set the 
thresholds and determine CT values of the primer/probe amplification plots. The resulting 
data were exported as Microsoft Excel spreadsheets and analysed using qbasePLUS 
data software (Biogazelle, Belgium Version 1.5).  
For murine tissue, 18S rRNA gene was found to have the greatest expression 
stability in whole joint tissue and so was used in all subsequent qPCR reactions (figure 
2.20). The genes for 18S rRNA, UBC and Beta-actin were found to be the most stably 
expressed candidate reference genes in human chondrocytes (figure 2.21A). Similarly, 
the genes for 18S rRNA, GAPDH and Beta-actin were found to be the most stably 
expressed candidate reference genes in RASFs (figure 2.21B).  
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The cDNA samples were analysed for these reference genes, and a specific 
normalisation factor was calculated by taking the geometric mean of the CT values of 
these genes, as recommended in the literature (Hellemans et al., 2007; Vandesompele 
et al., 2002).   
 
Figure 2.20 Reference gene selection for murine front paw qPCR analysis 
Complementary DNA (cDNA) samples of murine front paws from different treatment 
groups were run in a qPCR reaction with a panel of reference genes to determine 
average expression stability, expressed as geNormM-values (average pairwise variation 
of a gene with all other reference genes). ACTB, Mus musculus actin beta cytoplasmic 
mRNA; YWHAZ, Mus musculus phospholipase A2 mRNA; GAPDH, Mus musculus 
glyceraldehude-3-phosphate dehydrogenase mRNA; UBC, Mus musculus ubiquitin C 
mRNA; RPL13A, Mus musculus ribosomal protein L13a mRNA; 18S, Mus musculus 18S 
rRNA gene. 
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Figure 2.21 Reference gene selection for human qPCR analysis 
Complementary DNA (cDNA) from a random selection of human A) chondrocyte and B) 
RASF samples were run in a qPCR reaction with a panel of reference genes to determine 
the most stably expressed reference genes. Average expression stability, expressed as 
geNorm M (average pairwise variation of a gene with all other reference genes). 
Reference genes with GeNorm M values ≤ 0.5 (denoted by the dotted line on the Y-axis) 
are considered stably expressed. GAPDH= Homo sapiens glyceraldehyde-3-phosphate 
dehydrogenase mRNA, CYC1= Homo sapiens cytochrome c-1 mRNA, YWHAZ= Homo 
sapiens phospolipase A2 mRNA, ACTB= Homo sapiens actin beta mRNA, UBC= Homo 
sapiens ubiquitin C mRNA, 18S= Homo sapiens 18S rRNA gene.  
  84 
2.3.2.6 Relative quantification (RQ) analyses 
From the raw CT values, ΔCT (delta CT) was calculated by subtracting the CT of 
the target gene (e.g. NAMPT) from the CT of the reference gene (Beta-actin) for each 
sample: 
ΔCT = CT(target) – CT(reference) 
 Next, the ΔΔCT values were determined by subtracting the ΔCT values of treated 
samples (e.g. IL-1β stimulated) from those of untreated samples (e.g. medium controls): 
ΔΔCT = CT(treated) – CT(untreated) 
 Once the ΔΔCT was determined for every individual sample, the Relative 
Quantity of gene expression (RQ) was determined using the comparative CT method: 
RQ = 2-ΔΔCt 
RQ determines the change in expression of a target nucleic acid sequence 
relative to the same sequence in an untreated control.  
2.4 Statistical analyses 
All data acquired were processed using Microsoft® Excel 2008 for Mac. Graphs 
were generated and statistical analyses performed using GraphPad Prism Version 4.0a.  
Prior to performing statistical tests, all data were tested for normality using the 
Kolmogorov-Smirnov normality test. If the data did not meet the assumption for normality, 
then non-parametric analyses were carried out. Details of both types of test are 
described below. All data points were graphically presented with mean ± standard error 
of the mean (S.E.M). All data were expressed as P-values. Values of P≥0.05 were 
considered not significant, P<0.05 were considered significant, and P<0.01 considered 
highly significant. In this thesis, the term experimental replicates is used when one 
biological sample (e.g. a cDNA sample or culture supernatant) is analysed multiple times. 
The term biological replicates refers to when different samples (e.g. different cell 
sources) are used for different replicates.  
2.4.1 Parametric tests 
Student’s unpaired two-tailed t-tests with 95% confidence intervals were 
performed to determine differences between two treatment groups at a single time point. 
Welch’s T-test was used in cases where variances were found to be unequal between 
data sets, as determined by F-tests.  
One-way analysis of variance (ANOVA) was performed to compare the means of 
two or more treatment groups, such as for time course and dose response analyses upon 
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stimulation of cells or tissues (e.g. with eNAMPT or IL-1β). Bonferroni post-tests were 
used to perform a pair-wise comparison of the various treatment groups.  These analyses 
were also performed to test different treatment groups at a single time point, for example 
the effect of eNAMPT in the presence of absence of APO866.   
Two-way ANOVA analyses with no repeat measures were used to determine the 
interaction between treatment groups over time, for example in experiments looking at 
the effects of APO866 in explants longitudinally. Bonferroni post-tests were used to 
compare mean values from different treatment groups for each time point.  
Pearson’s Correlation coefficient, two-tailed with 95% confidence intervals (CI), 
was used to determine relationships between two different variables (e.g. histology score 
vs. fluorescence) at a single time point. Significant deviation from zero (P-value) and the 
Pearson r correlation coefficient (r value) were reported for each correlation analysis. 
Graphs were presented with a line of best fit drawn to show the relationship between the 
two variables. 
2.4.2 Non parametric tests 
If the dataset was not normally distributed, then for the comparison of two 
treatment groups, Mann-Whitney U test used to determine whether the two groups were 
significantly different.  
For comparisons of more than two treatment groups of non-parametric data, 
Kruskal-Wallis analyses with Dunns post-tests were performed to compare the medians 
of the different treatment groups. 
Spearman’s Rank correlation coefficient was used to determine non-parametric 
relationships between two different variables. 
2.4.3 Power analyses  
G*Power version 2 was used to perform A priori power analyses on datasets 
where appropriate (Erdfelder et al., 1996). These analyses were performed for in vivo 
studies, in order to determine the sample sizes required to obtain a yield significant 
difference between variables or treatment groups.  
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Chapter 3: Exogenous NAMPT and catabolic protease 
production in vitro 
3.1 Introduction 
In this first experimental chapter, the principle aim was to investigate the effects 
of eNAMPT on the production of mediators of the early degradative and inflammatory 
processes in human fibroblasts. In this introduction, I describe the role of fibroblasts in 
these processes, through the production of MMPs and TIMPs. I then summarise current 
knowledge of eNAMPT signalling and its role in MMP production, and what is currently 
known about APO866 and its specificity for eNAMPT.  
3.1.1 Fibroblasts as a model for matrix remodelling 
RASFs exhibit an activated destructive phenotype that is markedly altered from 
those of a normal synovial joint. RASFs taken from RA patients have been used 
extensively to study processes in established disease. However, this chapter aimed to 
study the effect of eNAMPT on early initiation of pro-degradative and pro-inflammatory 
mediators of disease. A caveat of using RASFs is that the altered phenotype they 
possess does not reflect the cell types present within a naïve (i.e. healthy) joint. However, 
whilst RASFs can be easily obtained from surgical waste of patients undergoing joint 
replacement surgery, synovial fibroblasts from healthy joints are not as easily obtainable. 
For this reason, human fibroblast cell lines such as the HFFF2 cell line are useful models 
for studying early inflammatory processes in naïve cells. As a well characterised, 
homogeneous cell line, they confer certain advantages over RASFs, which are subject 
to great variability, as patients may be in different stages of disease, or taking different 
therapeutics. In addition, the HFFF2 cell line proliferate rapidly and are resilient and 
amenable to processes such as transfection (McFarlane et al., 2011).  
3.1.2 MMPs and TIMPs in cartilage catabolism in RA 
Normal fibroblasts help chondrocytes to maintain articular cartilage through the 
secretion of factors involved in both matrix deposition and matrix degradation (Konttinen 
et al., 2000). The balance of MMPs and their endogenous inhibitors (TIMPs) is crucial 
for maintenance of articular cartilage (figure 3.1.1). Of all the different classes of MMPs 
and TIMPs present within the synovial joint, the ratio of MMP-3 to TIMP-1 is one of the 
most important in RA disease pathogenesis. MMP-3 plays a vital role in the initiation of 
joint damage, through the activation of the collagenase MMP-1 (Van Meurs et al., 
1999a). Although there are four TIMPs in vertebrates, all of which are capable of 
inhibiting MMP-3, immunolocalisation studies of synovial samples have shown that 
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TIMP-1 is the principle inhibitory factor within these tissues (Hembry et al., 1995). 
Therefore, levels of MMP-3 and TIMP-1 were assessed in this chapter.  
Under normal physiological conditions, MMP gene expression is relatively low in 
synoviocytes. TIMPs are of a lower molecular weight than MMPs; with TIMP-1 and MMP-
3 approximately 28 and 54 kDa in size, respectively. Because of this, TIMPs are normally 
present in molar excess (Cunnane et al., 2001). However, in RA MMPs are upregulated 
in molar excess of endogenous TIMPs. This local imbalance between proteinases and 
inhibitors is believed to play a central role in the destruction of articular cartilage 
(reviewed by Rowan, 2001).  Analyses of levels of MMPs and TIMPs in the serum, show 
that concentration ratios of TIMP-1:MMP-3 are lower in RA patients (6.6) compared with 
those with undifferentiated disease (12.1). Additionally, higher molar ratios correlated 
with high metalloproteinase activity (Cunnane et al., 2001). In all the studies conducted, 
MMP-3 is consistently the most abundant in RA synovial fluid, present at concentrations 
ranging from 22-110 μg/ml  (Yoshihara et al., 2000).  
 
Figure 3.1.1 The role of synovial fibroblasts in cartilage matrix turnover 
In normal tissue, synovial fibroblasts help chondrocytes maintain articular cartilage. They 
are stimulated by both anti- and pro-inflammatory stimuli, via a variety of cell-surface 
receptors, resulting in activation of gene transcription. Synthesis and secretion of matrix 
components and TIMPs is balanced with pro-degradative enzymes such as MMPs. 
TGFβ1, Transforming growth factor beta 1; TIMP, Tissue inhibitor of  metalloproteinases; 
MMP, matrix metalloproteinases; ADAMTS, A disintegrin and metalloproteinase with 
thrombospondin motifs. Image adapted from (Aigner et al., 2006).  
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3.1.3 Extracellular NAMPT activity in disease processes 
Recent work has shown a distinct correlation between circulating eNAMPT levels 
and markers of cartilage destruction in the sera and synovial fluid of arthritis patients 
(Duan et al., 2011). In addition, eNAMPT levels have been associated with DAS 28 score 
in RA patients, which is the measure of the number of tender or swollen joints (Brentano 
et al., 2007). Otero and colleagues were the first to report enhanced eNAMPT levels in 
the plasma of RA patients, with mean levels in RA patients (100.35 ng/ml) significantly 
greater than eNAMPT levels in non-arthritic controls (89.56 ng/ml) (Otero et al., 2006). 
Similar observations have been reported in synovial fluid samples (Nowell et al., 2006). 
Although eNAMPT is also detectable in the synovial fluid of osteoarthritis patients (mean 
concentration 64 ng/ml), levels are elevated in RA patients (150 ng/ml) (Nowell et al., 
2006). However, although eNAMPT levels were shown to be higher in RA patients, these 
studies did not address whether this difference in eNAMPT levels is biologically relevant. 
Since these studies, there has been considerable interest in the role of circulating 
eNAMPT in this condition. In disease, numerous cells actively secrete eNAMPT, 
including synovial fibroblast-like cells (Brentano et al., 2007). Previous studies suggest 
that eNAMPT is released from cells via a non-classical secretory pathway (Revollo et al., 
2007b, Tanaka et al., 2007). The eNAMPT protein induces MMP-1 and MMP-3 gene 
expression in RASFs (Brentano et al., 2007), as well as MMP-9 mRNA levels in human 
THP-1 monocytes (Dahl et al., 2007) and MMP-3 and -13 mRNA and protein in murine 
chondrocytes (Gosset et al., 2008); suggesting a role for eNAMPT in the upregulation of 
MMP gene expression from cells within the synovial joint. However, these studies have 
mainly focussed on mRNA expression.  Moreover, none have assessed the levels of 
TIMP protein levels in relation to MMP levels in the presence of eNAMPT.  
As well as inducing mediators of cartilage catabolism, eNAMPT has been 
implicated in the production of inflammatory mediators. Overexpression of eNAMPT has 
been shown to augment TNFα induced CXCL8 secretion five-fold in human pulmonary 
epithelial cells (Li et al., 2008a). In a separate study, the addition of eNAMPT protein 
caused a 20-fold induction of CCL2 secretion in human endothelial cells (Adya et al., 
2009). 
3.1.4 APO866 and its inhibition of eNAMPT 
APO866 is a potent and specific inhibitor of eNAMPT, binding in a tunnel at the 
interface of the NAMPT dimer and competing with the nicotinamide substrate for the 
active site (Khan et al., 2006). Previous studies have shown that APO866 added to cells 
in combination with eNAMPT inhibits eNAMPT induced NF-κB activation and inducible 
nitric oxide synthase (iNOS) induction in human aortic smooth muscle cells (Romacho 
  89 
et al., 2009), and also eNAMPT induced PGE2 release in human chondrocytes (Jacques 
et al., 2012).   
In the context of MMP expression, Fan and colleagues (2011) found that APO866 
blocked eNAMPT-mediated induction of MMP-9 four-fold in human macrophages. 
APO866 also inhibited extracellular matrix metalloproteinase inducer, EMMPRIN, in 
human macrophages (Fan et al., 2011). To date, the effect of eNAMPT inhibitor APO866 
on MMP and TIMP production has yet to be investigated in fibroblasts, which are a major 
source of MMPs within the RA synovial joint. Use of APO866 within in a fibroblast cell 
line will provide novel insights into the role of eNAMPT in the induction of degradative 
processes in naïve cells.  
 3.1.5 Chapter aims 
The role of eNAMPT has not yet been studied in the context of early degradative 
processes. Additionally, it is not fully established whether APO866 can inhibit the effects 
of this protein in vitro. Therefore, the specific objectives of this chapter were as follows: 
 Determine the effect of NAMPT antagonist APO866 on eNAMPT-
mediated MMP-3 and TIMP-1 release. 
 Determine the effect of exogenous (e)NAMPT protein on MMP-3 and 
TIMP-1 secretion in a human fibroblast cell line (HFFF2). 
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3.2 Materials and methods 
All experiments in this chapter were carried out on a human foetal foreskin 
fibroblast cell line (HFFF2) and cultured as described in section 2.1.2.3. Cells were 
cultured in 6-well plates to 80-90% confluency, before being washed twice with sterile 
PBS and starved in serum-free DMEM medium for 48 hours. Cells were then washed 
again before the addition of the medium containing supplements. Details of stimulation 
assays are given below. 
Firstly, in order to assess the effect of APO866 on HFFF2 cell viability, serum-
starved cells were washed and treated with serum-free DMEM supplemented with 0-100 
nM APO866 for 24 hours, before culture media was removed and cell viability assayed 
by MTT assay (section 2.1.6.1). To assess the inhibitory effect of APO866 on eNAMPT 
stimulated cells, HFFF2 cells were washed, before pre-incubation with either untreated 
serum-free DMEM, or DMEM containing 10 nM APO866 (provided by TopoTarget A/S, 
Denmark). Cells were pre-incubated with APO866 for 1 hour, before the addition of 200 
ng/ml eNAMPT. In order to demonstrate specificity of APO866, cells were also cultured 
as shown above, but with the addition of 2.5 ng/ml IL-1β in the presence or absence of 
10 nM APO866.  Finally, a dose response of eNAMPT stimulation was performed. 
Serum-starved HFFF2 cells were incubated with serum-free DMEM containing 0-400 
ng/ml of human recombinant eNAMPT overnight (18-24 hours). Cell culture supernatants 
were collected and stored at -80°C for analysis of protein levels by ELISA (section 2.1.3). 
Levels of MMP-3, TIMP-1, CCL2 and CXCL8 were determined. 
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3.3 Results 
 3.3.1 APO866 did not affect HFFF2 cell viability 
Firstly, an MTT assay was performed as described in section 2.1.6.1. The 
purpose of this assay was to determine a suitable working concentration of APO866 for 
use in inhibitory studies. Concentrations assayed ranged from 0-100 nM, based on 
published in vitro studies performed in other cell lines (Busso et al., 2008, Van Gool et 
al., 2009). APO866 had no significant effect on cell viability relative to an untreated 
medium control, even at concentrations of 100 nM APO866 (P=0.727, figure 3.3.1), and 
upon extending the time course up to 24 hours. All subsequent experiments in this 
chapter were performed with 10 nM APO866. This dose was previously shown to 
abrogate MMP-9 protein levels four-fold in monocytes stimulated with 200 ng/ml 
eNAMPT (Fan et al., 2011).  
 
 
Figure 3.3.1 MTT assay to assess viability of APO866-treated cells 
 HFFF2 (one cell source, n=3 experimental replicates per condition) were incubated with 
escalating doses of APO866 for 24 hours (section 3.2). Cells were subsequently 
analysed for viability using an MTT assay. The viability of treated cells was determined 
by calculating the amount of formazan product relative to non-treated control wells. Error 
bars depict standard error of the mean (S.E.M). Kruskal-Wallis tests with Dunn’s multiple 
comparison post-test analyses were performed to determine the significance levels 
between treatment groups. The experiment was performed using a single HFFF2 cell 
line. MTT, thiazolyl blue tetrazolium bromide. 
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3.3.2 APO866 inhibits eNAMPT, but not IL-1β-induced MMP-3 in HFFF2 cells 
HFFF2 cells were cultured with or without 200 ng/ml eNAMPT in the presence or 
absence of 10 nM APO866. This particular concentration of eNAMPT was chosen, as it 
is physiologically relevant, and was shown to induce MMP gene expression and protein 
levels in previous studies (Brentano et al., 2007, Fan et al., 2011). The addition of 200 
ng/ml eNAMPT resulted in a 2.5-fold increase in MMP-3 concentration compared to the 
unstimulated control (mean ± S.E.M, 2.09 ± 0.93 ng/ml and 5.38 ± 2.99 ng/ml, 
unstimulated control and eNAMPT stimulated, respectively; figure 3.3.2A). However, this 
was not statistically significant (P=0.1568).Co-incubation of eNAMPT with 10nM 
APO866 significantly lowered levels of MMP-3 compared to cells stimulated with 
eNAMPT alone (P=0.0467).  
TIMP-1 was not affected by the addition of 200 ng/ml of eNAMPT compared to 
the unstimulated control (0.99 ± 0.65 ng/ml (unstimulated), 0.88 ± 0.53 ng/ml (eNAMPT); 
(P=0.8153; figure 3.3.2B). The addition of both eNAMPT and APO866 also had no effect 
on TIMP-1 release compared to eNAMPT alone (P=0.9014). 
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Figure 3.3.2 Effect of eNAMPT and APO866 on MMP-3 and TIMP-1 concentration 
 HFFF2 (n=4 experimental replicates) were stimulated with 200ng/ml eNAMPT for 18 
hours, in the presence or absence of 10 nM APO866, and cell culture supernatants were 
assayed in duplicate for A) MMP-3 and B) TIMP-1 levels. Error bars depict standard error 
of the mean (S.E.M). Significance levels between means of the different treatment 
groups were determined using a two-tailed unpaired t test. *=P≤0.05, ns=not significant 
(P>0.05).  
 
To determine whether APO866 inhibition of MMP-3 was specific to eNAMPT 
incubated cells, HFFF2 cells were stimulated with 2.5 ng/ml IL-1β, alone or in 
combination with 10 nM APO866.IL-1β caused a (7-fold) significant increase in MMP-3 
production (P=0.036; figure 3.3.3A). The addition of APO866 had no significant effect on 
MMP-3 production in IL-1β stimulated cells (P=0.997).  
Overall, TIMP-1 levels were not significantly different between IL-1β incubation 
(P=0.8539). Like eNAMPT, IL-1β had no stimulatory effect on TIMP-1, with protein levels 
comparable to values observed in unstimulated medium controls (P=0.776; figure 
3.3.3B). 
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Figure 3.3.3 Effect of APO866 on IL-1β-induced MMP-3 and TIMP-1 concentration 
 HFFF2 cells (n=6 experimental replicates) were stimulated with 2.5 ng/ml IL-1β for 18 
hours, in the presence or absence of 10 nM APO866, and cell culture supernatants were 
assayed in duplicate for A) MMP-3 and B) TIMP-1 levels. Error bars depict standard error 
of the mean (S.E.M). Significance levels between means of the different treatment 
groups were determined using a two-tailed unpaired t test. *=P≤0.05, ns=not significant 
(P>0.05).  
 
 
3.3.3 eNAMPT caused a dose-dependent increase in MMP-3 production in HFFF2 cells 
The addition of eNAMPT for 18 hours caused a significant dose-dependent 
increase in MMP-3 release in human fibroblasts (P=0.0237; figure 3.3.4A). In contrast, 
these same culture supernatants showed no significant change in TIMP-1 protein levels, 
even when stimulated with 400 ng/ml eNAMPT (P=0.715; figure 4.3.1B).  
Although eNAMPT caused a dose-dependent effect on MMP-3, it was observed 
that the mean MMP-3 concentration from cells stimulated with 200 ng/ml eNAMPT was 
a third of that seen when the equivalent dose was used in an earlier experiment (figure 
3.3.2). For this reason, the stability of eNAMPT in response to consecutive freeze-thaw 
cycles was questioned in the following section.  
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Figure 3.3.4 Dose effect of eNAMPT on MMP-3 and TIMP-1 concentration 
 HFFF2 (n=4 experimental replicates) were stimulated with eNAMPT (0-400 ng/ml) for 
18 hours and A) MMP-3 and B) TIMP-1 levels in culture supernatants were assayed in 
duplicate by ELISA. Error bars depict standard error of the mean (S.E.M). Pearson’s 
correlation coefficient was used to determine the relationship between eNAMPT 
concentration and resulting MMP-3 and TIMP-1 concentrations. 
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3.3.4 eNAMPT activity was affected by freeze/thaw cycles 
The effect of eNAMPT on MMP-3 production diminished over time. The eNAMPT 
concentration-dependent production of MMP-3 in HFFF2 cells was repeated in cells of 
the same passage but using two different batches of eNAMPT. The parallel studies 
compared eNAMPT that had been subjected to one freeze/thaw cycle, versus freshly-
reconstituted reagent. Freshly-reconstituted eNAMPT was more potent with regards to 
MMP-3 production than the batch that had been previously frozen (figure 3.3.5).  
 
Figure 3.3.5 Effect of freeze-thaw on eNAMPT activity 
Representative plots of MMP-3 production using either fresh or frozen eNAMPT 
preparations (n=1 experimental replicate per eNAMPT batch, assayed in duplicate by 
ELISA). The experiments were performed in parallel with the same source of HFFF2 
cells. 
 
3.3.5 Cellular response to eNAMPT decreased over time and between batches 
In addition to the quality of the eNAMPT protein, an additional factor considered 
was the effect of cell passage on responsiveness to eNAMPT. A study in RASFs showed 
that cells at passage 7-8 differed greatly from cells at passage 2-4, with over 10% of 
genes differentially expressed (Neumann et al., 2010). To see whether HFFF2 cells were 
likewise affected, MMP-3 values obtained were plotted against the passage of the cells 
used.  Comparisons of MMP-3 values obtained in individual experimental replicates 
showed that cells of a higher passage (>15) were less responsive to eNAMPT stimulation 
compared with stimulations carried out in cells of an earlier passage (figure 3.3.6A). 
Passage number also affected levels of MMP-3 from untreated medium control cells, 
with cells of a higher passage also exhibiting lower basal levels of MMP-3 (figure 3.3.6B). 
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Figure 3.3.6 Effect of passage on MMP-3 production 
 A) HFFF2 cells (n=1 experimental replicate per passage source) were stimulated with 
200 ng/ml eNAMPT. Culture supernatants were plated in duplicate and assayed for 
MMP-3 levels, which were plotted by cell passage number. B) Basal MMP-3 
concentration from culture supernatants of untreated HFFF2 (n=2 experimental 
replicates presented per passage number). P= cell passage. 
 
3.3.6 eNAMPT causes a dose-dependent increase in CCL2 and CXCL8 release in 
HFFF2 cells 
Extracellular NAMPT has been previously shown to induce levels of release of 
both chemokine C-C motif-ligand 2 (CCL2) and CXC motif-ligand 8 (CXCL8), two 
chemokines involved in leukocyte recruitment (Li et al., 2008a, Adya et al., 2009). 
Therefore, cell culture supernatants previously assayed for MMP-3 and TIMP-1 were 
also assayed for release of these chemokines to determine whether the variability in 
MMP-3 levels due to eNAMPT reagent (figure 3.3.5) or cell passage (figure 3.3.6) applied 
to other proteins, or was restricted to MMP-3.  
Incubation with 400 ng/ml eNAMPT induced a dose-dependent induction of CCL2 
compared with untreated control cells (P=0.001; figure 3.3.7A). Culture supernatants of 
cells treated with both eNAMPT and APO866 had significantly lower levels of CCL2 
compared with those stimulated with eNAMPT alone (P=0.0407; figure 3.3.7C). The 
addition of eNAMPT had a dose-dependent effect on CXLC8 production (P=0.0148; 
figure 3.3.4B), with a dose of 400 ng/ml eNAMPT inducing CXCL8 75-fold. Although 200 
ng/ml eNAMPT did not significantly induce CXLC8 compared with the control 
(P=0.1886), co-incubation of eNAMPT with APO866 significantly attenuated CXCL8 
production (P=0.0406; figure 3.3.7D). Overall, the same reduction in potency was 
apparent from CCL2 and CXCL8 values, reiterating that eNAMPT reagent and cell 
passage were factors in experimental variability. 
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Figure 3.3.7 Effect of eNAMPT on chemokine release in HFFF2 cells 
HFFF2 cells (one cell source, n=4 experimental replicates) were stimulated with 
eNAMPT (0-400 ng/ml) for 18 hours, and A) CCL2 and B) CXCL8 levels assayed in 
duplicate by ELISA. Pearson’s correlation coefficient was used to determine the effect of 
eNAMPT concentration on subsequent MMP-3 concentration. In a separate experiment, 
HFFF2 cells (n=6 experimental replicates) were stimulated with 200 ng/ml eNAMPT for 
18 hours, in the presence or absence of 10 nM APO866, and cell culture supernatants 
were assayed for C) CCL2 and D) CXCL8 by ELISA. Each point represents the mean 
value for each concentration, with error bars depicting standard error of the mean 
(S.E.M). Significance levels between means of the different treatment groups were 
determined using a two-tailed unpaired t test. *=P≤0.05, ns=not significant (P>0.05). 
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3.4 Discussion 
3.4.1 eNAMPT causes a dose-dependent increase in MMP-3 release 
Previous studies have shown that the mean level of NAMPT detected in synovial 
fluid in RA patients is 150 ng/ml (Nowell et al., 2006). Similar titres have also been 
detected in circulating plasma (Otero et al., 2006) and sera (Brentano et al., 2007) of RA 
patients. Therefore, the concentrations used in these in vitro studies are comparable to 
those seen in patients. The initial aim was to determine whether the stimuli used are 
capable of eliciting a pro-degradative effect in a naïve cell line. The addition of eNAMPT 
caused a statistically non-significant dose-dependent increase in MMP-3 release from 
HFFF2 cells. Induction of MMP-3 mRNA and protein has been previously reported in 
immature mouse articular chondrocytes (Gosset et al., 2008), and Brentano and 
colleagues (2007), reported that down-regulating eNAMPT expression using RNA 
interference causes a significant down-regulation of basal MMP-3 gene expression in 
synovial fibroblasts (Brentano et al., 2007). Despite this, IL-1β remains the more potent 
inducer of MMP-3, with mean values of 13 ng/ml compared with 4.7 ng/ml seen for 
eNAMPT incubation (figures 3.3.2 and 3.3.3).  
3.4.2 eNAMPT does not stimulate production of TIMP-1 
In addition to regulation at the level of transcription, MMPs are controlled at the 
protein level by TIMPs. Therefore, the effect of eNAMPT on the release of MMP inhibitor, 
TIMP-1, was also determined. The addition of eNAMPT did not induce TIMP-1 protein in 
HFFF2 cells, despite the apparent induction of MMP-3. This is different to previous 
findings in HUVECs, which showed that eNAMPT attenuates TIMP-1 and TIMP-2 gene 
expression after 4 hours of stimulation (Adya et al., 2008).  This discrepancy may be due 
to the timings of the supernatant harvest. HUVECs show a significant drop in expression 
of TIMP-1 and -2 mRNA after 4 hours, and TIMP-1 and -2 protein after 24 hours. One 
possible explanation is that at the time point used in this current study eNAMPT had not 
had enough time to exert an effect on TIMP-1 levels. Alternatively, it may be the case 
that cells were not sufficiently affected by the addition of eNAMPT. Likewise to eNAMPT, 
IL-1β had no discernible effect on TIMP-1 levels in our study. It may be that whilst IL-1β 
can induce TIMP-1 in certain cell types (Wilczynska et al., 2006), this may not be true 
for fibroblasts. Adya and colleagues used VEGF as a positive control for MMP 
upregulation and TIMP downregulation in HUVECs. Therefore, future studies involving 
eNAMPT control of MMP/TIMP expression could utilise VEGF for this purpose.  
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3.4.3 APO866 inhibits eNAMPT-induced, but not IL-1β-induced MMP-3 release 
Pre-incubation of cells with the NAMPT inhibitor APO866 appeared to inhibit the 
induction of MMP-3 by eNAMPT. APO866 inhibition was not attributed to cell death, as 
an MTT viability assay showed that 24 hours of exposure to 100 nM APO866 does not 
exert a cytotoxic effect in HFFF2 cells (figure 3.3.1). In addition, IL-1β-mediated MMP-3 
release was not inhibited by APO866, suggesting APO866 is a potent and highly specific 
inhibitor of eNAMPT. Studies in RASFs show that IL-1β induces NAMPT mRNA 
expression (Brentano et al., 2007). If APO866 does inhibit IL-1β-induced iNAMPT 
activity, the downstream effect of this iNAMPT inhibition on MMP expression could be 
masked by the other, possibly overwhelming, cellular changes that occur in response to 
IL-1β. However, this apparent inhibitory effect by APO866 should be interpreted with 
caution, as eNAMPT itself did not significantly enhance MMP-3 production in this 
particular experiment.  
An inhibitory effect of APO866 on eNAMPT-induced MMP activity has been 
previously reported in THP-1 derived macrophages, with APO866 inhibiting eNAMPT-
stimulation of both EMMPRIN and MMP-9 (Fan et al., 2011). It is possible that APO866 
may inhibit eNAMPT enzymatic activity outside of the cell inhibiting the conversion of 
nicotinamide from the culture medium into NMN. This NMN may either be subsequently 
taken up by cells, or bind to a surface receptor to activate signalling pathways, resulting 
in the production of MMP-3. This idea is reinforced by the fact that NMN causes eNAMPT 
mimetic effects in vascular smooth muscle cells (Wang et al., 2009b), human aortic 
smooth muscle cells (Romacho et al., 2009), human THP-1 derived macrophages (Fan 
et al., 2011), and murine chondrocytes (Jacques et al., 2012). The effects of exogenous 
NMN on human fibroblasts were not determined in this chapter, as the above findings 
had not been published at the time of carrying out these experiments. However, the 
effect of NMN on MMP expression and release in fibroblasts should be considered in 
future experiments. 
Despite evidence from previous studies (Wang et al., 2009b), it remains to be 
seen exactly how NMN may exert these eNAMPT mimetic effects. If cells actively take 
up NMN, it could work to increase cellular NAD+ pools, which may in turn affect the 
stability or phosphorylation of various signalling molecules. For example, increased 
NAD+ availability may increase activity of SIRT1, which has been shown to interact with 
and deacetylate the RelA/p65 subunit of NF-κB (Yeung et al., 2004). However, even if 
NMN does function this way, there is still the issue of whether or not eNAMPT can 
produce this compound extracellularly. A recent study in mouse plasma has shown that 
although eNAMPT is enzymatically active, it is incapable of forming NMN extracellularly, 
  101 
due to a requirement for ATP and PRPP, which are lacking in extracellular spaces (Hara 
et al., 2011). 
Some groups propose that eNAMPT engages with a putative receptor to exert 
an immunomodulatory role (Brentano et al., 2007, Moschen et al., 2009). APO866 
binding may cause a slight conformational change to eNAMPT, potentially affecting its 
capacity to bind to cell surface receptors. Khan and colleagues reported such a change 
in the Tyr240 and Tyr18’ residues of the murine NAMPT molecule upon binding with 
APO866 (Khan et al., 2006). In addition, Kim et al (2006) found that the conformation of 
the NAMPT/APO866 complex differed from the structure of unbound NAMPT by 2.46 Å 
(angstrom) (Kim et al., 2006). Whether this change is sufficient to impact upon possible 
receptor/ligand interactions remains to be seen.  Further work needs to be done to 
determine the relative contributions of iNAMPT and eNAMPT on MMP release in 
fibroblasts. For example, stimulation of cells with eNAMPT, in conjunction with inhibitors 
of transcription factors activated by eNAMPT, may determine if downstream effects on 
MMP release are comparable to the effects of iNAMPT inhibition. 
3.4.4 NAMPT activity is diminished following repeated freeze-thaw cycles 
The results of initial experimental replicates demonstrated a stimulatory effect on 
MMP-3 release at concentrations exceeding 50 ng/ml, although this effect was less 
apparent in subsequent experimental repeats. The initial stimulation assays involving 
eNAMPT showed very strong dose-dependent induction of MMP-3. Significant changes 
in MMP production upon eNAMPT stimulation became diminished in each successive 
experiment, with later observations showing no induction of MMP-3 by eNAMPT at all. 
A number of tests were performed to determine the source of these inconsistencies, 
which ranged from assessing the effect of cell passage, to comparing two different 
HFFF2 cell sources, as well as both fresh and frozen aliquots of the eNAMPT protein.  
The results of these tests suggest that activity of the eNAMPT protein became 
reduced during prolonged periods of storage, even when kept at -80°C. There are few 
published reports of eNAMPT protein added to cells in vitro compared with other 
cytokines. Therefore, information regarding the storage and use of eNAMPT is 
somewhat limited. It was eventually determined that lyophilised eNAMPT, reconstituted 
and added directly to cells, induced MMP-3 release more strongly than aliquots of protein 
that had been used from frozen stocks (figure 3.3.5). Therefore, recombinant eNAMPT 
protein should be handled with great care and consideration and used fresh whenever 
possible, to ensure its activity is retained.  
There have been both recorded and anecdotal reports that the NAMPT protein 
lacks stability (Lin et al., 1972, Rongvaux et al., 2002). Lin and colleagues reported 
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extreme lability of enzymatic activity of the NAMPT enzyme3 in total extracts of 
recombinant protein purified from rat erythrocyte, with the paper citing pH and the 
presence (or absence) of ATP as possible effectors of enzymatic activity (Lin et al., 
1972). More recently, Rongvaux’s group (2002) found that the purified recombinant 
NAMPT protein consistently expressed very weak enzymatic activity, therefore they used 
a complementation test in a prokaryotic host to demonstrate the activity of NAMPT 
(Rongvaux et al., 2002). However, it is noteworthy that both these studies looked 
specifically at the enzymatic functions of NAMPT, and not its reported signalling role.  
3.4.5 eNAMPT activity is lost over successive passage in HFFF2 cells 
If eNAMPT signalling is responsible for induction of MMP-3, a possible 
explanation for a drop in this activity is through loss of the eNAMPT receptor, which might 
arise from successive cell passage or through serum withdrawal. For example, 
expression of the TNF superfamily member death receptor 3 (DR3) in monocytic cell 
lines has been shown to drop gradually when cultured for prolonged periods of time 
(Wang, E.C.; personal communication). A similar effect has been reported in a human 
breast adenocarcinoma cell line, where late passage cells become less responsive to 
TGFβ than earlier passage cells. This was attributed to lower levels of TGFβ receptor 
type II (TGFBR2) in late passage cells (Ko et al., 1998). Similarly, early passage bone 
marrow mesenchymal stem cells (BMSCs) display a unique set of chemokine receptors 
that are lost in culture-expanded BMSCs of later passage (Honczarenko et al., 2006). In 
RASFs, expression of cytokine receptors including insulin-like growth factor 1 receptor 
(IGF-R1) are altered as a result of successive passage and freezing (Neumann et al., 
2010). Therefore, it may be that the HFFF2 cell line is affected in a similar manner.  
Another possibility is that the growth phase of cells in culture has an effect on 
receptor expression. This has been shown for a diverse range of receptors, including the 
transferrin receptor (Musgrove et al., 1984), CXC chemokine receptor 3 (CXCR3) 
(Romagnani et al., 2001), and thyroid hormone receptor β (Maruvada et al., 2004), with 
most showing maximal receptor expression at the G2/M phase. It is possible that cell 
growth may have become arrested in this current study, possibly due to over-confluency 
of monolayer cultures, or prolonged serum starvation. 
The addition or withdrawal of serum may have an effect on cytokine receptor 
dynamics. In our laboratory, we traditionally serum starve all our cells for 48 hours prior 
to cytokine stimulation to ensure that no serum effects could alter the results. Upon a 
                                               
3 Originally designated the name nicotinamide mononucleotide pyrophosphorylase in 
this paper 
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review of the literature, it was apparent that many groups stimulate with eNAMPT protein 
in vitro in the presence of serum (Brentano et al., 2007, Dahl et al., 2007), or may only 
starve cells for a maximum period of 24 hours (Gosset et al., 2008, Jacques et al., 2012), 
sometimes in the presence of low (<0.3%) serum (Wang et al., 2009b, Romacho et al., 
2009, Fan et al., 2011). Low serum and limited serum withdrawal may therefore be 
required in future studies to help retain cellular response to eNAMPT. Another possibility 
is that there may be a cofactor present in serum required by eNAMPT to induce its effects 
upon cells.  
3.4.6 Basal MMP-3 levels diminished over time  
 Initially, the amount of MMP-3 and TIMP-1 present in HFFF2 cells appeared 
consistent with basal levels previously seen in RASFs (Noss et al., 2011, Fearon et al., 
2006).  However, as experiments continued, a drop in basal expression of MMP-3 was 
observed over time. Low MMP-3 detection levels in culture supernatants may be partially 
attributed to problems with the ELISA kits used (e.g. problems with quality of antibody 
aliquots), although this is unlikely. It is likely that this drop in basal MMP-3 production is 
a reflection of loss of viability over repeated passage of cells. 
3.4.7 Summary 
The data herein confirm that IL-1β causes a significant effect on MMP-3 protein 
levels in HFFF2 culture supernatants. Initial studies suggested a dose-dependent effect 
on MMP-3 release by eNAMPT. However, problems with reproducibility mean these 
findings are inconclusive and further investigation is warranted. To improve experimental 
reproducibility, future studies should carefully consider: (1) the preparation and biological 
shelf-life of eNAMPT; ideally using fresh batches whenever possible; (2) the replicative 
history of the cell culture under scrutiny, thus utilising cells that have undergone a 
minimum number of population doublings, and (3) the potential importance of serum in 
the cellular response to eNAMPT.  Addition of eNAMPT does not affect production of 
TIMP-1; suggesting eNAMPT activity may contribute to a local imbalance of MMPs and 
TIMPs that occurs in the synovium during RA pathogenesis.   
The data indicate that APO866 may inhibit eNAMPT-mediated MMP-3 release in 
HFFF2 cells. Further studies are needed to establish whether APO866 is capable of 
blocking eNAMPT activity in RASFs and other synovial cells, and to elucidate the role of 
exogenous NMN in these processes. Drawing from information gathered in this chapter 
and reports in the literature, the potential roles of eNAMPT in MMP regulation are 
summarised in the schematic shown in figure 3.4.1.  
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Figure 3.4.1 Proposed functions of eNAMPT in HFFF2 cells 
 [1] Similarly to IL-1β, eNAMPT is believed to act as an extracellular signalling ligand, 
inducing signalling cascades that result in the upregulation of MMP-3. APO866 inhibits 
eNAMPT mediated MMP-3 release. This could be via two mechanisms: [2] by interacting 
with and inhibiting eNAMPT binding to its receptor, or [3] reducing the eNAMPT 
enzymatic product NMN. NMN may itself signal as a secondary metabolite, or be taken 
up by the cell to promote intracellular NAD+, and NAD+-dependent factors. [4] TIMP-1 
expression is not altered by either the addition of IL-1β or eNAMPT, thereby contributing 
to a local imbalance of MMP:TIMP ratios. 
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Chapter 4: The effect of NAMPT inhibition on catabolic 
protease production in vivo 
4.1 Introduction 
The main aim of this chapter was to assess the bioactivity of NAMPT antagonist 
APO866 in vivo in the collagen-induced arthritis (CIA) model.  The effects of APO866 on 
in situ MMP production and cartilage pathology were measured as primary outcomes. 
This brief introduction summarises the advantages of the CIA model over alternative 
animal models, and how it can be utilised to assess early disease processes within the 
synovial joint. As detection of MMP activity was a priority in this chapter, fluorescence 
probes activated by MMP enzymatic activity are introduced as to detect protease activity 
in live CIA mice.  
4.1.1 Animal models of arthritis 
 Animal models of inflammatory arthritis have been used extensively in research 
to study disease pathogenesis and for the evaluation of therapeutic agents. These 
models are relatively easy to perform with good reproducibility of data. One such model 
is the CIA model. Although originally established in the rat (Trentham et al., 1977), the 
murine CIA model is now used routinely as the benchmark to evaluate therapeutic 
entities with potential application in rheumatoid arthritis. The model involves 
immunisation of mice with CII, usually bovine or from chicken sternal cartilage. This 
results in a T- and B- cell response to autologous CII and thus disease manifestation. 
The CIA shares many histopathological features in common with RA (Table 4.1.1). 
Additionally, as CII (the target tissue of RA) is a major component of cartilage, this is a 
useful model for the study of cartilage degradation. Cartilage breakdown is measurable 
in CIA using subjective histological scoring systems. Histological evidence of cartilage 
degradation has been detected in joint tissues using proteoglycan stains such as 
Safranin O (Griffiths et al., 1995), hematoxylin and eosin (H&E) (Konda et al., 2010) and 
toluidine blue (Ishikawa et al., 2005). A recent study showed that MMP-derived collagen 
degradation-quantified by newly-developed ELISAs for collagen breakdown products is 
significantly increased in sera of CIA animals compared with control animals (Siebuhr et 
al., 2012). Upon injection of collagen in Freund’s complete adjuvant, disease onset 
typically occurs in most animals between 21-25 days after the first injection. However, 
an injection of LPS can potentiate disease in animals when onset is slow (Caccese et 
al., 1992). 
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Table 4.1.1 Comparison of disease features of RA and CIA. 
Disease feature RA CIA References 
Immune complex Yes Yes (van den Berg, 2009) 
MHC association Yes Yes (Wooley et al., 1983) 
T cell role Yes Yes (Joosten et al., 1996) 
Cartilage autoimmunity Yes Yes (Trentham et al., 1977) 
Synovitis Yes Yes (Trentham et al., 1977) 
Cartilage and bone erosion Yes Yes (Trentham et al., 1977) 
Periosteal reaction No Yes (van den Berg, 2009) 
 
4.1.2 Assessment of disease severity mice with collagen-induced arthritis 
Established disease in the murine CIA model is traditionally monitored with a 
subjective scoring system, in conjunction with measurement of hind paw swelling using 
a caliper gauge (Brand et al., 2007). At the experimental end point, analyses may be 
carried out for the presence of autoantibodies or other serological markers of disease 
(reviewed by Mota et al., 2009). Histological examination can provide additional 
information pertaining to inflammatory infiltrate and cartilage erosion. Traditionally, serial 
sections of fixed tissue are taken from the sagittal plane, usually of the knee joint or the 
calcaneus region (Joosten et al., 1996). A commonly used staining regimen is 
haematoxylin and eosin (H&E) staining, which is used mainly for the examination of 
inflammatory infiltrate and exudate. Safranin O, Toluidine blue and Alcian blue are all 
commonly used stains for assessing the degree of proteoglycan depletion from the 
cartilage surface. More recently, researchers have started to image animals 
radiographically using systems such as the Faxitron M20, and have devised scoring 
systems to assess parameters such as bone erosion (Seeuws et al., 2010). Such 
techniques may confer advantages over subjective scoring systems, as software can 
perform quantitative analyses of images.  
4.1.3 Assessment of MMP activity in vivo 
As with RA, MMP production is greatly enhanced in the CIA model, particularly 
MMP-3 (Seeuws et al., 2010). However, whilst MMP titres have been determined in RA 
patient samples, there are relatively few published studies investigating MMP levels in 
the CIA model. Studies in RA sera and synovial fluid have shown enhanced levels of a 
number of MMPs in disease, including MMPs -1, -3, and -9 (Yoshihara et al., 2000, 
Cunnane et al., 2001, Tchetverikov et al., 2004). Of these, MMP-3 is the most abundant, 
with concentrations in synovial fluid often exceeding 100 μg/ml (Yoshihara et al., 2000). 
Also of interest is the collagenase, MMP-13. This MMP, which is preferentially produced 
by chondrocytes, is present at very low levels in normal tissues but is greatly induced by 
cytokine stimulation (Konttinen et al., 1999).  
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Traditionally, MMP activity within the CIA model has been monitored using 
various approaches, including: zymography of spleen cell supernatants (Chen et al., 
2004, Shen et al., 2007), ELISA analysis of sera (Seeuws et al., 2010) or 
immunohistochemistry (IHC) with the use of antibodies which recognise C-terminal 
neopitopes in the aggrecan core protein (Van Meurs et al., 1999b). These neopitopes 
are generated by activity of MMPs -1, 2, -3, -7, -8 and -9 (Hughes et al., 1995). However, 
these methods have their drawbacks: they can be time-consuming, and often require 
optimisation. Additionally, results may not be easily reproducible between laboratories 
and many of these techniques are carried out at the experimental end-point when much 
of the proteolytic degradation of cartilage has already occurred. 
In vivo imaging using near-infrared fluorophore (NIRF)-labelled imaging probes 
offers a way of studying markers of cartilage degradation, such as enhanced MMP 
activity, both longitudinally and non-invasively. Most commercially-available agents are 
activatable, meaning they are optically silent in their native (quenched) state, but 
fluoresce brightly upon enzyme-mediated release of their fluorochrome. Commercially-
available probes can be targeted to particular areas of interest, or distributed passively 
through blood vessels. Although these probes have been shown to work in preliminary 
studies on arthritis models (Kossodo et al., 2010), there is currently little published work 
involving in vivo detection of MMP activity. Notable against this dearth of information is 
a study of transient cerebral ischemia in mice (Liu et al., 2011), and an analysis of MMP 
activity in human femoral condyles (Jones et al., 2012). To date, MMP activatable probes 
have not been used within murine arthritis models. 
4.1.4 Assessing treatment efficacy in CIA 
The CIA model has been used in efficacy studies of a range of RA treatments, 
including anti-IL-1β (Joosten et al., 1999), anti-TNFα (Mukherjee et al., 2003), and anti-
IL-6 (Fujimoto et al., 2008) therapies. Our group discovered that when administered in 
established disease, doses of 0.08 mg/kg/h and 0.12 mg/kg/h APO866 had a significant 
impact on clinical scores, reflected in reductions in synovial inflammation and bone 
erosion. APO866 efficacy was further improved if administered as a prophylactic, i.e. 
prior to the onset of disease. Real-time PCR analyses also showed reduced expression 
of MMPs -3 and -13 in this animal model (unpublished data).  Busso and colleagues 
studied the effects of APO866 in early onset CIA (Busso et al., 2008). In this experiment, 
CIA animals were treated with 2, 5 or 10 mg/kg APO866 twice daily, via the 
intraperitoneal route. APO866 treatment ameliorated disease severity and decreased 
proinflammatory cytokine secretion in affected joints. Studies in our group have 
investigated the efficacy of APO866 administered via minipump. An osmotic pump 
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containing the drug is implanted into animals subcutaneously, allowing continual dosing 
with less researcher intervention. The doses used in our lab were calculated based on 
the maximum tolerated dose determined in human trials (Holen et al., 2008).  
Activatable fluorescent agents may enable researchers to study the efficacy of 
potential therapeutics in the live animal, to supplement traditional end-point analyses. 
Similar longitudinal studies have already been carried out in the CIA and Zymosan 
models, looking at the effects of MTX (Wunder et al., 2004) and dexamethasone (Caglic 
et al., 2011) on cysteine protease-activated fluorescence. Cysteine proteases are 
primarily involved in intracellular protein turnover, though at least some of them are 
believed to be involved in numerous pathologies, including RA (Caglic et al., 2011). The 
authors found that treatment with MTX and dexamethasone significantly decreased 
fluorescence signal in paws compared to the untreated CIA mouse (Wunder et al., 2004, 
Caglic et al., 2011). It is possible that fluorescent agents could be used to assess the 
efficacy of APO866 treatment in vivo.  
 
4.1.5 Chapter aims 
The main aim of this chapter was to assess the bioactivity of NAMPT antagonist 
APO866 in vivo in the collagen-induced arthritis (CIA) model, with particular emphasis 
on its effects on MMP expression and activity, and cartilage integrity. The specific 
objectives of this chapter were to: 
 Induce murine collagen-induced arthritis in a reproducible manner and assess 
disease severity using a combination of established techniques. 
 Develop and establish in vivo imaging protocols for the longitudinal assessment 
of MMP enzymatic activity in live mice (i.e. imaging on more than one occasion).  
 Evaluate in vivo MMP activity against clinical scores, radiology, histopathology 
and MMP mRNA expression 
 Assess the treatment efficacy of NAMPT antagonist, APO866 using in vivo 
imaging protocols and established techniques. 
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4.2. Materials and methods 
4.2.1 CIA induction and imaging protocol in the MMPSense680 evaluation study 
In this proof-of-concept study, six male DBA-1 animals (Harlan) were started on 
the collagen-induced arthritis protocol (section 2.2.1). Animals were observed at least 
twice a week for clinical signs of arthritis after the administration of the second 
intradermal injection of collagen on day 21, (section 2.2.1.1). All animals developed 
arthritis by day 26 (figure 4.2.1A). Three of the animals were humanely killed by day 31 
of the experiment, as their clinical scores exceeded the severity limits specified in the 
legislative authority specified in our project licence (see timeline; figure 4.2.1B).  
On day 33, the three remaining animals were each injected with 2 nmol of 
MMPSense680 probe (section 2.2.2.1). Imaging and region-of-interest (ROI) analyses 
were performed as described in section 2.2.2.2. Probing and imaging had been 
postponed up until this point, to coincide with the arrival of an in vivo imaging expert from 
Advanced Molecular Vision (AMV; Lincolnshire, UK), who facilitated the imaging and ROI 
analyses. Animals were imaged in the Kodak FX Pro 24 hours after probe administration. 
Fluorescence images were captured at emission 630nm after excitation at 700 nm 
quickly followed by whole body X-ray images. In order to assess fluorescence signal 
drop off, animals were imaged daily, up until day 36, when the animals were killed. 
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Figure 4.2.1 Experimental timeline of the MMPSense680 evaluation study 
Six animals were used in this study. All six were immunised with collagen at days 0 and 
21. From day 21 onwards, animals were observed at least twice a week. By day 33, three 
animals were removed from the experiment; the three remaining animals were injected 
(i.v) with MMPSense680 and imaging commenced daily until the experimental endpoint 
at day 36. B) Three animals had to be removed from the experiment on days 28 and 31.   
i.d., Intradermal; i.v., Intravenous; Obs, observation. 
 
4.2.2 CIA induction and imaging protocol in the MMPSense 750 FAST evaluation study  
In separate experiments, an alternative activatable fluorescent agent 
(MMPSense750 FAST, PerkinElmer) was used. MMPSense750 FAST was also tested 
with a view to assess its applicability, in longitudinal studies, for measuring MMP activity 
in actively inflamed joints of mice with CIA. Since this was also a proof-of-concept study, 
and for ethical reasons, only a small number of mice were used (three female DBA-1 
mice from an in-house colony). CIA was induced in only two mice. A third non-immunised 
mouse was used as the age-matched control for the experiment. In this experiment only 
one of the immunised mice demonstrated clinical signs of arthritis at day 27 whilst the 
remaining immunised mouse, uncharacteristically, developed CIA on day 34. No animals 
were removed from the study for ethical reasons and all remained experimental until 
endpoint (see timeline; figure 4.2.2).  
At the first clinical sign of arthritis (day 27), the one arthritic animal and the naïve 
control were injected intravenously with 2 nmol MMPSense750 FAST (section 2.2.2.1). 
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Probe solution was protected from light and stored at 4°C until further use. Animals were 
imaged using the Xenogen IVIS 200 imager, and ROI analyses performed (section 
2.2.2.2). The remaining immunised mouse was also imaged and served as “no-probe” 
control for the experiment. It was used as a reference to determine endogenous 
background levels of fluorescence in an age-matched mouse. In order to measure any 
potential reduction in fluorescence signal over time; both mice were imaged daily until 
day 34. The day 34 fluorescence reading for each mouse provided the background for 
the next stage of the experiment. Both mice (with CIA) were injected with 2 nmol 
MMPSense750 FAST probe, re-imaged and sacrificed 6 hours later. Background 
fluorescence values were subtracted from the values acquired 6 hours after injection of 
the probe. MMP-specific fluorescent activity was calculated using the equation (below) 
where T is time (in hours) after injection of probe: 
MMP fluorescence (Tx) = probe fluorescence (Tx) - pre-probe fluorescence (T0) 
 
 
 
Figure 4.2.2 Experimental timeline of the MMPSense750 evaluation study 
Three animals were used in this study. Two animals were immunised with collagen at 
days 0 and 21. One animal was not immunised and acted as a naïve control. From day 
21 onwards animals were observed at least twice a week. One CIA with arthritis and one 
naïve were injected (i.v) with MMPSense750 on day 27. All animals were imaged daily 
until day 34. All animals were probed with MMPSense 750 and subsequently imaged 
once more on day 34, before sacrifice at the experimental endpoint. i.d., Intradermal; i.v., 
Intravenous; Obs, observation. 
 
4.2.3 CIA induction and MMPSense 750 imaging protocol in the APO866 treatment study 
From the first two experiments, the MMPSense750 imaging agent was chosen 
for the final larger study, due to the ease of use of the Xenogen imaging system. Twelve 
male DBA-1 animals (Harlan) were purchased for this study. CIA was induced in ten 
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mice and two mice were used as naïve age-matched (non-immunised) controls. Two of 
the CIA immunised animals had to be removed from the experiment on days 21 and 23 
prior to administration of probe or treatment. The first animal was killed as it showed 
signs of distress. The second animal died two days later, possibly due to anaesthesia 
sequelae. As no clinical signs of arthritis were seen in the remaining eight animals by 
day 25, mice were treated with a single i.p. injection of LPS, as described in section 
2.2.1, in order to increase the rapidity and uniformity of disease.   By day 27, six out of 
the eight remaining immunised mice showed clinical signs of arthritis (see timeline; figure 
4.2.3A).  
 On day 27, all remaining immunised mice (n=6 with arthritis and n=2 no arthritis) 
and non-immunised controls (n=2 naïve) were injected with MMPSense750 FAST. All 
mice were imaged 24 hours post-injection (day 28) and every 24 hours thereafter until 
experimental endpoint (see section 2.2.2.3). Immediately after the imaging protocol was 
completed, CIA immunised animals (n=8) were assessed for arthritis. The mice were 
then divided into two treatment groups (n=4 per group) that were matched in arthritis 
severity (determined by clinical score). One group was implanted with an osmotic 
minipump set to release vehicle (propylene glycol in saline, section 2.2.3.1). The second 
group was implanted with osmotic minipumps set to release APO866 dissolved in sterile 
saline at a rate of 0.08 mg/kg/h. One mouse in each group showed no signs of arthritis 
(clinical score=0) at day 28 or until experimental end point (day 32). The non-immunised 
controls (n=2) received no treatment (figure 4.3.2B). 
The day 32 fluorescence reading, when minimal fluorescence from the initial 
MMPSense750 FAST probe injection was detected, was taken as background. Mice 
were injected with one further dose of MMPSense750 FAST probe (2 nmol). The mice 
were re-imaged 24 hours after this 2nd injection, then killed and tissue harvested for 
subsequent analyses (section 4.2.4). MMPSense750 FAST fluorescence values were 
corrected for background fluorescence as described in section 4.2.3.  
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Figure 4.2.3 Experimental timeline of MMPSense750 APO866 treatment study  
Twelve animals were used in this study. Ten animals were immunised with collagen at 
days 0 and 21. Two animals were not immunised and acted as a naïve controls. From 
day 21 onwards, animals were observed at least twice a week. On day 25, immunised 
animals were given a single i.p injection of LPS. On day 27, all animals were injected 
(i.v) with MMPSense750. On day 28, CIA animals were arranged into groups and treated 
by osmotic minipump. Naïve control animals were not treated with minipumps. Imaging 
continued daily until day 32, when animals were re-probed and re-imaged, prior to 
sacrifice at the experimental end point on day 33. B) Two animals had to be removed 
from the CIA experimental group on days 21 & 23. i.d., Intradermal; i.p, intra-peritoneal; 
LPS, Lipopolysaccharide; i.v., Intravenous; Obs, observation. 
4.2.4 Post-mortem analyses 
Hind limbs were removed and analysed by radiology (sections 2.2.1.2) and 
histopathology (section 2.2.1.3). Fore limbs were removed and analysed by radiology 
and qPCR (section 2.3.2). MMPs -1a, -3, -9 and -13 were analysed by qPCR because 
their expression is elevated in the RA synovium (Konttinen et al., 1999), (refer to Table 
1.2). In addition, MMPs -9 and -13 preferentially cleave and activate the MMPSense 
probes (refer to figures 2.15 and 2.16 in materials and methods).  
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4.3 Results 
The findings of the three individual experiments are presented in turn; the two 
MMP probe evaluation studies and the MMPSense750 APO866 treatment study. 
Arthritis induction data, clinical scores, in vivo imaging and mRNA analysis are 
presented. In addition, cDNA samples extracted from archived paws were analysed by 
qPCR to determine the dose-dependent effect of APO866 upon MMP expression in the 
joint. Finally, data were combined to determine the relationship between MMP activity 
(as determined by in vivo imaging) and other disease parameters. 
4.3.1 MMPSense680 evaluation study 
4.3.1.1 Animals in MMPSense680 evaluation study developed arthritis 
For the initial study, six animals were immunised at day 0, and again at day 21, 
as described in section 4.2.1. By day 21, one animal displayed swelling in a front paw, 
and by day 26 all six animals had established arthritis (figure 4.3.1A), as apparent by a 
change in clinical score (figure 4.3.1C) and paw diameter (figure 4.3.1D). Paw diameters 
started to noticeably increase by day 26, and peaked at day 28, before subsiding. 
Weights of the animals dropped gradually in line with the rise in arthritis severity (figure 
4.3.1E), which was attributed to impaired feeding as a result of decreased mobility 
(Griffiths et al., 1995). Loose pellets were distributed in the cage to counter this effect. 
Three of the mice were sacrificed prior to starting the imaging schedule because their 
combined clinical score exceeded the maximum (14) allowed within the project licence; 
one on day 28 and two on day 31 (figure 4.3.1B). The three remaining animals were 
used to trial the MMPSense680 probe. 
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Figure 4.3.1 Arthritis incidence and survival in MMPSense680 evaluation study 
N=6 animals were induced with CIA. A) Arthritis incidence in study group. B) Percentage 
of animals removed from the study; by day 31, three animals remained in the study. 
Animals were monitored for: C) clinical score, D) paw diameter and E) body weight. Data 
points Data plotted as mean ± standard error of the mean (S.E.M). i.d., intradermal 
booster injection of collagen; i.v., intravenous injection of MMPSense680 
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4.3.1.2 MMPSense680 probe was detected in arthritic limbs 
Imaging data was first collected on day 34. The affected limbs fluoresced brightly, 
with swollen paws exhibiting visibly greater fluorescence than paws with milder swelling 
(figure 4.3.2). Although care was taken to ensure no probe was injected into the tail 
subcutaneously, tails also fluoresced slightly. The net intensity values were determined 
for each imaging time point and plotted over time for front and hind paws (figure 4.3.3). 
Although there was a clear signal drop-off for all limbs, particularly between 24-48 hours 
post-injection, fluorescence was still readily detectable by the experimental endpoint, 
particularly within the hind limbs. 
 
 
Figure 4.3.2 Detection of MMPSense680 fluorescence  
Panel shows X-ray images of the three CIA animals, with fluorescent intensity shown as 
a pseudocolour overlay using the KODAK FX Pro imaging system. Whole animal images 
were taken on day 34 (24 hours post-injection) and every 24 hours thereafter. Boxes 
within each image depict high power hind paw images. Intensity scale [minimum=100, 
maximum=250 relative fluorescent units (rfu)]. 
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Figure 4.3.3 MMPSense680 fluorescent signal drop off 
Net intensity readings (rfu) of each individual limb (n=3 animals, n=6 limbs) were taken 
every 24 hours until the experimental endpoint, using the KODAK FX Pro. A) Front paw 
readings taken at 24, 48 and 72 hours post-injection, at which point the experiment was 
terminated B) Hind paw readings. Data plotted as mean ± standard error of the mean 
(S.E.M) net intensity value (n=3 animals, n=6 limbs).  
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4.3.1.3 MMPSense680 fluorescence intensity correlated with clinical score 
The net intensity values of the individual limbs taken 24 hours after probe 
administration (day 34) were plotted against respective paw diameter and clinical score 
values observed on that day. Net fluorescence intensity significantly correlated with 
clinical score (P=0.0027 r=0.9828; figure 4.3.4A). A priori (prospective) power analysis 
confirms that a sample size of n=10 limbs would have been sufficient to yield a significant 
(P≤0.05) correlation between net fluorescence intensity and clinical score. Net intensity 
correlated positively but not significantly with paw diameter (P=0.1302 r=0.688; figure 
4.3.4B). A priori power analysis suggests a sample size of n=14 limbs would be required 
to yield a significant (P≤0.05) correlation between net fluorescence intensity and paw 
diameter.  
 
Figure 4.3.4 Comparing MMPSense680 fluorescence with arthritis index 
An ROI analysis tool was used to determine the net fluorescent intensity of each 
individual limb. A) Correlation of clinical scores of front and hind limbs at day 34 with their 
respective net intensity values (three animals, n=12 limbs). B) Correlation of paw 
diameter of hind limbs at day 34 with their respective net intensity values (three animals, 
n=6 limbs). Correlation was determined using Pearson’s Correlation coefficient. A priori 
power analysis was used to determine the sample size required to reject the null 
hypothesis of no significant correlation between the two variables based on the effect 
size (R-value).  
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4.3.1.4 MMPSense680 fluorescence was localised in areas of radiological and 
histological damage 
All animals were sacrificed on day 36, hind limbs were harvested and high power 
x-ray images taken (see section 2.2.1.2). X-ray images showed evidence of soft tissue 
swelling in the hind paws, as well as signs of osteopenia, erosion (i.e. loss of continuity 
of cortical bone), and periosteal reaction (figure 4.3.5B[i]-[iii]), particularly within the MCP 
joints. It was noted that areas of radiological damage coincided with areas of greater 
MMPSense680 fluorescence intensity (figure 4.3.5A). Once x-rayed, hind paws were 
processed, fixed and sectioned for histological analyses as described in section 2.3.1. 
Histological staining showed evidence of inflammatory infiltrate, sub-synovial exudate 
and loss of cartilage integrity, as evidenced by loss of continuity of Safranin O staining 
of the joint surface (figure 4.3.5C[iv]-[vi]). Histological damage was particularly evident 
around the bones of the mid-foot and the individual MCP joints. 
Correlation analyses were carried out to determine the association between 
MMPSense680 fluorescence intensity and radiology and histology scores. In all cases 
the sample size (n=6 limbs) was insufficient to infer a positive association between the 
variables. A priori power analyses based on r-value determined a sample size of 13 limbs 
would be required for a positive association between net intensity and radiology score 
(P=0.2517, r=0.5562; figure 4.3.5D). The associations between MMPSense680 
fluorescence with histological (P=0.4806, r=0.3621; figure 4.3.5E) and cartilage erosion 
scores (P=0.3335, r=0.4815; figure 4.3.5F) were weak. The sample size was too small 
for accurate statistical interpretation (n>40 limbs required).
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Figure 4.3.5 Comparison of MMPSense680 fluorescence distribution with 
radiological and histological disease parameters  
A) A hind paw of a live animal imaged at day 34 (24 hours post-injection with 
MMPSense680), using the KODAK in vivo FX Pro. B) The same hind limb immediately 
after sacrifice (day 36), x-rayed at high power exhibiting: i) osteopenia ii) erosions iii) 
periosteal reaction. Tissues were fixed and processed, and 7 μm sections mounted and 
stained with Safranin O and fast green. C) High power image of an MCP joint, exhibiting: 
iv) inflammatory infiltrate v) sub-synovial exudate vi) cartilage degradation. Scale bars 
represent 500 μm. Fluorescence net intensity values of individual hind paws from day 34 
(three animals, n=6 limbs) were related to their respective radiology scores and histology 
scores, and correlation determined using Pearson’s correlation coefficient. Net 
intensities were related to D) radiology, E) histology and F) cartilage erosion scores. A 
priori power analysis used to determine the sample size required to yield a significant 
correlation between the two variables indicated sample sizes of >10 paws would be 
required. 
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4.3.1.5 MMPSense680 activity did not correlate with MMP mRNA expression 
Gene expression levels of MMPs -1a, -3, -9 and -13 (figure 4.3.6A-D) from 
extracted cDNA of homogenised front paws did not significantly correlate with 
MMPSense680 fluorescence intensity readings from day 34. In fact, in some cases 
brightly-fluorescing limbs yielded relatively low levels of MMP gene expression. A priori 
power analyses indicate much larger sample sizes would be needed to yield a significant 
effect; therefore MMP enzymatic activity (as assessed by MMPSense680 fluorescence) 
cannot be meaningfully related to MMP gene expression in this experiment.  
 
 
Figure 4.3.6 Relating MMPSense680 probe intensity to MMP mRNA 
 Whole front paws (three animals, n=2 limbs per animal) from day of sacrifice (day 36) 
were homogenised for qPCR analysis. Relative quantity of gene expression (RQ) was 
determined by analysing cDNA samples in duplicate and relating ΔCT values of arthritic 
animals to those of a naïve control animal (n=2 limbs). Individual RQ readings for A) 
MMP-1a, B) MMP-3, C) MMP-9, and D) MMP-13 were correlated to the respective net 
intensity of their front paws 24 hours post-injection (day 34). Correlation analysis was 
carried out using Pearson’s Correlation coefficient. A priori power analysis was used to 
determine the sample size required to reject the null hypothesis of no significant 
correlation between the two variables based on the effect size (r-value).
  122 
4.3.2 MMPSense750 FAST evaluation study 
The first study stood as a preliminary proof-of-principle study of the MMPSense 
680 probe. The second study was initiated to test the applicability of an alternative 
fluorescent probe, MMPSense750 FAST. Two female DBA-1 mice were immunised at 
day 0, and again at day 21, as described in section 4.2.2. A third DBA-1 mouse served 
as a naïve control. Clinical signs of arthritis were first observed in one mouse at day 24, 
but the other animal remained unaffected until day 34, when it presented with swelling in 
the proximal interphalangeal (PIP) joint (figure 4.3.7A). Clinical scores and paw 
diameters increased in the arthritic animal from day 24 (figure 4.3.7B). Paw diameter 
increased in comparison to the naïve control, with swelling peaking at day 29 before 
falling slightly in subsequent observations (figure 4.3.7C). As with the initial study, 
disease severity was accompanied by a loss in weight (figure 4.3.7D). Weight loss did 
not exceed the 20% limit specified in the project licence.  
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Figure 4.3.7 Experimental arthritis in the MMPSense750 evaluation study 
The two CIA animals (labelled CIA 1 and CIA 2) and the naïve control were observed at 
least twice weekly from the day of the second i.d. (day 21). Animals were monitored for: 
A) arthritis incidence, B) clinical score, C) paw diameter and D) body weight. i.d., 
intradermal booster injection of collagen; i.v., intravenous injections of MMPSense750 
probe; CIA, Collagen-induced arthritis animal. 
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4.3.2.1 MMPSense750 fluorescence was enhanced in arthritis compared with a naïve 
control 
An i.v. injection of MMPSense750 was to be administered in animals at the first 
clinical sign of arthritis; in one CIA immunised animal, this occurred day 27. The entire 
volume (70 μl) of the probe was successfully injected into the tail vein of this mouse and 
the naïve control. The second CIA mouse was not injected with the probe until day 34, 
as there were no signs of disease until this time (explained further in section 4.3.2.3). 
Imaging was carried out immediately upon injection of the probe (0h) and every 24 hours 
thereafter, using the Xenogen IVIS 200, as detailed in section 2.2.2.3. Analysis of whole 
animal fluorescent overlays showed that the limbs fluoresced strongly, particularly the 
hind paws, up to 120h post-injection (figure 4.3.8). MMP fluorescence was considerably 
more intense in the arthritic mouse than in the naïve mouse, as evident from the 
pseudocolour display. MMPSense fluorescence was apparent at the injection site in the 
base of the tail for all both of the mice injected with the probe.  
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Figure 4.3.8 Detection of MMPSense750 Fast 
Panel shows photographic images of the three mice, with fluorescent intensity shown as 
a pseudocolour overlay using the Xenogen IVIS 200 imaging system. Two mice were 
administered MMPSense750 FAST, the naïve control (CON) and the one mouse with 
clinical signs of arthritis (middle column). The other CIA mouse did not receive 
MMPSense750 FAST (no probe). Whole animal images were taken on day 27 
(immediately after probe administration and every 24 hours thereafter up to 120h post-
injection (time course continued overleaf). Boxes within each image depict high power 
hind paw images. Red boxes show the ROIs used in the analysis. Intensity scale 
(minimum=5 x 10-6, maximum=1.0 x10-5 units).  
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Figure 4.3.8 (continued from previous page): Detection of MMPSense750 Fast
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4.3.2.2 MMPSense750 fluorescence was still detectable five days post-injection 
Fluorescence efficiency was monitored daily from day 27 to 32 to determine 
signal drop-off. Although the MMPSense750 probe was not completely cleared by day 
32 (120h post-injection), fluorescence in the arthritic mouse had fallen close to those of 
the naïve (non-arthritic) control in both front paws (figure 4.3.9A) and hind paws (figure 
4.3.9B). In contrast to hind paws, there was negligible difference in front paw 
fluorescence between naïve and CIA mice (mean efficiency values 2.75 x 10-6 and 2.93 
x 10-6, naïve and CIA, respectively), indicating that fluorescence was not as enhanced in 
these tissues compared with hind paws.  
The results obtained from experiments with MMPSense680 were compared 
against the data acquired for MMPSense750. The drop in MMPSense750 versus 
MMPSense680 fluorescence efficiency over the first 72 hours post injection was plotted 
(figure 4.3.10). These data show the half-life of the MMPSense750 probe was 57.2 hours 
(front paws) and 61.3 hours (hind paws) compared against 1.3 hours (front paws) and 
3.6 hours (hind paws) for MMPSense680. These data contradict the manufacturer’s 
guide, which claim a half-life of 5 hours for the MMPSense750 probe (Groves et al., 
2010).  
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Figure 4.3.9 MMPSense750 FAST signal drop off 
Mice (n=2 limbs per animal) were imaged on day 27 (0h), prior to injection of 
MMPSense750 using the XENOGEN IVIS 200. Mice were then imaged 24 hours post-
injection, and every 24 hours thereafter, up until 120 hours post-injection (day 32). The 
no probe mouse was CIA immunised but with no clinical signs of disease. Raw 
fluorescence values (four per animal) were determined at every time point using ROI 
analysis.  A) Drop in efficiency values in front paws by 120 hours. B) Hind paw efficiency 
values from 0-120 hours. Data points were graphically presented with mean ± standard 
error of the mean (S.E.M).  Values here are raw values obtained from ROI software, not 
corrected for background autofluorescence. 
  
  129 
 
 
 
Figure 4.3.10 Comparison of MMPSense680 and MMPSense750 probe clearance 
Raw fluorescence values from arthritic mice were taken from each time point up until 72 
hours post-injection to determine which probe had the fastest rate of clearance. From 
these raw values a percentage drop/rise in fluorescence relative to the first imaging time 
point (24 hours p.i.) was determined for each subsequent time point. A) MMPsense680 
free-form ROI net intensity values using KODAK MI software. Rate of decay from 24 
hours p.i. was calculated using one-phase exponential decay (Prism) and determined 
using non-linear regression analyses (three mice, n=6 front and hind limbs). Front paws: 
half-life=1.26 hours, K=0.06 units/h, hind paws: half-life=3.59 hours, K=0.19 units/h.  B) 
MMPSense750 efficiency values using the IVIS 200 system with ROI analysis of a fixed 
dimension around the limb. Fluorescence from the first imaging time point 24 hours p.i. 
(one mouse, n=2 front and hind limbs). The plateau values taken from the no-probe 
control were used to accurately determine half-life. Front paws: half-life=57.24 hours, 
K=0.012 units/h, hind paws: half-life=61.3 hours, K=0.011 units/h. F= half-life of front 
paws, H= half-life of hind paws.  
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4.3.2.3 MMP fluorescence signal differed in early and advanced disease 
On day 34, the second CIA immunised mouse had begun to exhibit very early 
clinical signs of arthritis (i.e. a swollen PIP joint, and clinical score of 1). This mouse was 
injected with MMPSense probe, as well as the first CIA mouse and the naïve control. For 
this part of the experiment, this former ‘no probe control’ was subsequently referred to 
as an early arthritis (EA) animal. The other CIA mouse, whose clinical score on day 34 
was 14, was referred to as the advanced arthritis (AA) animal. Six hours post-injection, 
the early arthritis animal exhibited a small area of enhanced fluorescence, which was 
localised to the single proximal interphalangeal (PIP) joint in the left hind paw (figure 
4.3.11). The front paws remained unaffected, and showed no evidence of fluorescence. 
In contrast, the mouse with advanced arthritis demonstrated a large degree of 
fluorescence in all limbs (figure 4.3.11). Although MMPSense750 fluorescence had 
reduced in intensity in the naïve and advance arthritis animal from the previous injection 
administered on day 27, a small amount of residual fluorescence remained, which was 
taken into account in the analysis. Overall, these data reiterate the sensitivity of the 
MMPSense probes, and how in situ MMP activity is a good reflection of the disease state 
of the animal.  
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Figure 4.3.11 MMPSense750 FAST fluorescence images on day 34 
Panel shows photographic images of the three mice, with fluorescent intensity shown as 
a pseudocolour overlay using the Xenogen IVIS 200 imaging system. All animals were 
administered MMPSense750 FAST: the naive control (CON), the mouse with advanced 
arthritis (AA), and the mouse with early arthritis (EA). Whole animal images were all 
taken on days 34 and 35, immediately before probe administration (top panel) and 24 
hours post-injection (bottom panel). Boxes within each image depict high power hind 
paw images. i) High power magnification of early arthritic hind paw, showing enhanced 
fluorescence in one of the proximal interphalangeal joints (PIPJ). Red boxes show the 
ROIs used in the analysis. Intensity scale (minimum=5.0 x 10-6, maximum=1.0 x10-5 
units.  
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4.3.2.4 Early signs of arthritis were detectible in radiological and histological examination 
The three experimental animals (described above) were sacrificed at day 
34.Their hind paws were X-rayed and scored (section 2.2.1.2). The hind paws from the 
naïve and early arthritis mice (CIA onset day 34) exhibited no signs of radiological 
damage. In contrast, the hind paws of the mouse with advanced arthritis (CIA onset day 
24) showed signs of osteopenia and erosions around the cortical bone (figure 4.3.12). 
This was reflected in the radiology scores obtained (figure 4.3.12D). Due to the small 
sample size, no statistical analyses were performed on these data.  
Hind paws were then processed for histological analyses (section 2.3.1). The 
advanced arthritis animal had evidence of inflammatory infiltrate and signs of cartilage 
erosion (figure 4.3.13). This was in contrast to the naïve control (figure 4.3.13A), which 
showed no evidence of damage. One paw from the mouse with early arthritis showed 
some evidence of disease, with a high number of inflammatory cells localised around 
one of the proximal interphalangeal (PIP) joints and no other pathology (figure 4.3.13C). 
These differences were reflected in the histological (figure 4.3.13D) and cartilage erosion 
scores (figure 4.3.13E).  
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Figure 4.3.12 Comparison of radiographic images of hind paws 
Representative hind paw images taken at time of sacrifice (day 34), from A) naive control 
mouse, B) mouse with advanced arthritis (AA) and C) mouse in the early stages of 
disease (EA). D) Radiology scores obtained from each mouse (n=2 limbs per mouse). 
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Figure 4.3.13 Histological assessment of disease 
A) A representative hind paw of the naïve control mouse (CON). Boxed area: High power 
magnification of the hind-foot region from a normal tissue section showing i) normal 
adipose tissue, ii) no synovial exudate, and iii) normal healthy cartilage. B) Histological 
image of a mouse with advanced arthritis (AA) Boxed area: High power magnification of 
the diseased hind-foot region contains substantial iv) synovial infiltrate, v) exudate and 
vi) some loss of continuity of Safranin O staining, indicating early signs of cartilage 
erosion. C) High paw from early arthritis (EA) mouse. Boxed area: swollen proximal 
interphalangeal joint. D) Histology and E) Cartilage erosion scores taken from each 
mouse (n=2 limbs for each).  
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4.3.3 MMPSense750 APO866 treatment study 
The final in vivo imaging experiment involved the use of MMPSense750 FAST as 
a tool to monitor changes in MMP activity resulting from inhibiting NAMPT (using 
APO866) in animals with established CIA. 
By day 27, 75% arthritis incidence was achieved in CIA animals (figure 4.3.14A). 
Of all the surviving immunised animals, two did not develop arthritis. Data from these 
animals are not presented in the main analyses, but are presented separately in section 
4.3.3.8.  During the course of the experiment, two animals were removed from the study, 
leaving eight immunised animals and the two naïve control mice (figure 4.3.14B).  
 
 
 
Figure 4.3.14 Experimental arthritis in MMPSense750 APO866 treatment study  
A) Arthritis incidence graph of animals immunised with collagen (n=10 animals; CIA) 
compared to naïve controls (n=2 animals; CON). B) Percentage of animals removed from 
analysis throughout the course of the study. i.d., intradermal booster injection of collagen; 
LPS, injection of lipopolysaccharide.  
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4.3.3.1 CIA animals were evenly distributed into groups prior to minipump treatment 
based on clinical score 
CIA animals showed signs of arthritis at day 28. However, scores were varied 
and there were no significant differences in front or hind paw clinical scores between CIA 
and control animals (P<0.0001 for both front and hind paws, figures 4.3.15A and B, 
respectively). Hind paws of CIA animals were markedly swollen compared with control 
animals, as determined by a significant increase in paw diameter (P=0077; figure 
4.3.15C). No front paw measurements were taken, as this is not easily measurable by 
caliper. The two animals that did not develop disease were each placed into the VEH 
and APO groups, in the event that they may develop disease at a later date. However, 
this did not happen and therefore analyses of these animals have been kept separate 
and the data are presented in section 4.3.3.8.  
 
 
 
Figure 4.3.15 Clinical assessment of disease on day 28 (pre-treatment)  
Prior to treatment, collagen-immunised animals (CIA; six animals, n=12 limbs) were 
scored and compared to naïve control animals (CON; two animals, n=4 limbs). 
Immunised animals with no signs of arthritis were excluded from this analysis.  A) Front 
paw clinical score observations at day 28. B) Hind paw clinical score observations. C) 
Hind paw diameters measured on day 28. Lines on graph represent the mean values. 
Significant differences between means were determined using a two-tailed unpaired t 
test. **=P≤0.01, ***=P≤0.0001.   
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4.3.3.2 MMPSense750 fluorescence was consistent in CIA animals prior to treatment 
MMPSense750 probe was administered to all animals on day 27 and imaging 
occurred 24 hours later (i.e. day 28). As with the previous MMPSense750 study, the 
extent and intensity of fluorescence in both front and hind paws was noticeably greater 
in CIA animals compared to the naïve controls (figure 4.3.16). The CIA-immunised 
animals with no clinical signs of arthritis are presented elsewhere (figure 4.3.27). The 
increase in fluorescence was reflected in the ROI analyses, which showed significantly 
greater efficiency values in animals with established arthritis compared to the naïve 
controls. This was evident in both front paws (P<0.0001; figure 4.3.17A) and hind paws 
(P<0.0001; figure 4.3.17B); as confirmed by Dunn’s post-test analyses. All immunised 
animals were placed were then divided into VEH or APO treatment groups (n=4 per 
group), matched in arthritis severity (determined by clinical score).  
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Figure 4.3.16 Fluorescence intensity on day 28  
Panel shows photographic images of the six animals with established arthritis (CIA) and 
two naïve control (CON) animals, with fluorescent intensity shown as a pseudocolour 
overlay using the Xenogen IVIS 200 imaging system. All animals were administered 
MMPSense750 FAST on day 27 and whole animal images were taken on day 28, 
immediately before minipumps were inserted. Boxes within each image depict high 
power hind paw images. Intensity scale (minimum=5.0 x 10-6, maximum=1.0 x10-5 units).  
 
CIA 
CON 
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Figure 4.3.17 Fluorescence efficiency values on day 28  
Individual front and hind paw efficiency readings taken 24 hours after probe 
administration and immediately before minipumps were inserted (i.e. day 28). Values 
were corrected for background autofluorescence and arranged by treatment group. A) 
Front paw fluorescence efficiency values of animals with established arthritis (CIA; six 
animals, n=12 limbs) and naïve control (CON) group (two animals, n=4 limbs). B) Hind 
paw fluorescence efficiency. Significant differences between means were determined 
using a two-tailed unpaired t test. ***=P≤0.0001.  
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4.3.3.3 Clinical scores were significantly enhanced in vehicle, but not APO866-
treated CIA animals, four days post-treatment 
After four days after the commencement of treatment with 0.08 mg/kg/h APO866 
treatment (day 32), mean clinical scores were compared with those of vehicle animals. 
Although median clinical scores were generally lower in APO866-treated animals, this 
difference was not statistically significant compared with the vehicle controls. This was 
the case for both front paws and hind paws (P=0.0937 and P=0.00839; front and hinds 
paws, respectively; figures 4.3.18A and B). However, hind paw swelling in general was 
significantly attenuated in APO866-treated animals compared with vehicle controls 
(P=0.0307; figure 4.3.18C). This suggests that after four days of treatment, APO866 is 
beginning to attenuate paw swelling. 
 
 
Figure 4.3.18 Clinical assessment of disease on day 32 (post-treatment) 
Clinical scores of animals in the vehicle (VEH) group (three animals, n=6 limbs), 0.08 
mg/kg/h APO866 (APO) group (three animals, n=6 limbs) and naïve control (CON) group 
(two animals, n=4 limbs), four days after the commencement of treatment (day 32). A) 
Front paw clinical score observations at day 32. B) Hind paw clinical score observations 
C) Hind paw diameters measured on day 32. Lines on graph represent the mean values. 
Significant differences between means were determined using a two-tailed unpaired t 
test.*=P≤0.05, ns=not significant (P>0.05).  
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4.3.3.4 MMPSense750 fluorescence was significantly enhanced in vehicle, but not 
APO866-treated CIA animals 
On day 32, animals were imaged and fluorescence detected. From observation 
of the fluorescence images alone, the extent and intensity of MMP fluorescence had 
increased in all CIA mice over the treatment period. However, fluorescence in APO mice 
appeared visibly attenuated compared to vehicle-treated animals (figure 4.3.19). These 
observations were supported by ROI analyses, which showed that front paw 
fluorescence readings were significantly higher in the vehicle treated mice compared 
with animals treated with APO866 (P=0.0021; figure 4.3.20A). This was also the case 
with hind paw readings (P=0.0096; figure 4.3.20B).  These data indicate that MMP 
enzymatic activity was dampened in the limbs of animals treated with APO866. 
The changes in MMPSense fluorescence efficiency over time in the different 
treatment groups were also monitored (figure 4.3.21). From days 28 to 32, fluorescence 
efficiency readings from VEH animal front paws increased, though this was not 
statistically significant (P=0.0564; figure 4.3.21A). However, hind paw fluorescence 
values were significantly elevated by over 90% throughout the treatment period 
(P=0.0089; figure 4.3.21B). In the APO group, MMPSense fluorescence was significantly 
elevated over the treatment period in front paws (P=0.0211; figure 4.3.21C), but not in 
hind paws (P=0.7793; figure 4.3.21D). In fact, in some instances fluorescence efficiency 
in these animals decreased. This resulted in an overall drop of 12.1% in fluorescence 
efficiency between pre- and post-treatment values. Finally, fluorescence in naïve 
controls remained largely unchanged in all paws (P=0.9538 and P=0.0511; figures 
4.3.21E-F; front paws and hind paws, respectively). Overall, these data show that 
although APO866 treatment did not halt the progression of disease in CIA mice, it did 
slow it down somewhat, compared with treatment with a vehicle control.  
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Figure 4.3.19 Fluorescence intensity on day 32 (post-treatment) 
Panel shows photographic images of the six animals with established arthritis (VEH and 
APO groups) and two naïve control (CON) animals, with fluorescent intensity shown as 
a pseudocolour overlay using the Xenogen IVIS 200 imaging system. All animals were 
administered MMPSense750 FAST on day 32 and whole animal images taken 6 hours 
later and 4 days after minipumps were inserted, administering vehicle alone (VEH) or 
0.08 mg/kg/h APO866 (APO). Boxes within each image depict high power hind paw 
images. Intensity scale minimum=5.0 x 10-6, maximum=1.0 x10-5 units.  
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Figure 4.3.20 Fluorescence efficiency values on day 32 (Post-treatment) 
Individual front and hind paw efficiency readings taken 6 hours after probe administration 
(on day 32) and 4 days after minipumps were inserted, administering vehicle alone (VEH) 
or 0.08 mg/kg/h APO866 (APO). Values were corrected for background 
autofluorescence and arranged by treatment group. A) Front paw fluorescence efficiency 
values of animals in the vehicle (VEH) group (three animals, n=6 limbs), APO866 (APO) 
group (three animals, n=6 limbs) and naïve control (CON) group (two animals, n=4 
limbs). B) Hind paw fluorescence efficiency. Significant differences between means were 
determined using a two-tailed unpaired t test.**=P≤0.01, ns=not significant.
  144 
Figure 4.3.21 Changes in fluorescent efficiency pre- and post- APO866 treatment 
Vertical ‘before and after’ graphs show the changes in fluorescence efficiency readings 
in the vehicle (VEH) group (three animals, n=6 limbs), APO866 (APO) group (three 
animals, n=6 limbs) and naïve control (CON) group (n=4 limbs), pre-treatment (pre: day 
28) and post-treatment (post: day 32). Values were corrected for background 
fluorescence. Horizontal lines on graphs represent the mean values. Significant 
differences between means were determined using a two-tailed paired t test. *=P≤0.05, 
**=P≤0.01, ns=not significant (P>0.05).  
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4.3.3.5 Radiology, histology and cartilage erosion scores were not attenuated after 5 
days of APO866 treatment 
Overall, paw radiology scores in both VEH and APO treatment groups were 
significantly greater than those of the naïve controls (figure 4.3.24). APO866 radiology 
scores appeared attenuated compared to the vehicle treatment group; however, this 
difference was not statistically significant (P=0.1872 and P=0.061; front paws and hind 
paws, respectively.  
Low power images of histological sections from each hind paw were scored in a 
blinded manner for pathological changes (figure 4.3.24). There was a visible attenuation 
in degree of infiltrate in APO866-treated animals compared with the vehicle control 
(4.3.24A). Vehicle and APO866-treated animals both exhibited extensive histological 
damage compared with naïve controls. However, there was no significant difference in 
histological score between APO and VEH groups (P=0.495). Likewise, cartilage erosion 
scores did not differ between the two treatment groups (P=0.668; figure 4.3.24C). 
Collectively, these data imply that the APO866 treatment was insufficient to completely 
halt the progression of disease.  
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Figure 4.3.22 Fluorescence distribution and radiology 
Representative front paw fluorescence images of animals in vehicle (VEH) group, 
APO866 (APO) group and naïve control (CON) group taken on day 32 compared with 
their respective radiographic images taken on day of sacrifice (day 33).  
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Figure 4.3.23 Effect of APO866 treatment on radiology scores 
Radiology scores of animals in vehicle (VEH) group (three animals, n=6 limbs), 0.08 
mg/kg/h APO866 (APO) group (three animals, n=6 limbs) and naïve control (CON) group 
(two animals, n=4 limbs) on the day of sacrifice (Day 33). A) front paws and B) hind paws.  
Significant differences between means were determined using a two-tailed paired t test. 
*=P≤0.05, **=P≤0.01, ns=not significant (P>0.05).  
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Figure 4.3.24 Histological analyses of hind paws 
A) Representative histological images taken from of animals in vehicle (VEH) group 
(three animals, n=6 limbs), 0.08 mg/kg/h APO866 (APO) group (three animals, n=6 
limbs) and naïve control (CON) group (two animals, n=4 limbs) on the day of sacrifice 
(Day 33). High power magnification of histological images shows the extent of pro-
inflammatory infiltrate and exudate in VEH animals compared to APO. Images were 
scored for B) total histology score and C) cartilage erosion score. Significant differences 
between means were determined using a two-tailed paired t test. *=P≤0.05, **=P≤0.01, 
ns=not significant (P>0.05).  
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4.3.3.6 APO866 did not affect IgG2a antibody titres in CIA mice 
Sera samples taken from animals on days 21 and 33 were tested for CII-specific 
IgG2a. Samples obtained from animals with established disease (CIA) and naïve control 
animals (CON) were compared, along with those of immunised mice with did not develop 
disease (no arthritis; NA). In samples taken at day 21, as expected, animals immunised 
with collagen had significantly greater titres of IgG2a (P=0.0136; figure 4.3.25A). By day 
33, there IgG2a levels were elevated in CIA animals compared with day 21, and levels 
were significantly greater than in naïve controls (P=0.0392; figure 4.3.25B). There was 
no significant difference in IgG2a titre between VEH and APO treated animals post-
treatment, confirming that APO866 does not affect the immune response to collagen in 
CIA mice. 
 
Figure 4.3.25 IgG2a antibody titre of sera at days 21 and 33  
IgG2a antibody titre was determined in animals allocated to the two treatment groups 
(VEH and APO; n=3 animals per group), the two CIA animals that did not go on to 
develop arthritis (NA; n=2 animals) and the naïve control (CON; n=2) animals. A) IgG2a 
optical density (OD) values from sera taken at day 21. B) IgG2a OD values from sera 
taken at the experimental end-point on day 33. Differences between means were 
determined using a two-tailed paired t test. *=P≤0.05, ns=not significant (P>0.05).  
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4.3.3.7 APO866 did not have a significant effect on MMP gene expression 
Front paws snap-frozen on the day of sacrifice (day 33) were analysed by qPCR 
(section 2.3.2). The effect of APO866 treatment on MMP gene expression levels was 
evaluated (figure 4.3.26A-D). MMP mRNA expression was not significantly different 
between VEH and APO866 treatment groups (P=0.843, P=0.109, P=0.253, P=0.167; 
MMPs -1a, 3, 9 and 13, respectively). These gene expression data are contrary to 
MMPSense750 fluorescent data (figure 4.3.20), which showed that APO866 significantly 
attenuates MMP enzymatic activity.  
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Figure 4.3.26 Real-time PCR analyses of MMP expression in front paws 
Front paw cDNA of animals in vehicle (VEH) group (three animals, n=2 limbs per animal), 
0.08 mg/kg/h APO866 (APO) group (three animals, n=6 limbs) and naïve control (CON) 
group (two animals, n=4 limbs). A) MMP-1a, B) MMP-3, C) MMP-9 and MMP-13 gene 
expression. Samples were plated in duplicate and relative quantities of gene expression 
were determined relative to the untreated control (two animals, n=4 limbs; CON). 
Differences between means were determined using a two-tailed paired t test. ns=not 
significant (P>0.05).  
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4.3.3.8 Immunised (no arthritis) animals were comparable to naïve controls with respect 
to MMP fluorescence 
Two immunised mice never went on to develop CIA, and fluorescence efficiency 
was low in both mice up to experimental end point on day 32 (figure 4.3.27). 
Fluorescence values were calculated and compared to animals with established disease 
and naïve control animals; using ROI analysis software (figure 4.3.28). In both front and 
hind paws, fluorescence efficiency values (day 32) of arthritic animals were significantly 
greater than those of the immunised animals that did not go on to develop arthritis; (and; 
front paws (P=0.0009) and hind paws (P=0.0089) respectively. Fluorescence efficiency 
values of non-arthritic animals were comparable to the naïve controls. These data, 
combined with clinical score, paw diameter and IgG2a observations confirm that the 
animals had not developed arthritis by the experimental end-point.  
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Figure 4.3.27 MMPSense750 fluorescence in animals with no arthritis 
Animals (n=2) immunised with collagen that did not develop clinical signs of arthritis were 
each placed into vehicle and APO866 treatment groups (animal 1 and animal 2; VEH 
and APO, respectively) and probed and imaged with the arthritic (n=6) and control (n=2) 
animals. Panel above shows each animal pre-treatment (day 28), and again post-
treatment (day 32).  
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Figure 4.3.28 Comparison of MMPSense750 fluorescence efficiency of animals 
with and without arthritis 
Raw efficiency values from day 28 and 32 corrected for background fluorescence. A) 
Fluorescence efficiency of front paws of animals with clinical signs of arthritis (six 
animals, n=12 limbs) compared to animals with no clinical signs of arthritis (two animals, 
n=4 limbs) and naïve control animals (two animals, n=4 limbs). B) Fluorescence 
efficiency of hind paws pre-treatment. Fluorescence efficiency of C) front paws and D) 
hind paws of animals post-treatment. Kruskal-Wallis tests with Dunn’s multiple 
comparison post-test analyses were performed to determine the significance levels 
between treatment groups. **=P≤0.01, *=P≤0.05, ns=not significant (P>0.05).   
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4.3.4 Using archived CIA tissue to study the concentration-dependent effect of APO866 
upon MMP gene expression within an inflamed joint 
MMPSense750 FAST imaging data demonstrated that APO866 treatment 
reduced the biological activity of MMPs in vivo (figure 4.3.20) whilst real-time PCR data 
showed that APO866 enhanced MMP expression in the joint (figure 2.3.26). The small 
number of animals used in the study could have contributed to the disparity in the data. 
For this reason archived tissue, harvested from a sufficiently powered (six mice per 
group), unpublished study, were evaluated to study the relationship between APO066 
and MMP expression in CIA joints. In this study, mice with established CIA had been 
treated for 12 days with either 0.08 mg/kg/h or 0.12 mg/kg/h APO866. A control group 
received vehicle (propylene glycol in saline). All medicaments were administered via 
minipumps (as above). A fourth group of naïve age-matched mice received no treatment. 
To use more mice to perform additional in vivo CIA studies was deemed unethical when 
archived tissues were available to serve our experimental purpose. 
Real-time PCR analyses were performed (section 2.3.2), and all values were 
determined relative to naïve control mice (figure 4.3.29). Overall, Kruskal Wallis analyses 
indicated a significant difference between all four treatment groups (VEH, 0.08 mg/kg/h 
APO, 0.12 mg/kg/h APO, and CON) for all MMPs analysed by qPCR (P=0.001, 
P=0.0019, P=0.0063, P=0.0008; MMPs -1, -3, -9 and -13, respectively). Samples from 
animals treated with 0.12 mg/kg/h APO866 had MMP gene expression levels 
comparable to the naïve control, indicating a dose-dependent attenuation of MMP 
expression compared with untreated vehicle controls.  
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Figure 4.3.29 Effect of treatment duration and dosage on MMP expression levels 
Archived paw samples were compared for relative quantities of MMP gene expression. 
For each treatment group, one front paw from each animal was homogenised (n=6 mice, 
one paw per animal) and real-time analyses were performed. Individual ΔCT values were 
related to naïve controls (n=6 mice, one paw per animal). QPCR was performed on 
samples plated in duplicate and RQ analyses were performed for A) MMP-1a, B) MMP-
3, C) MMP-9 and D) MMP-13. Kruskal-Wallis tests with Dunn’s multiple comparison post-
test analyses were performed to determine the significance levels between treatment 
groups. **=P≤0.01, *=P≤0.05, ns=not significant (P>0.05).  
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4.3.5 Comparison of MMPSense750 fluorescence with other disease parameters 
One of the objectives of this chapter was to establish an in vivo imaging protocol 
suitable for longitudinal studies using the CIA model. Subsequently, the next objective 
was to determine how MMP enzymatic activity relates to other conventional disease 
parameters, such as clinical score. In order to do this, the data from the two independent 
animal experiments utilising MMPSense750 FAST (described in sections 4.2.2 and 
4.2.3) were combined. The pooled dataset comprised of three naïve control animals, and 
five untreated CIA animals with established disease. Data from APO866-treated animals 
and CIA animals that did not develop signs of disease (section 4.3.3.8) were not 
incorporated.  
 
4.3.5.1 MMPSense750 fluorescence was significantly correlated with clinical score and 
paw diameter 
Firstly, fluorescence efficiency values were related to the respective arthritis 
index scores obtained from the animals at the time of imaging. Comparisons were made 
after the administration of both the first and second i.v. injections on days 28 and 32-34 
respectively. The first injections of imaging probe were administered at the first sign of 
established disease on day 27 (median clinical score=1) and animals imaged 24 hours 
thereafter. At this stage, MMPSense750 fluorescence was significantly associated with 
front paw clinical score (P=0.0002; figure 5.3.30A), but not hind paw clinical score 
(P=0.1259; figure 5.3.30B) or paw diameter readings (P=0.1635; figure 5.3.30C). For 
both experiments using MMPSense750, the second set of probe injections was 
administered when most animals had reached the advanced stages of arthritis (median 
clinical score=4.0), which occurred between days 32-34. At this point, there was a highly 
significant association between fluorescence efficiency and clinical score in both front 
paws (P≤0.0001; figure 5.3.30D) and hind paws (P=0.0005; figure 5.3.30E), as well as 
paw diameter measurements (P≤0.0001, figure 5.3.30F).  
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Figure 4.3.30 Correlation of MMPSense750 FAST fluorescence efficiency and 
conventional disease markers in early and late arthritis 
Fluorescence efficiency values obtained from ROI analyses after the first (day 28; seven 
animals, n=14 limbs) and second (days 32-34; eight animals, n=16 limbs) i.v. injections 
of MMPSense750 FAST probe were related to respective clinical score and paw 
diameter observations from time of probe administration. Data shown are a combination 
of two individual experiments involving CIA and naïve animals injected with 
MMPSense750 probe. A) Front paw, B) Hind paw clinical scores, and C) hind paw 
diameters related to fluorescence efficiency values obtained after first i.v. D) Front paw 
and E) Hind paw clinical scores, and F) hind paw diameter related to fluorescence 
efficiency after administration of second i.v. Correlation analyses were performed using 
Pearson’s Correlation Coefficient.  
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4.3.5.2 MMPSense750 fluorescence was significantly correlated with radiological and 
histological damage and MMP mRNA expression 
In experiments two (section 4.3.2) and three (section 4.3.3), animals were 
sacrificed on days 34 and 33, respectively. For the former, only hind paws were 
harvested for x-ray imaging. However, for the latter experiment, both front and hind paws 
were imaged. The MMPSense750 fluorescence efficiency values taken prior to sacrifice 
were significantly associated with radiology score in both front paws (P=0.0006; figure 
4.3.31A) and hind paws (P=0.0349; figure 4.3.31B). In addition, histology and cartilage 
erosion scores of the affected hind paws were also significantly correlated with 
MMPSense750 fluorescence efficiency (P=0.0007 and P=0.035; figures 4.3.31C and 
4.3.31D, respectively), indicating that MMP activity is highest in paws with the greatest 
abundance of pro-inflammatory infiltrate and cartilage erosion.  
Finally, MMP fluorescence readings of hind paws from day of sacrifice were 
related to respective relative quantities of MMP gene expression (figure 4.3.32), as 
quantified by real-time qPCR. With the exception of MMP-9 (P=0.005; figure 4.3.32B), 
MMP gene expression was significantly correlated with MMPSense fluorescence 
efficiency (P=0.0041, P≤0.0001, P=0.0033; MMPs -1, -3 and -13, respectively). 
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Figure 4.3.31 MMPSense750 fluorescence and radiology 
Fluorescence efficiency values obtained from ROI analyses after the first (day 28; seven 
animals, n=14 limbs) and second (days 32-34; eight animals, n=16 limbs) i.v. injections 
of MMPSense750 FAST probe were related to respective MMPSense750 efficiency 
values obtained 6 hours after the second i.v. injection of probe (days 32-34) were related 
to respective radiology scores of A) front, and B) hind paws harvested at time of sacrifice 
on the same day. Fluorescence efficiency was also related to C) histology, and D) 
cartilage erosion scores of hind paws harvested on the day of sacrifice (day 32-34). Front 
paw observations were taken from one experiment only (n=10 limbs), whilst hind paw 
observations were combined from two independent experiments using MMPSense750 
(n=16 limbs). Correlation analyses were performed using Pearson’s Correlation 
Coefficient. 
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Figure 4.3.32 MMPSense750 fluorescence and relative expression of MMPs 
MMPSense750 efficiency values of front paws obtained 6 hours after the second i.v. 
injection of probe (days 32-34) were related to relative quantity of gene expression (RQ) 
data obtained from real-time PCR analyses of RNA extracted from front paws harvested 
on day of sacrifice (days 32-34). Data shown are a combination of two individual 
experiments involving CIA animals injected with MMPSense750 probe. RQ values were 
determined by relating ΔCT values of arthritic animals (n=10 limbs) to those of a naïve 
control animals (n=6 limbs). Individual RQ values for A) MMP-1a B) MMP-3 C) MMP-9 
and D) MMP-13 were correlated to the respective front paw fluorescence efficiency 
values. Correlation analysis was carried out using Pearson’s Correlation coefficient.  
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4.4 Discussion 
4.4.1 Murine collagen-induced arthritis was induced in experimental animals 
DBA-1 mice were chosen for their genetic susceptibility to CIA, which has been 
widely reported in the literature (Courtenay et al., 1980, Brand et al., 1996). Arthritis 
incidence in this strain is typically 80-100% (Brand et al., 2007). Of the eighteen animals 
immunised with collagen throughout the course of the three experiments, fourteen 
animals exhibited signs of disease; meaning incidence in these studies (approximately 
78%) was slightly lower than anticipated. Low arthritis incidence is typically attributed to 
denatured CII, or a poor quality emulsion due to insufficient mixing of the CII with 
Freund’s complete adjuvant (Brand et al., 2007). In the present study, the CII was made 
up fresh for each experiment (as detailed in section 2.2.1), and the emulsion was 
homogenised thoroughly in a glass syringe and tested prior to use by dropping into icy 
water. The age of the animals can also be ruled out as a problem, as they were all aged 
between 7-8 weeks when purchased. Animals were given time to acclimatise to their 
environment and appeared healthy prior to the start of the study. Whilst every effort was 
made to ensure accurate and reproducible delivery of the collagen emulsion into the 
animals, it is possible that the slightly lowered incidence of disease noted in this study 
may relate to the efficiency of collagen delivery. 
Disease onset occurred typically within 25 days of the first intradermal injection 
of CII. In experiment three, disease onset failed to occur at this point; however, a single 
intra-peritoneal injection of LPS rapidly potentiated the onset of arthritis, and 
synchronised disease in most of the animals. The addition of LPS is associated with 
increased production of anti-CII IgG and IgG2a antibodies as well as various kinds of 
cytokines (such as 1L-1β), exacerbating the autoimmune joint inflammation (Caccese et 
al., 1992). As expected, the induction of arthritis in all animal experiments resulted in a 
characteristic monophasic progression of disease which included paw swelling and 
erythema in individual limbs, and an increase in hind paw diameter (Brand et al., 2007). 
A subjective clinical scoring system showed that disease progressively worsened in all 
animals with established disease, with many reaching the maximum allowable clinical 
score within 10 days of disease onset.  
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4.4.2 MMP enzymatic activity was monitored successfully in vivo with NIRF imaging 
probes 
MMP activatable fluorescent probes were used to study local MMP enzymatic 
activity within murine joints in both diseased and naïve mice. Firstly, the commercially-
available probe, MMPSense680, was tested on animals with established arthritis. In the 
first experiment, MMPSense680 was detected in the affected paws of the animals 24 
hours post-injection. The localisation of the fluorescence is similar to that seen in studies 
by Wunder and colleagues, who tested a cathepsin-specific imaging probe in CIA 
animals (Wunder et al., 2004). Observations of individual limbs hinted that paws with 
less swelling did not fluoresce as intensively as those with a greater degree of swelling. 
Overall, the preliminary data indicated that MMPs are a promising biomarker for 
monitoring longitudinal disease progression in this animal model. However, one limitation 
of using MMPSense680 was that the Kodak in vivo imaging system used to detect its 
fluorescence emissions did not permit an efficient flow of anaesthetic agent (see below).  
The preliminary observations of the MMPSense680 study were followed up with 
two experiments using another imaging probe, MMPSense750 FAST. This probe, 
although similar in terms of specificity, has been reported to possess a smaller molecular 
weight, and supposedly a faster rate of clearance (Groves et al., 2010). In addition, this 
probe allowed imaging in the IVIS 200 system, which contained a gas anaesthesia 
manifold; allowing for easier handling of the animals within the chamber. It was 
anticipated this probe would be more suitable for longitudinal studies, as animals could 
be injected with fluorescent probes twice during the course of the study. As with 
MMPSense680, MMPSense750 FAST fluorescence was enhanced in affected limbs of 
CIA animals. Arthritic animals injected with the probe showed significantly higher levels 
of fluorescence compared with non-arthritic animals. This corroborates previous 
published data, which showed a 7-fold increase in fluorescent intensity in arthritic paws 
compared with non-arthritic paws (Wunder et al., 2004). 
 When re-probed and re-imaged, fluorescence was enhanced in animals in the 
advanced stages of disease compared to early disease. As these imaging probes are 
quenched in the absence of MMP activity, the data in this chapter suggest that MMP 
activity is enhanced as disease progresses. Interestingly, in early disease, some 
fluorescence readings were elevated despite only mild paw swelling. Subsequent 
scoring showed that these limbs went on to develop advanced disease. This suggests 
that MMP activity becomes elevated in some paws prior to clinical manifestation of 
disease, indicating that MMP fluorescence may be useful as a predictive marker of 
disease onset.  
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Longitudinal data acquired through in vivo imaging with MMPSense probes were 
compared with end-point disease parameters such as radiology, histology and qPCR 
analyses of MMP gene expression.  Combined from the two experiments utilising 
MMPSense750 showed a positive correlation between MMP fluorescence and the 
degree of radiological and histological damage, which had been hinted at in the 
MMPSense680 study. As with MMPSense680, distinct zones of intense fluorescence in 
pseudocolour overlays coincided with areas with a large degree of inflammatory infiltrate 
and cartilage erosion in corresponding histology sections. This suggests the presence of 
inflammatory cells and possibly chondrocytes producing excessive amounts of MMPs 
locally, and ties in with previous observations in RA (Ainola et al., 2005) and in the CIA 
model (Seeuws et al., 2010). Although MMPSense fluorescence was associated with an 
increase in extent of cartilage erosion, other parameters of radiological damage such as 
osteopenia were not observed. This is possibly due to the acute nature of the disease 
progression, meaning that although cartilage was affected, the short duration of the 
disease left insufficient time for the development of bone erosions. If disease had been 
allowed to progress further, it is likely that more extensive radiological damage may have 
occurred.  It is also worth noting that joints with cartilage damage show a preference for 
worsening of this damage, rather than the development of bone erosions (van der Heijde, 
2011). Therefore, extent of MMP production is unlikely to predict the degree of 
radiological damage.  
Data combined from experiments two and three indicated a significant correlation 
between MMPSense750 FAST fluorescence and corresponding MMP gene expression 
data, for all MMPs with the exception of MMP-9. This is interesting, as although 
MMPSense750 FAST has a broad activation profile, it is particularly susceptible to MMP-
9 activation (refer to figure 2.15). The specificity of the probe for MMP-9 may explain why 
some paw extracts yield MMP-9 gene expression, yet the respective MMPSense 
fluorescence values are high.   
This chapter focused on a variety of MMPs known to be upregulated in the RA 
synovium, including MMPs -1, -3, -9 and -13 (Konttinen et al., 1999, Yoshihara et al., 
2000, Tchetverikov et al., 2004). Generally, MMP expression analysed by qPCR was 
enhanced in CIA animals compared with naïve controls. This ties in with previous 
studies, that have shown upregulation of MMPs -1, -3 (Mun et al., 2009), -9 and -13 
(Oestergaard et al., 2006) in the joint tissue of CIA animals. More recently, an increase 
in MMP-3 levels has been associated with many pathological features of CIA, including 
inflammation, cartilage destruction and bone erosion (Seeuws et al., 2010); indicating 
that expression and activity of these MMPs is a useful indicator of extent of cartilage 
erosion.  
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4.4.3 A short treatment with APO866 in established arthritis reduced arthritis index and 
MMP activity, but not MMP gene expression 
For the final experiment, MMPSense750 FAST was used to determine the effect 
of APO866 treatment on disease severity in the CIA model longitudinally. The dose of 
0.08 mg/kg/h was chosen for this study, as previous work within the group showed that 
this dose was sufficient to reduce clinical score and paw diameters compared to the 
untreated vehicle. After four days of treatment, APO866-treated animals had significantly 
lower clinical scores compared to the untreated vehicle control. A previous study by 
Busso et al (2008) found that APO866 treatment results in significantly reduced mean 
arthritic score within 10 days of the commencement of treatment (Busso et al., 2008). In 
this study, APO866 was administered intraperitoneally at doses of 2-10 mg/kg every 12 
hours, for 14-15 days from the first signs of disease. The lowest dose, equivalent to 0.17 
mg/kg/h, was lower than the dose used in this chapter. The concentration of APO866 
used in this chapter was carefully considered, and equivalent to the maximum tolerated 
dose in humans (Holen et al., 2008). The method of continuous drug infusion by 
minipump has numerous advantages over administering drugs by injection. The main 
advantage is that minipump infusion involves less researcher intervention. In addition, 
studies comparing the two methods of administration show that continual drug infusion 
allows for greater bioavailability and less wasted compound (Bedard et al., 2011, Kondo 
and Togari, 2011). This may explain why a comparable therapeutic effect was seen in 
the current study, despite the relatively low dose of APO866 used. 
Despite the therapeutic effects observed with respect to arthritis index, 
radiological and histological damage was not affected by a short APO866 treatment 
compared with the vehicle control. This suggests that although disease had begun to 
regress in response to APO866 treatment, a large degree of damage had already 
occurred due to the rapid nature of the disease progression. These findings are in 
contrast with those of Busso and colleagues, who observed significant decreases in 
inflammatory infiltrate and synovial hyperplasia in histological sections of APO866-
treated animals (Busso et al., 2008). Sera levels of NAMPT have been associated with 
a higher degree of radiological damage in patients with RA (Rho et al., 2009); however, 
APO866 did not significantly affect radiology score compared with the vehicle control. 
Again, this could be attributed to the timing and dosage of APO866 administration.  
In contrast with MMP fluorescence data, MMP mRNA expression was slightly 
enhanced in APO866-treated animals compared with the controls receiving vehicle, 
although this effect was not statistically significant. It is unclear why MMP gene 
expression remained high, whilst MMP enzymatic activity was attenuated by APO866. 
One possibility is that APO866 inhibited NAMPT produced by circulating T lymphocytes 
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and synoviocytes, thus reducing MMP fluorescence. However, the dosage used may 
have been insufficient to inhibit NAMPT activity in cells within deeper tissues of the 
inflamed joint, such as the joint cartilage.  
4.4.4 APO866 treatment reduced MMP gene expression in murine front paws in a time 
and dose-dependent manner 
Following qPCR analyses of the current studies in this chapter, archived samples 
from animals treated for different dose regimens were used for qPCR analyses. In 
contrast to findings from the short-term APO866 treatment, expression of all MMPs was 
significantly attenuated in a time and dose dependent manner. Busso and colleagues 
observed a dose-dependent effect in their studies in the CIA model, with maximal 
therapeutic response at the highest dose of 10 mg/kg. The beneficial effect of APO866 
was apparent within ten days following the commencement of treatment (Busso et al., 
2008). Although this study did not perform analyses of MMP gene expression, 
histological examination of tissues indicated greater retention of Safranin O staining of 
cartilage in APO866-treated animals; suggesting attenuation of MMP expression. These 
data support the findings of this chapter, that APO866 efficacy is apparent between 4-14 
days of commencement of treatment.  
4.4.5 APO866 has no impact upon IgG2a production 
Sera taken from animals in experiment three was also tested for CII-specific 
IgG2a, a marker for antibody response to collagen. During disease development, anti-
collagen antibodies bind to the joint cartilage and initiate the complement cascade. In 
the current study, IgG2a titres were analysed in sera, as IgG2a production is associated 
with activated Th1 (T helper type I) cells-which drive the immune response resulting in 
inflammation (reviewed by Brand et al., 2003). The Th2-associated IgG1 subclass is also 
detectable in diseased animals; however, mice that develop CIA generally have a high 
ratio of IgG2a:IgG1 (Brand et al., 1996). In the current study, vehicle and APO866-
treated animals showed no significant differences in IgG2a levels. This is in contrast to 
anti-TNF receptor and anti-B cell treatments, which actively lower levels of Th1 driven 
IgG2a antibodies (Mukherjee et al., 2003, Yanaba et al., 2007), suggesting that 
therapeutic efficacy of APO866 is not due to direct reduction of auto-antibodies.  
4.4.6 A multi-parameter approach can accurately assess the effects of NAMPT blockade 
Taken together, these data suggest that traditional longitudinal disease 
parameters such as clinical score, cartilage erosion and radiology may not provide an 
accurate reflection of MMP gene expression and enzymatic activity in vivo. Conversely, 
MMP activity and expression data, taken alone, do not sensitively reflect the efficacy of 
APO866 treatment; particularly when assessing such short-term treatment regimens as 
  167 
those used in this current study. Clinical score and paw diameter observations remain 
the best markers for disease, whilst traditional radiological and histological analyses 
provide the best insight into the extent of joint inflammation and cartilage erosion. 
However, in vivo imaging could emerge as a useful tool in assessing local MMP activity 
in joints and treatment response longitudinally. The same animal can potentially be re-
probed and re-imaged multiple times, meaning valuable longitudinal data can be 
obtained using fewer animals. Although the probes used in this study only assess MMP 
activity, a variety of commercially-available probes have been developed to assess other 
aspects of disease, such as bone turnover. Quantitative PCR analyses did not yield a 
difference in MMP gene expression between vehicle and APO866 after four days of 
treatment. However, it was very effective at showing a time and dose-dependent effect 
of APO866 on MMP gene expression. The advantage of qPCR analysis is that once RNA 
has been extracted from paws, a number of target genes can be assessed, so a large 
amount of data can be generated quickly. Therefore, a multi-parameter approach 
provides the most comprehensive means to monitor CIA disease and APO866 efficacy. 
4.4.7 APO866 may dampen local MMP activity at sites of cartilage invasion 
Quantitative PCR analyses of murine front paws in this chapter showed a 
significant increase in expression of MMPs -1a, -3, -9 and -13 in CIA animals compared 
with naïve controls. MMPs -1 and -3 are both predominantly expressed in the synovial 
cells comprising the pannus that invades the articular cartilage. In contrast, MMPs -9 and 
-13 are generally expressed in the neutrophils and macrophages (MMP-9) and 
chondrocytes (MMP-13). These data, combined with MMP fluorescence distribution 
data, suggest that the synovial cells are the major source of MMP expression and 
activity. For future studies, localisation of MMP activity could be confirmed by 
immunohistochemical analyses, with the use of antibodies that specifically recognise 
neoepitope sequences generated by MMP-mediated cleavage of aggrecan (Fosang et 
al., 2003).  
4.4.8 Summary 
In this chapter, a combination of established and novel techniques were 
employed to monitor disease progression in a murine arthritis model, with the eventual 
aim of assessing the efficacy of NAMPT blockade by APO866. It was discovered that 
near infra-red fluorescent imaging probes can assess both the extent and localisation of 
MMP activity in the live animal; providing novel insights into the process of cartilage 
degradation in animal disease models. MMP enzymatic activity increased in line with 
paw swelling and erythema in affected limbs, highlighting it as a useful marker of 
inflammation as well as cartilage catabolism. MMP enzymatic activity was not directly 
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related to radiological and histological markers of disease in affected limbs, as well as 
MMP gene expression.  
Treatment with APO866 attenuated disease progression in animals, causing a 
reduction in clinical score. There was no significant effect on cartilage degradation, 
histology and radiology scores, although this may be due the short duration of the 
treatment. Finally, qPCR analyses of archived samples confirmed that APO866 has a 
time and dose-dependent effect on MMP gene expression, suggesting that NAMPT plays 
an important role in the underlying processes involved in matrix destruction in 
inflammatory disease.   
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Chapter 5: The effect of iNAMPT blockade on articular 
cartilage destruction ex vivo 
5.1 Introduction 
The principle aim of this chapter is to assess the direct effect of NAMPT inhibition on 
cytokine-induced articular cartilage destruction ex vivo, using chondrocyte monolayer 
and bovine explant culture systems.  
5.1.1 Assessment of articular cartilage breakdown ex vivo 
The mechanical properties of cartilage are highly dependent on the integrity of its 
extracellular matrix (ECM), which consists primarily of type II collagen and 
supramolecular aggregates of aggrecan and hyaluronic acid, stabilised by link protein. 
The initial step in cartilage degeneration is the enzymatic degradation of aggrecan by 
aggrecanases (e.g. ADAMTS-4 and -5) and MMPs (e.g. MMP-1 and -3), resulting in its 
fragmentation (reviewed by Cawston and Young, 2010). The ensuing loss of GAG-
bearing aggrecan fragments from the ECM compromises the water holding capacity of 
the tissue and exposes the underlying collagen framework, making it more vulnerable to 
biomechanical load and other degradative enzymes, particularly collagenases such as 
MMPs -1 and -13 (figure 5.1.1). Further enzymatic degradation, coupled with load, 
results in fatigue failure of the collagen framework, cell death and tissue destruction 
(reviewed by Aigner et al., 2006).   
Researchers employ a combination of techniques to elucidate the sequence of 
catabolic events involved in articular cartilage destruction using both cartilage explants 
and chondrocyte cultures. The metabolism of chondrocytes grown as monolayers can 
differ from those occurring within cartilage, as chondrocytes undergo de-differentiation 
in monolayer growth conditions, becoming fibroblastic within a few passages. 
Chondrocytes retain their in vivo phenotype with greater fidelity in cartilage explants, as 
they remain embedded within their native 3D ECM (Sondergaard et al., 2006). Moreover, 
the degradative processes resulting in the progressive breakdown of this ECM can be 
fully evaluated. Explants are typically extracted from the full depth of the articular 
cartilage tissue that lines bovine or porcine synovial joints, and cultured ex vivo in 
supplemented medium for extended periods of time. To simulate arthritis, the cartilage 
explants are exposed to catabolic agents (e.g. interleukin-1) and the subsequent loss of 
cartilage integrity over time assessed by a variety of sensitive biochemical and 
histological assays. These systems thus permit appraisal of the therapeutic efficacy of 
anti-rheumatic agents. Several groups have used articular cartilage explant cultures to 
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examine the effect of the DMARDs, namely Methotrexate, Leflunomide and 
Sulfasalazine on IL-1β-induced PG loss (Van Der Veen et al., 1996, Neidel et al., 1998, 
Panico et al., 2003, Lakey and Cawston, 2009).   In these studies, to mimic the chronic 
exposure to cytokine assault, culture media containing IL-1β either with or without 
DMARDs were replenished every few days.  
 
 
Figure 5.1.1 Destruction of matrix components in articular cartilage  
Healthy cartilage owes its properties to an organised network of collagen fibrils and 
highly hydrophilic, supramolecular aggregates of aggrecan and hyaluronic acid, 
stabilised by link protein. PG loss occurs during early cartilage degradation. Continued 
PG depletion eventually weakens the collagen fibril network, resulting in matrix 
degradation. 
 
5.1.2 Role and regulation of iNAMPT in chondrocyte-mediated catabolism 
In this chapter, articular cartilage explant cultures were used to investigate the 
role of intracellular NAMPT (iNAMPT) in a model of chronic cytokine assault. Previous 
work shows that eNAMPT is upregulated in the serum and synovial fluid of patients 
suffering from rheumatoid arthritis (Nowell et al., 2006), and that synovial fluid eNAMPT 
positively correlates with the degradation biomarker of collagen II (CTX-II), and aggrecan 
(AGG1 and AGG2) (Duan et al., 2011). Furthermore, NAMPT protein is immunolocalised 
at sites of pannus invasion into the articular cartilage of patients with RA (Brentano et 
al., 2007).  The results of chapter four have also shown that the inhibition of NAMPT in 
vivo, using the small molecule selective inhibitor APO866, reduces MMP expression and 
activity in the paws of animals with collagen-induced arthritis (section 4.3.3). Together, 
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these observations suggest an active role for NAMPT in local degradative processes in 
articular cartilage. 
The NAMPT or NAM salvage pathway is not the only pathway involved in NAD+ 
biosynthesis; there are at least three other known pathways for generating NAD+, 
including the de novo pathway involving Tryptophan and QPRT, and the Preiss-Handler 
pathway involving NA and NAPRT (section 1.3.4). However, NAMPT may be unique 
amongst these enzymes, in that it has been shown to be upregulated by a variety of 
stimulators, including cytokines, Toll-like ligands and hypoxia (Brentano et al., 2007, Bae 
et al., 2006). With regards to human and murine chondrocytes, NAMPT mRNA and 
protein expression has been shown to be upregulated six-fold by the addition of 10 ng/ml 
IL-1β (Gosset et al., 2008). Up until now however, the expression of the other rate-limiting 
NAD biosynthesis enzymes (NAPRT and QPRT) in joint cells has not been investigated. 
The Gosset study (Gosset et al., 2008) showed that, like the synovial fibroblasts 
described in section 1.1.2 of this thesis, the addition of eNAMPT not only upregulated 
pro-degradative MMPs in chondrocytes, it also upregulated ADAMTS -4 and -5 and the 
catabolic mediator, prostaglandin E2 (Gosset et al., 2008). A variety of cofactors depend 
on NAD+ availability to perform their functions, HDACs, which can act as potent 
transcriptional coactivators or corepressors (Roth et al., 2001).  Studies have shown that 
inhibition of iNAMPT in human and rabbit chondrocytes reduce intracellular NAD+ levels 
and the activity of a NAD+-dependent, chromatin-modifying enzyme and HDAC, silent 
mating type information regulation 2 homolog 1 (SIRT1) (Dvir-Ginzberg et al., 2008, 
Hong et al., 2011). Reduction in SIRT1 activity in this way resulted in chondrocyte 
dedifferentiation, with reduced gene expression of collagen 2a(1), 2b(1) and aggrecan 
in vitro (Hong et al., 2011, Dvir-Ginzberg et al., 2008). Young and colleagues added 
NAD+ independent HDAC inhibitors to explants, and found that cytokine induced MMP 
expression was inhibited (Young et al., 2005).  
However, these studies did not investigate the effect of iNAMPT inhibition on PG 
loss and MMP expression; key indicators of early degradative processes. APO866, 
through reduction of intracellular NAD+, may indirectly inhibit NAD+-dependent HDACs, 
thereby reducing MMP expression in cartilage and the implication for NAD+ depletion in 
chondrocytes warrants investigation.  
5.1.3 Chapter aims 
In the previous chapter, treatment with APO866 in the murine CIA model 
attenuated disease severity and MMP mRNA expression in a dose-dependent manner. 
Moreover, in vivo imaging showed a reduction in MMP activity within the paws of 
APO866-treated mice compared to vehicle-treated control mice. However, the role of 
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iNAMPT in cartilage-mediated MMP production is yet to be investigated. Cytokines have 
been shown to upregulate NAMPT gene expression in vitro, yet the regulation of the 
other NAD enzymes has not been investigated thus far.  
In this chapter, the aims were to investigate the cytokine regulation of other NAD+ 
enzymes in chondrocytes and to assess the impact of inhibiting iNAMPT activity on 
cytokine-induced cartilage breakdown. 
In order to achieve these aims, the specific objectives of the chapter were as follows:   
 Assess the effects of IL-1β and NAMPT antagonist, APO866, on chondrocyte 
gene expression in vitro. 
 Determine the impact of APO866 on IL-1β-induced cartilage breakdown ex vivo, 
using biochemical and histological technique. 
 Assess the cytotoxic effects of long-term exposure to high and low doses of 
APO866. 
 Assess the effects of NAD+ biosynthesis substrates NMN and NA on cartilage 
catabolism and cellular metabolism.  
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5.2 Materials and methods 
5.2.1 Chondrocyte culture 
Human Articular chondrocytes (HACs) were extracted as outlined in section 
2.1.2.1. HACs were cultured for 24 hours in serum-free chondrocyte-specific medium 
supplemented with 1% (v/v) Nutridoma-SP before stimulation with 10 ng/ml IL-1β, alone 
or in combination with 10 nM APO866. Cells were stimulated for 24 hours, media 
removed and 1 ml of TRI-Reagent added to cells. RNA was extracted and qPCR 
performed as outlined in section 2.3.2.  
5.2.2 Explant cytokine stimulation studies 
All explant studies were performed on biopsy cores of full-depth articular cartilage 
taken from the MCP/MTP joint of 7-day old calves. Extraction and preparation of tissue 
for ex vivo culture was performed as described in section 2.1.5.1. Explants were cultured 
in 500 μl serum-free DMEM supplemented with 2-20 ng/ml human IL-1β, 10-100 nM 
APO866, and 100 μM NMN or NA. Cultures were maintained for up to 21 days, medium 
was removed every 48 hours and stored at -20°C, prior to analysis by DMMB assay 
(section 2.1.5.2), gelatin zymography (section 2.1.5.3) or LDH assay (section 2.1.6.2). 
Cells were then supplemented with fresh medium. At the experimental end-point, 
explants were halved and weighed. One half of each explant was papain digested for s-
GAG analysis, whilst the remaining halves were fixed for histological analyses (section 
2.3.1).  
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5.3 Results 
5.3.1 IL-1 induces NAMPT, but not NAPRT or QPRT gene expression in HACs. 
In order to determine how stimulation with IL-1β, in the presence or absence of 
APO866, affects the gene expression of NAD+ biosynthesis genes in vitro, HACs were 
analysed by qPCR. The addition of 10 ng/ml IL-1β significantly enhanced NAMPT gene 
expression compared with untreated control cells (P=0.008; figure 5.3.1). NAMPT 
expression was attenuated in cells co-incubated with both IL-1β and APO866 compared 
with IL-1β alone (P=0.043). This effect was not significant. Expression of NAPRT and 
QPRT were not significantly affected by treatment with IL-1β and/or APO866 (P=0.260 
and P=0.134; NAPRT and QPRT, respectively).  
IL-1β alone significantly induced MMP-1 and MMP-3 mRNA levels compared with 
an untreated control (P=0.046 and P=0.038; MMP-1 and MMP-3, respectively; figure 
5.3.2). The cDNA from cells co-incubated with both IL-1β and APO866 showed 
attenuated MMP gene expression compared with IL-1β alone, although this effect was 
not significant (P=0.067 and P=0.078; MMP-1 and MMP-3, respectively).  
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Figure 5.3.1 Effect of IL-1β and APO866 on NAD+ enzyme expression in HACs  
HACs (single donor, n=3 experimental replicates per condition) were stimulated for 24 
hours with 10 ng/ml IL-1β alone, or in combination with 10 nM APO866. Extracted RNA 
samples were analysed in duplicate for NAMPT, NAPRT, and QPRT gene expression 
by qPCR. Samples were normalised to UBC, beta-Actin 18S rRNA and GAPDH 
reference genes. The relative quantity of NAMPT gene expression (RQ) in treated cells 
was compared to zero hour unstimulated control cells. All data points are graphically 
presented with mean ± standard error of the mean (S.E.M). Significance levels between 
means of the different treatment groups were determined using a two-tailed unpaired t 
test. *P≤0.05, **=P<0.01. 
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Figure 5.3.2 Effect of IL-1β and APO866 on MMP expression in HACs 
HACs (single donor, n=3 experimental replicates per condition) were stimulated for 24 
hours with 10 ng/ml IL-1β alone or in combination with 10 nM APO866. Extracted RNA 
samples were analysed in duplicate for MMP-1 and MMP-3 gene expression by qPCR. 
Samples were normalised to UBC, beta-Actin, 18S rRNA and GAPDH reference genes. 
The relative quantity of MMP gene expression (RQ) in treated cells was compared to 
zero hour unstimulated control cells. All data points are graphically presented with mean 
± standard error of the mean (S.E.M). Significance levels between means of the different 
treatment groups were determined using a two-tailed unpaired t test. *=P≤0.05. 
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5.3.2 APO866 attenuates IL-1β-mediated PG depletion ex vivo 
Following on from monolayer culture analyses, the effects of IL-1β on cartilage 
metabolism were explored in full-depth cultures of bovine articular cartilage, with specific 
focus on the rate of proteoglycan release. Overall, there was a significant difference in 
s-GAG loss between explants cultured in medium alone, and explants continually 
incubated with low dose (2 ng/ml) IL-1β, as determined by Two-way Analysis of variance 
(P≤0.0001; figure 5.3.3). However, Bonferroni post-test analyses showed that there was 
no significant difference at any given time point. As expected, time had an overall 
significant effect on s-GAG release (P≤0.0001). Explants cultured in media alone showed 
continuous Safranin O staining throughout the tissue, with a distinct zone of depletion 
nearer the cartilage superficial zone. However, explants incubated with low doses of IL-
1β exhibited complete loss of PG staining from the superficial zone, and some evidence 
of loss in the deeper zone (figure 5.3.4). Analysis of supernatants from explants treated 
with low doses of IL-1β and APO866 showed only a slight attenuation of s-GAG release 
into the media, but showed the greatest retention of Safranin O staining out of all the 
cultured explants.  
Figure 5.3.3 Effect of low-dose cytokine and APO866 on s-GAG release  
Bovine cartilage explants (n=3 explants per condition) were cultured for 14 days in the 
presence of 2 ng/ml IL-1β (IL-1(2)) with or without 10 nM APO866 (APO(10)). Levels of 
s-GAG in explant culture supernatants were determined by DMMB assay and presented 
as cumulative s-GAG loss over the experimental culture period. Differences in s-GAG 
release were determined by two-way ANOVA. s-GAG, sulphated glycosaminoglycans;  
  178 
Figure 5.3.4 Proteoglycan content of explants after low dose IL-1β and/or APO866 
exposure  
Bovine cartilage explants (n=3 explants per condition) were cultured for 14 days in serum 
free medium, or supplemented with 2 ng/ml human IL-1β (IL-1), 10 nM APO866 (APO), 
or a combination of the two (IL-1/APO). At the end of the culture period explants (n=1 
explant per condition) were fixed, sectioned and stained with Safranin O. The intensity 
of the red Safranin O staining was used as an indicator of PG content within the cartilage. 
Scale bars indicate 500 μm. The arrow indicates PG depletion from the articular surface. 
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Supernatants of explants cultured in the presence of high dose (20 ng/ml) IL-1β 
contained greater levels of s-GAG than those with 2 ng/ml IL-1β (figure 5.3.5A). Overall, 
two-way ANOVA analyses showed that these higher doses of IL-1β had a highly 
significant effect on s-GAG release, differing significantly in mean levels of s-GAG 
release from the fourth day of culture onwards, as determined by Bonferroni post-test 
analyses. This was reflected in analyses of papain digests, with IL-1β treated explants 
containing markedly lower levels of residual s-GAG (8.94 ± 5.08 μg/ml/mg; figure 5.3.5B) 
compared with those cultured in medium alone (32.49 ± 12.65 μg/ml/mg).  However, 
residual s-GAG levels in papain cartilage extracts did not differ between treatment 
groups overall (P=0.0578). Cartilage explants were analysed histologically for extent of 
PG depletion (figure 5.3.6), by assessing loss using both subjective and objective scoring 
systems (refer to figures 5.3.7A and 5.3.7B). Explants incubated in medium alone 
showed some PG depletion from the articular surface and the edges of the tissue, with 
fast green counter stain visible in these regions (figure 5.3.6). In contrast, explants 
treated with high dose IL-1β exhibited extensive loss of Safranin O staining, 
corroborating DMMB data (figure 5.3.5).  
As with lower doses of APO866, higher doses (100 nM) had no significant effect 
on s-GAG release compared with the medium control (figure 5.3.5A). However, explants 
incubated in high dose APO886, in combination with high dose IL-1β, showed significant 
differences in mean s-GAG values, compared to those incubated in IL-1β alone, 
becoming extremely significant (P≤0.0001) after six days of explant culture (figure 
5.3.5A).  Papain digests also showed greater retention of s-GAG in explants cultured 
with IL-1β and APO866 (34.81 ± 12.52 μg/ml/mg), compared to those cultured in IL-1 
alone (figure 5.3.5B), which was also reflected in both subjective and objective histology 
scoring (P=0.039 and P=0.0051, respectively).  
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Figure 5.3.5 Effect of high-dose cytokine and APO866 on s-GAG release  
Bovine cartilage explants (n=3 explants per condition) were cultured for 21 days in the 
presence of 20 ng/ml IL-1β with or without 100 nM APO866. A) Levels of s-GAG in 
explant culture supernatants were determined by DMMB assay, and presented as 
cumulative s-GAG loss over the experimental culture period. The difference in s-GAG 
release between IL-1β and IL-1/APO treated explants over time was determined by two-
way ANOVA. Astrices indicate significance levels between mean s-GAG values of IL-1β 
treated explants compared to IL-1/APO ***P≤0.0001 B) Levels of residual explant s-
GAG, were assessed in papain digests of the explants and differences determined by 
Kruskal Wallis One-way ANOVA with Dunn’s multiple comparison post-tests. All s-GAG 
values were corrected for explant wet weight. Error bars depict S.E.M.  
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Figure 5.3.6 Proteoglycan content of explants after high dose IL-1β and/or APO866 
exposure  
Bovine cartilage explants (n=3 explants per condition) were cultured for 21 days in serum 
free media alone, or supplemented with 20 ng/ml IL-1β alone or in combination with 100 
nM APO866. Explants were assessed for PG loss by Safranin O staining. Scale bars 
indicate 500 μm. 
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Figure 5.3.7 Histological assessment of proteoglycan loss  
Bovine cartilage explants (n=3 explants/histological sections per condition) were scored 
for extent of PG depletion in the presence or absence of high dose (20 ng/ml) IL-1β and 
high dose (100 nM) APO866. Bars represent mean ± standard error of the mean (S.E.M). 
A) Subjective and B) objective scoring of explants was performed. Two-tailed unpaired 
t-tests were performed to determine the significant differences between treatment 
groups. *=P≤0.05, **=P≤0.01. 
  183 
5.3.3 APO866 causes cell death in cartilage explants 
High power examination of histological sections revealed that long-term ex vivo 
culture affects both the morphology and viability of chondrocytes within the cartilage 
ECM. The lacunae of cartilage cores fixed immediately upon extraction, T0, were replete 
with chondrocytes with well-stained nuclei (figure 5.3.8[i]). Cartilage explants cultured in 
either media alone or IL-1 had a similar histological appearance to T0 explants (figure 
5.3.8).  
The histological appearance of cartilage explants treated with APO866 was 
strikingly different to untreated controls: many lacunae contained cellular debris (figure 
5.3.8[ii]) with weakly stained or shrunken nuclei, or were devoid of cells (figure 5.3.8[iii]). 
Explants co-incubated with APO866 in combination with IL-1β also exhibited a large 
degree of cell loss, with an abundance of empty lacunae (figure 5.3.9). This indicated 
that long-term exposure to APO866 had an adverse effect on explants.   
To assess cytotoxicity, culture supernatants were analysed every 2-3 days for 
lactate dehydrogenase (LDH) release. Supernatants of explants cultured in medium 
alone or 2-20 ng/ml IL-1, contained negligible levels of LDH throughout the culture 
period (figure 5.3.10). However, supplemented media from explants exposed to APO866 
at even the lowest doses tested in this experimental system (10 nM), showed significant 
levels of LDH at day 12 of culture (figure 5.3.10A). At the lower doses, 10 nM APO866, 
together with 2 ng/ml IL-1 shifted the peak of LDH release from days 12 to day 10 of 
culture. However, at the higher doses 100 nM APO866, together with 20 ng/ml IL-1 did 
not shift the peak of LDH release (Figure 5.3.10B). The patterns of LDH release observed 
indicated a sudden and nearly complete expiration of chondrocytes as a direct result of 
APO866 treatment.  
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Figure 5.3.8 Morphological characteristics of chondrocytes ex vivo; Explants 
cultured with or without high dose APO866 
Representative histology of explants immediately fixed upon dissection (T0), or cultured 
for 21 days in medium alone (MED) or with 100 nM APO866 [APO(100)]. Sections of the 
mid-zone stained with Safranin O are shown. i) and ii) High power image of healthy cells 
within the lacuna, showing dark blue nuclear staining of chondrocytes within the ECM, 
iii) High power image of cells with no haematoxylin staining, indicating dying or dead 
cells within the lacuna. Scale bars indicate 100 μm.  
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Figure 5.3.9 Morphological characteristics of chondrocytes ex vivo; Explants 
cultured with high dose APO866, with or without high dose IL-1 
Representative histology of explants cultured for 21 days in 20ng/ml IL-1 [IL-1 (20)] or 
IL-1β with 100 nM APO866 [IL-1(20)/APO(100)]. Sections of the mid-zone stained with 
Safranin O are shown. iv) High power of healthy cells within the lacuna, v) high power of 
cells with no hematoxylin staining. Scale bars indicate 100 μm.  
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Figure 5.3.10 Effect of APO866 on LDH release from explants  
Explant supernatants taken after every 48 hours of culture (n=3 samples per time point) 
were analysed for LDH release from cells. Fluorescence intensity values (in relative 
fluorescent units) were normalised to a maximum LDH release control sample, and are 
presented as percentage maximum LDH release in a cumulative plot. In two independent 
experiments, explants were stimulated with: A) 2 ng/ml IL-1β, alone or in combination 
with 10 nM APO866, or B) 20 ng/ml IL-1β, with or without 100 nM APO866. The 
differences in LDH release were determined by two-way ANOVA. Astrices indicate 
significance levels between mean %max LDH values of treatment groups. ***=P≤0.0001 
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5.3.4 The NAD+ precursors, NMN and NA, rescue APO866 induced chondrocyte cell 
death 
Due to the role of NAMPT as a NAD+ biosynthetic enzyme, it was hypothesised 
that the release of LDH in medium from APO866-treated chondrocytes may have been 
attributed to a catastrophic depletion of intracellular NAD+ in these cells, resulting in 
chondrocyte cell death. The effects of both NMN and NA on cartilage rescue were tested; 
NMN is the product of the NAMPT enzyme, whilst NA is the precursor of NAD+ via an 
alternative pathway, involving NAPRT.  Both the addition of either NMN or NA (100 μM) 
prevented APO866-induced LDH release into the culture supernatants (figure 5.3.11A 
and B). The addition of either NMN or NA also prevented APO866-induced LDH release 
in IL-1-stimulated explants.  
Figure 5.3.11 Effect of NMN and NA on explant cell viability  
Explant supernatants taken after every 48 hours of culture (n=3 samples per time point) 
were analysed for LDH release from cells. Fluorescence intensity values (in relative 
fluorescent units) were normalised to a maximum LDH release control sample, and are 
presented as percentage maximum LDH release in a cumulative plot. In two independent 
experiments, explants were stimulated with: A) 100 μM NMN or B) 100 μM NA, alone or 
with 20 ng/ml IL-1β and 100 nM APO866, The difference in LDH release between the 
treatment groups over time was determined by two-way ANOVA.  
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5.3.5 NMN and NA enhance IL-1β -induced s-GAG loss and MMP activity 
During the first 10 days of explant culture, NMN alone or in combination with 
APO866 had no significant effect on s-GAG release compared to the medium control 
(figure 5.3.12A). In contrast, NA alone significantly attenuated s-GAG release compared 
with the medium control, with cumulative s-GAG release becoming significantly altered 
from day 12 of explant culture (5.3.12B).  
Compared to explants co-cultured with high doses of IL-1 and APO866, the 
addition of 100 μM NMN enhanced s-GAG release in explants, with levels exceeding 
those observed in the presence of IL-1β alone from the tenth day of explant culture, as 
determined by two way ANOVA and Bonferroni post-tests (figure 5.3.13A). The addition 
of 100 μM NA also significantly enhanced s-GAG release in explants co-cultured with 
high doses of IL-1 and APO866; an effect seen in the first six days of culture; before 
reaching a plateau at levels normally seen with IL-1 alone (figure 5.3.13B).  
At the experimental end-point, papain digests showed there was no significant 
difference in s-GAG retention between explants cultured with or without high dose IL-1β 
(P=0.1592), or between explants cultured in high dose APO866 with or without IL-1 
(P=0.2827; figure 5.3.14). However, explants treated with APO866 combined with NMN 
exhibited significantly higher levels of s-GAG compared with the medium control 
(P=0.03). NA also enhanced s-GAG retention in APO866-treated explants compared 
with the medium control. However, this effect was not significant (P=0.182). In contrast, 
incubation of explants with a combination of high doses of IL1, APO866 and NMN 
caused a significant loss of s-GAG from explants (P=0.0002) compared to explants 
incubated with high dose APO866 and NMN alone. This was not apparent in explants 
cultured with NA (P=0.0862). 
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Figure 5.3.12 Effect of NMN and NA on APO866-induced s-GAG release from 
explants  
Culture supernatants (n=3 per condition) were analysed for s-GAG content by DMMB 
assay. All s-GAG values obtained from culture supernatants were corrected for explant 
wet weight. A two-way analysis of variance was performed to determine the effects of 
100 μM A) NMN [NMN(100)] and B) NA [NA(100)] on s-GAG release in the presence or 
absence of 100 nM APO866 [APO(100)], compared with the medium control (MED). 
Astrices indicate significance levels between mean cumulative s-GAG values of 
treatment groups. ***=P≤0.0001. 
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Figure 5.3.13 Effect of NMN and NA on IL-1β induced s-GAG release  
Culture supernatants (n=3 per condition) were analysed for s-GAG content by DMMB 
assay. All s-GAG values obtained from culture supernatants were corrected for explant 
wet weight. A two-way analysis of variance was performed to determine the effects of 
100 μM A) NMN [NMN(100)] and B) NA [NA(100)] on s-GAG release in the presence or 
absence of 20 ng/ml IL-1β [IL-1(20)] and 100 nM APO866 [APO(100)], compared with 
the medium control (MED). Astrices indicate significance levels between mean 
cumulative s-GAG values of treatment groups. *=P≤0.05, **=P≤0.01. 
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Figure 5.3.14 Effect of NMN and NA on GAG retention in cartilage extracts  
Bovine cartilage explants (n=3 explants per condition) were papain digested and levels 
of s-GAG determined by DMMB assay. Two-tailed unpaired t-tests were performed to 
determine significance levels between means of explants treated with 100 nM APO866 
[APO(100)] alone, or combined with 100 μM NMN or NA. All treatments were in the 
presence or absence of 20 ng/ml IL-1β Astrices indicate statistical significance levels 
between explant s-GAG retention in the presence or absence of 20 ng/ml IL-1β. 
***=P≤0.0001. 
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 Gelatin zymography was performed on culture supernatants to determine 
whether increases in IL-1β-induced s-GAG release in the presence of NMN and NA 
coincided with an increase in gelatinase release and activity. Gelatin zymograms showed 
diffuse bands of both pro- and active MMPs -2 and -9 (figure 5.3.15). Supernatants from 
explants stimulated with 20 ng/ml IL-1β alone showed enhancement in total MMP-2 and 
MMP-9 activity from around 12 days, with MMP-9 showing a greater propensity to 
increase at this time. Concurrent with the mass cell death observed at around day 10 in 
explants treated with 100 nM APO866 (figure 5.3.10), the addition of APO866 decreased 
release of MMP -2 at this time point, with MMP-9 bands barely detectable at any time 
point. Chondrocyte rescue with either NMN or NA shifted the enhancement of gelatinase 
activity from day 12 to day 10, and total MMP-2 activity was significantly enhanced in 
these explants. 
These observations were reinforced by densitometry analyses (performed as 
described in section 2.1.5.3), which indicated that mean levels of MMP-2 and MMP-9 
activity in supernatants were significantly attenuated in explants cultured with a 
combination of IL-1β and APO866 compared with those incubated with IL-1β alone 
(figure 5.3.16A and B), from days 10 (MMP-2) and 12 (MMP-9).  In contrast, the addition 
of either 100 μM NMN or NA in IL-1/APO866-treated explants enhanced the activity of 
MMP-2 and MMP-9 (figure 5.3.16C and D). Supernatants of IL-1/APO866-treated 
explants co-cultured with NMN showed significantly greater mean levels of MMP-2 
compared with those incubated with IL-1β alone (figure 5.3.16C). Although the NMN or 
NA treatments had an overall significant effect on MMP-9 release (P≤0.0001), Bonferroni 
post-tests did not detect a significant difference at any given time point.  
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Figure 5.3.15 Gelatin zymograms of explant supernatants 
Explant culture supernatants were analysed for MMP-2 and -9 activity using gelatin 
zymography. Explants were cultured for a total of 21 days in the presence of 20 ng/ml 
IL-1β, alone [IL-1(20)] or in combination with 100 nM APO866 [IL-1(20)/APO866(100)]. 
In addition, groups of explants were cultured with the above in combination with 100 μM 
of NMN [IL-1(20)/APO(100)/NMN(100)] or NA [IL-1(20)/APO(100)/NA(100)]. 
Supernatants from each day of medium refreshment (days 2-21) were loaded 
sequentially onto an SDS-PAGE gel. Three gels were run per experimental condition 
(n=3), each containing a series of culture supernatants from a single explant. A 
representative gel from each condition is shown.  
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Figure 5.3.16 The effect of NMN and NA on cytokine-induced MMP activity 
Densitometry analysis was performed on gelatin zymograms (n=3 gels per treatment 
group) to determine the mean net intensity values for bands pertaining to total MMP-2 
and MMP-9. Net intensity of A) total MMP-2 and B) total MMP-9 from explant 
supernatants incubated with 20 ng/ml IL-1β with or without 100 nM APO866.  Error bars 
depict S.E.M.  A two-way analysis of variance was performed to determine the 
differences in net intensity between IL-1 (IL-1), and IL-1/APO866 (IL-1/APO) treatment 
groups. Net intensity of C) total MMP-2 and D) total MMP-9 in IL-1β/APO866-treated 
explant supernatants supplemented with 100 μM NMN (IL-1/APO/NMN) or NA (IL-
1/APO/NA). A two-way ANOVA was performed to determine differences in net intensity 
between the treatment groups.  **=P≤0.01, ***=P≤0.0001.  
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5.4 Discussion 
5.4.1 APO866 had no significant effect on IL-1β-induced MMP expression in human 
chondrocytes 
Studies performed on human primary chondrocytes in this chapter confirmed that 
NAMPT gene expression is significantly induced by IL-1β, which ties in with previous 
published work in murine (Gosset et al., 2008) and rabbit (Hong et al., 2011) 
chondrocytes. However, expression of NAPRT and QPRT were not affected. These 
findings suggest that neither the alternative salvage pathway or the de novo pathway are 
affected by cytokine signalling, and that the Nam salvage pathway is the preferred 
pathway for NAD+ biosynthesis in chondrocytes. It also suggests that NAMPT may be 
required for cytokines such as IL-1β to mediate a response.  
The action of iNAMPT on cytokine-mediated induction of MMPs -1 and -3 was 
also investigated and the results show that co-incubation of IL-1β with APO866 did not 
significantly affect IL-1-induced MMP gene expression in HACs, although expression 
was slightly attenuated. Previous studies in human chondrocytes have shown that 
addition of APO866 causes a reduction in cartilage-specific gene expression (Dvir-
Ginzberg et al., 2008). Although these experiments were performed in non-activated 
cells, the results suggested that intracellular NAD+ indirectly affects the regulation of 
matrix turnover in chondrocytes. IL-1β induces expression of MMP-1, -3 and -13 in HACs 
through activation of NF-κB and MAPK signalling pathways (Liacini et al., 2002, Tsutsumi 
et al., 2008). NAMPT and SIRT have been shown to boost activation of ERK and p38 
MAP kinases. Inhibition of NAMPT with APO866 inhibited activation of these kinases. 
Overexpression of a dominant negative Sirt1 retrovirus had a similar effect, suggesting 
both are essential for IL-1β-induced ERK signalling (Hong et al., 2011). Therefore, 
manipulation of sirtuins through reductions in cellular NAD+ may reduce IL-1β induced 
MMP transcription. IL-1β-induced MMP transcription was not completely attenuated by 
APO866, suggesting that IL-1β may continue to signal through NF-κB.  
5.4.2 APO866 attenuation of IL-1β-induced s-GAG loss in explants is due to cytotoxicity  
In contrast to medium controls, explants exposed to cytokine stimulation 
exhibited a time and dose-dependent increase in s-GAG release into the surrounding 
medium. These data demonstrate that cytokine stimulation causes an induction of 
catabolic protease production within the native chondrocytes, resulting in cleavage and 
subsequent loss of cartilage ECM components. This was confirmed in papain digests of 
cartilage explants, as cytokine stimulation resulted in significantly lower levels of s-GAG 
retention compared with explants cultured in medium alone. Gelatin zymography 
indicated that expression of MMP-9 is markedly induced by around day 12 of culture. 
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This late onset of MMP activity compared with aggrecanase activity has been observed 
in other explant culture studies, where type II collagen-derived fragments are typically 
detected in supernatants between 14-21 days of culture (Karsdal et al., 2008, Wang et 
al., 2009a). Taken together with the findings from the DMMB assays, these data suggest 
IL-1β stimulation caused enhanced loss of cartilage ECM components through the 
upregulation of proteolytic enzymes such as MMPs.  
Explants incubated with APO866 exhibited a sharp decrease in s-GAG and MMP 
release from around day 10 of culture. Both inducible MMP-9 and constitutively 
expressed MMP-2 were greatly attenuated. It was originally thought that this was due to 
a therapeutic effect of APO866. However, these observations coincided with a complete 
loss of cell viability; suggesting the drop in MMP release was in fact a result of 
catastrophic cell death.  
5.4.3 APO866-induced cytotoxicity is prevented by NMN and NA 
The concentrations of APO866 used in ex vivo culture ranged from 10-100 nM; 
the latter dose has been previously used in murine chondrocytes stimulated for 24 hours 
(Jacques et al., 2012). Studies in murine and human monocytes showed that 4 hours 
stimulation with 100 nM APO866 does not affect cell viability, despite proven depletion 
of intracellular NAD+ (Busso et al., 2008). Additionally, a study in HeLa cells showed that 
100 nM APO866 causes an initial reduction in NAD+ after 6 hours of exposure, followed 
by a plateau phase, before the advent of further depletion after 24-96 hours APO866 
exposure (Pittelli et al., 2010). Unfortunately NAD+ levels could not be quantified in 
explants, as attempts to extract the cofactor from cells proved unsuccessful. However, a 
gradual drop of NAD in chondrocytes, as a result of chronic exposure to APO866 may 
explain the cytotoxic effect of APO866 on explants.  
Intracellular NAMPT catalyses the conversion of Nam to NMN, which is 
subsequently converted to NAD+ by NMNAT-1 (figure 1.8). In this chapter the addition of 
NMN (i.e. bi-passing iNAMPT activity) rescued chondrocytes from APO866-induced 
cytotoxicity, suggesting that depletion of cellular NAD+ was indeed the cause of cell death 
in these explants. This could also be confirmed in future studies by the addition of NAD+ 
to explants or cells, or through quantification of intracellular NAD+ in the explants. The 
importance of iNAMPT to cell survival is not surprising, as the Nam salvage pathway is 
the main means of NAD+ production in mammals (reviewed by Bogan and Brenner, 
2008).  In addition to Nam, NA is an alternative precursor of NAD+ via the Preiss-Handler 
pathway (figure 1.8). 
Incubation of explants with NA also inhibited APO866-induced chondrocyte 
cytotoxicity, demonstrating that in the absence of iNAMPT chondrocytes can utilise 
  197 
alternative pathways of NAD+ biosynthesis. Together, these data confirm that the 
inhibition of iNAMPT by APO866 has a rate-limiting effect on cell viability and that 
chondrocyte viability is NAD+ dependent. The fact that NA is able to rescue chondrocytes 
from iNAMPT-depletion suggests that NAD+ may also be synthesised independently of 
iNAMPT in these cells. A pre-clinical study has shown that the addition of NA in vitro can 
inhibit APO866-induced cytotoxicity in cancer cell lines (Olesen et al., 2010). Besides 
this study, there has been little research into the effects of depletion and repletion of 
NAD+ in vitro. NAD+ depletion has also been shown to have a cytotoxic effect in T 
lymphocytes, where APO866 causes autophagic cell demise (Bruzzone et al., 2009). As 
with the current study, activated T lymphocytes were more sensitive to NAMPT inhibition 
than resting cells (Bruzzone et al., 2009). It is thought that transformed cells (e.g. cancer 
cells or activated cells) have a higher basal turnover of NAD+, and so are particularly 
sensitive to depletion of this cofactor. Additionally, some cell lines (e.g. HepG2) are 
unable to utilise NA (Hasmann and Schemainda, 2003), highlighting a possible 
mechanism for targeted inhibition of activated cells. Both NMN and NA not only 
counteracted the cytotoxic effects of APO866, they also appeared to enhance cytokine-
mediated induction of catabolic proteases; as apparent by enhanced and accelerated 
release of S-GAG and detection of MMP activity by gelatin zymography. This suggests 
that regulation of catabolic proteases in chondrocytes is NAD+ dependent, though not 
necessarily iNAMPT dependent. It also indicates that an increase in cellular NAD+ 
availability may have a downstream effect on transcription of MMPs and other matrix-
degrading enzymes.  
5.4.5 Summary 
The findings of this chapter show that iNAMPT is important for both cartilage 
matrix turnover and also chondrocyte survival (summarised in figure 5.4.1). Real-time 
PCR analyses indicate that NAMPT is the only NAD+ biosynthesis enzyme induced by 
IL-1β stimulation of human chondrocytes, hinting that the Nam salvage pathway is 
associated with pro-inflammatory and pro-degradative processes. Inhibition of iNAMPT 
activity in vitro suggested that NAMPT is involved in IL-1β-induced MMP gene 
expression. However, inhibition of iNAMPT by APO866 in long-term cartilage explant 
culture resulted in complete chondrocyte cell death within 10 days. This cytotoxicity is 
attributed to a catastrophic depletion of intracellular NAD+, as the addition of NAD+ 
metabolites, NMN and NA, prevented cytotoxicity presumably through the replenishment 
of NAD+. These data suggest that cell survival and cartilage catabolism are NAD+ 
dependent. 
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Figure 5.4.1 Summary schematic of chondrocytes and cartilage integrity ex vivo 
Panel 1: chondrocytes within the cartilage matrix, which most components remaining 
intact. Panel 2: Pro-inflammatory cytokine stimulation results in rapid loss of s-GAG, 
followed by eventual breakdown of collagen fibrils. Panel 3: Co-incubation with cytokines 
and NAMPT antagonist APO866 inhibits s-GAG loss, though subsequently cell damage 
and cytotoxicity occurs in a time and dose-dependent manner. Panel 4: The cytotoxic 
effects of APO866 can be counteracted with the addition of either NAMPT product NMN 
or alternative NAD+ precursor NA. However, cytokine stimulation in the presence of these 
co-factors exacerbates s-GAG loss from the cartilage extracellular matrix.  
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Chapter 6: Regulation of iNAMPT in synovial fibroblasts 
in vitro 
6.1 Introduction 
In RA, fibroblast-like synoviocytes within the synovial intimal lining of the 
diarthrodial joint become phenotypically distinct from normal fibroblasts. These 
fibroblasts are one of the major constituents of ‘pannus’, the invasive granulation tissue 
that invades and erodes the joint articular cartilage and bone, along with synovial 
macrophages. Synovial fibroblasts are believed to be the primary effectors of articular 
cartilage destruction in RA (reviewed by Bartok and Firestein, 2010). They play a key 
role in the perpetuation of disease through the production of pro-inflammatory cytokines 
such as IL-1β (section 1.2.3) and proteases such as MMPs (section 1.2.4) that contribute 
to the breakdown of the articular cartilage tissue. This has been demonstrated in 
cadherin-11 knockout mice. These mice, which lack a synovial intimal lining, are 
protected from arthritis-induced cartilage damage, but not bone erosion (Lee et al., 
2007).  
Understanding of the pathogenesis of RA has been greatly facilitated by the use 
of fibroblasts isolated from the synovial tissues of diseased patients, often named 
fibroblast-like synoviocytes (FLS) or RASFs in the literature (Bartok and Firestein, 2010). 
RASFs are the major NAMPT-expressing cells in synovial tissue, and NAMPT is 
predominantly expressed at sites of cartilage invasion in these tissues (Brentano et al., 
2007). In RASFs, NAMPT is upregulated in response to LPS, TLR ligand Poly(I-C), TNFα 
and IL-1β (Brentano et al., 2007). To my knowledge, the above findings are the only 
published findings concerning the regulation of NAMPT in human RASFs. This study 
demonstrates the contribution of NAMPT to the inflammatory milieu within an RA joint. 
This could subsequently promote articular cartilage degradation. The latter will be 
explored in this chapter. 
There are several possible mechanisms whereby NAMPT could modulate RASF-
dependent joint inflammation and degenerative processes; by virtue of its cytokine-like 
activity, its role in NAD+ biosynthesis, or both. My work will contribute to the elucidation 
of NAMPT-dependent degenerative and inflammatory mechanisms in RASFs.  
NAD+ plays a major role as a coenzyme in numerous oxidation-reduction 
reactions, including the generation of ATP (Ziegler, 2000). Recently, a functional link 
between NAD+ metabolism and inflammation has been proposed; in a human monocytic 
THP-1 cell line, intracellular NAD+ levels promote TNFα synthesis in activated cells. It 
was shown that SIRT6, a member of the sirtuin family, regulates TNFα production at a 
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post-transcriptional step in these cells (Van Gool et al., 2009).  It is possible that NAD+ 
levels could control sirtuin activity, impacting upon MMP expression.  The impact of 
sirtuins on MMP expression has not been published previously, therefore the proof of 
concept mechanistic studies described in this chapter will explore the role of sirtuins in 
modulating cytokine-mediated MMP expression by RASF.   
Sirtuins, along with PARPs, are “NAD+-consuming” proteins that require NAD+ as 
a substrate for their activities. They are a group of HDACs that couple protein 
deacetylation to NAD+ hydrolysis, to form O-acetyl-ADP-ribose and Nam. Deacetylation 
impacts upon the function of many transcription factors, affecting a wide variety of cellular 
functions (reviewed in North and Verdin, 2004). There are seven types of sirtuins in 
mammals (SIRT1-7), of which SIRT1 is the most extensively studied. Of relevance here, 
Revollo et al (2004) found that upregulation of iNAMPT increased the transcriptional 
regulatory function of SIRT1 in mouse fibroblasts by increasing cellular NAD+ (Revollo 
et al., 2004).  
The exact role of sirtuins in RA disease pathogenesis has yet to be elucidated. 
SIRT1 is elevated in RA synovial tissues, and like NAMPT is predominantly localised 
within the synovial lining (Niederer et al., 2011). In addition, SIRT1 expression is induced 
upon stimulation with the pro-inflammatory cytokine TNFα, and SIRT1 overexpression 
increases LPS- and TNFα-induced IL-6 and CXCL8 production in RASFs (Niederer et 
al., 2011). However, despite this apparent pro-inflammatory effect, many studies have 
reported a potential anti-degradative role for sirtuins. Oxidative stress-dependent 
reduction of SIRT1 causes an increase in MMP-9 expression in human monocytes 
(Nakamaru et al., 2009), and sirtuin enhancer resveratrol inhibits MMP-2 and -9 
expression in stimulated human sarcoma cells (Lee and Kim, 2011). Finally, SIRT1 
knockdown increases the basal expression of MMPs -1 and -3 in human dermal 
fibroblasts (Ohguchi et al., 2010). The regulation of sirtuins by NAD+, and their 
subsequent role in MMP expression in RASFs, has yet to be investigated in vitro. 
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6.1.2 Chapter aims 
The constitutive expression of NAMPT in RASFs (Brentano et al., 2007) and its 
upregulation in response to cytokine stimulation suggest a possible role in cartilage 
destruction at the articular cartilage-pannus interface. However, it is unclear whether 
NAMPT exerts its activity directly as a cytokine-like molecule, or indirectly through 
regulation of intracellular NAD+. A greater understanding of the regulation of NAMPT in 
synovial fibroblasts may provide novel insights into mechanisms of RA disease 
pathogenesis, and help to ascertain a link between NAMPT, intracellular NAD+ and MMP 
expression. Therefore, using human RASFs, the specific objectives of this chapter were: 
 To determine the effect of pro-inflammatory cytokines on iNAMPT gene 
expression in vitro. 
 To study the expression of alternative, rate-limiting, NAD+ biosynthetic pathway 
enzymes in response to pro-inflammatory cytokine stimulation.  
 To investigate the effect of the cytokines IL-1β, TNFα and OSM on expression of 
MMPs -1 and -3. 
 To measure the expression of NAD+ dependent deacetylase SIRT1.  
 To evaluate the effect of sirtuin and PARP antagonists on cytokine-mediated 
MMP protein expression. 
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6.2 Materials and methods 
Human RASFs were extracted and cultured as detailed in section 2.1.2.2. Cells 
were seeded onto 12-well plates (3x104 cells/ml). Cells were serum-starved for 48 hours 
prior to stimulation assays. Stimulations were then performed as described below. The 
media was removed and 1 ml of TRI-Reagent® then added to cells. RNA was extracted 
and qPCR performed as outlined in section 2.3.2. 
6.2.1 Cytokine dose response  
A dose response of the pro-inflammatory cytokines IL-1β, TNFα and OSM was 
carried out to determine the concentration required to induce NAMPT gene expression 
in RASF cell lines. Cytokine solutions (up to 20 ng/ml) were freshly prepared in serum-
free medium, they were added to RASFs that had been serum-starved for 48 hours in 
advance of stimulation. Control wells contained RASF incubated in serum-free medium 
only. Experiments ended 6 hours post-stimulation when RASF were homogenised with 
TRI Reagent®. 
6.2.2 Cytokine time course  
A short-term time course assay was performed to determine the timing of gene 
expression of NAMPT and other genes of interest. RASFs were incubated for up to 6 
hours with cytokine solutions (1 ng/ml of IL-1β, TNFα or OSM) prepared with serum-free 
medium.  Cytokine stimulations were run in parallel on the same RASF cell line. At 
endpoint medium was aspirated and stored and TRI Reagent added to the cells in each 
well. A zero hour control was made by washing serum-starved unstimulated cells with 
PBS and adding TRI Reagent® immediately.  
6.2.3 NAD+ depletion assay 
As iNAMPT is a rate-limiting NAD+ enzyme (Revollo et al., 2004), the effect of 
iNAMPT inhibition on intracellular NAD+ levels in RASFs was determined using both in-
house and commercially-available NAD+ detection assays (section 2.1.4).  RASFs were 
seeded into T25 tissue culture flasks at a cell density of 2x105 cells/ml in complete tissue 
culture medium containing 10% FBS. Cells were left to settle for 48 hours, or until cells 
appeared to have entered the exponential phase of growth. This was estimated from 
observations using an inverted microscope. Cells were then washed in PBS and treated 
with culture medium supplemented with 5% FBS (serum was maintained to keep cells in 
exponential growth) and 10 nM APO866. Flasks were cultured for 0, 24, 48 and 72 hours. 
At the end of the designated culture periods, culture supernatants were collected for 
analysis of cell viability (section 2.1.6.2) and cells were extracted for NAD+ quantification 
(refer to section 2.1.4).  
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6.2.4 Sirtuin and PARP antagonist assay 
Serum-starved RASF were stimulated for periods of 6, 24, and 48 hours in the 
presence of 10 ng/ml IL-1β alone, or in combination with either 100 µM EX557 or 100 
μM PJ34 (Sigma-Aldrich Ltd, Dorset, UK), specific inhibitors of SIRT1 and PARP-1, 
respectively. Serum-starved cells were pre-incubated with the inhibitors for one hour 
prior to cytokine stimulation. At the end of the stimulation periods, cell culture 
supernatants were transferred to 2 ml microcentrifuge tubes and stored at -70°C for 
analysis by MMP-1 and MMP-3 protein levels by ELISA, as described in section 2.1.3. 
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6.3 Results 
6.3.1 NAMPT is upregulated by inflammatory cytokines in RASFs 
In the first experiment, a dose response was performed on three RASF lines, to 
determine if NAMPT gene expression could be induced by cytokine stimulation. RASFs 
were stimulated with escalating doses of IL-1β, TNFα or OSM (section 6.2.1) and 
NAMPT mRNA expression analysed by qPCR. IL-1β was the most potent inducer of 
NAMPT expression, with doses of 20 ng/ml resulting in a mean 30-fold increase in gene 
expression compared to untreated control cells cultured for the same period of time 
(figure 6.3.1A). However, there was great variability in the data, meaning there was no 
overall significant difference between IL-1β treatment groups, as determined by Kruskal-
Wallis analyses (P=0.225). NAMPT expression increased in a concentration-dependent 
manner upon addition of TNFα, and Kruskal Wallis analyses indicated a significant 
difference between treatment groups (P=0.043).Maximum upregulation was apparent in 
cells stimulated with 5 ng/ml of TNFα (figure 6.3.1B). OSM caused a small (but non-
significant) dose-dependent increase in NAMPT expression that reached its maximum 
level at 10 ng/ml (P=0.139, figure 6.3.1C).  
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Figure 6.3.1. Dose effect of pro-inflammatory cytokines on NAMPT gene 
expression 
Human RASFs (n=3 cell lines, with one biological replicate per condition) were washed 
and stimulated for 6 hours with varying doses of pro-inflammatory cytokines A) IL-1β, B) 
TNFα and C) OSM. RNA was extracted from cells, reverse-transcribed and analysed in 
duplicate for NAMPT expression using real-time quantitative PCR. The ΔCT values for 
cytokine-stimulated samples were determined and normalised to the CT values of 
reference genes 18S rRNA, Beta-Actin and GAPDH. The relative quantities of NAMPT 
gene expression (RQ) were determined by relating ΔCT values of cytokine-stimulated 
samples to unstimulated control cell samples. All error bars depict the standard error of 
the mean (S.E.M). Kruskal-Wallis tests with Dunn’s multiple comparison post-test 
analyses were performed to determine the significance levels between treatment groups. 
*=P≤0.05 
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NAMPT was induced by all three cytokines assayed, with induction at the lowest 
concentration of 1.25 ng/ml. A concentration of 1 ng/ml was used in the following 
experiment to determine the timing of NAMPT gene expression in RASFs from 0-6 hours 
post-stimulation. All cytokines had a stimulatory effect on NAMPT gene expression, 
within one hour of cytokine stimulation (figure 6.3.2). Stimulation of cells with IL-1β 
resulted in a significant upregulation of NAMPT expression at 4 and 6 hours post 
stimulation (P=0.024; figure 6.3.2A). Although TNFα elevated NAMPT expression, there 
was no overall significant difference between treatment groups (P=0.253; figure 6.3.2B).  
Like IL-1β, OSM stimulation resulted in a significant upregulation of NAMPT expression 
at 4 and 6 hour time points, with a significant difference in expression between treatment 
groups overall (P=0.018; figure 6.3.2C). 
 
 
Figure 6.3.2 Cytokine-induced NAMPT gene expression over time in RASFs  
Human RASFs (n=5 cell lines, one biological replicate per cell line) were stimulated for 
0-6 hours with 1 ng/ml of cytokines A) IL-1β, B) TNFα and C) OSM and analysed in 
duplicate for NAMPT gene expression by qPCR. The ΔCT values for cytokine-stimulated 
samples were normalised to the CT values of reference genes 18S rRNA, Beta-Actin and 
GAPDH. The relative quantity of NAMPT gene expression (RQ) in treated cells was 
compared to zero hour unstimulated control cells. All error bars depict the standard error 
of the mean (S.E.M). Kruskal-Wallis tests with Dunn’s multiple comparison post-test 
analyses were performed to determine the significance levels between treatment groups. 
*=P≤0.05. 
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6.3.2 Regulation of alternative NAD+ enzymes by inflammatory cytokines 
In the previous chapter, it was shown that IL-1β induces iNAMPT expression in 
chondrocytes, but does not affect expression of NAPRT and QPRT, enzymes involved 
in alternative NAD+ pathways (section 5.3.1). In this chapter, expression of these genes 
in response to cytokine stimulation was explored in RASFs. Expression IDO was also 
analysed by qPCR.  Like QPRT, IDO is a rate-limiting enzyme in the de novo NAD+ 
biosynthesis pathway (Iqbal and Zaidi, 2006). 
Over a culture period of 6 hours, all three cytokines failed to induce expression 
of Preiss-Handler pathway gene NAPRT (P=0.598, P=0.144 and P=0.884; IL-1β, TNFα 
and OSM, respectively; figure 6.3.3). As with NAPRT, expression of QPRT was not 
significantly affected by cytokine stimulation, as determined by Kruskal Wallis One way 
ANOVA (P=0.185, P=0.288 and P=0.554; IL-1β, TNFα and OSM, respectively; figure 
6.3.4A-C). However, expression was slightly enhanced compared with samples from 
medium control (0h) cells IDO expression was also not affected by the addition of IL-1β 
(P=0.623; figure 6.3.4D) or TNFα (P=0.394; figure 6.3.4E). There was no significant 
difference between OSM treatment groups (P=0.078); however, Dunn’s multiple 
comparison post-tests showed that IDO expression is significantly induced at 6 hours 
post-stimulation, compared with the zero hour control (figure 6.3.4E). This implies that 
IDO is induced by OSM stimulation in a time-dependent manner in human RASFs.  
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Figure 6.3.3 Effect of cytokine stimulation on regulation of Preiss-Handler NAD+ 
pathway gene expression  
Human RASFs (n=5 cell lines, one biological replicate per time point) were stimulated 
for 0-6 hours with 1 ng/ml of cytokines A) IL-1β,  B) TNFα or C) OSM. Samples were 
plated in duplicate and analysed by real-time qPCR for NAPRT, gene expression. The 
ΔCT values for cytokine-stimulated samples were normalised to the CT values of 
reference genes 18S rRNA, Beta-Actin and GAPDH. The relative quantity of NAPRT 
gene expression (RQ) in treated cells was compared to zero hour unstimulated control 
cells. All error bars depict the standard error of the mean (S.E.M). Kruskal-Wallis tests 
with Dunn’s multiple comparison post-test analyses were performed to determine the 
significance levels between treatment groups.  
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Figure 6.3.4 Effect of cytokine stimulation on regulation of de novo NAD+ pathway 
gene expression  
Human RASFs (n=5 cell lines, one biological replicate per time point) were stimulated 
for 0-6 hours with 1 ng/ml of cytokines IL-1β, TNFα or OSM. Samples were analysed in 
duplicate by real-time qPCR for QPRT and IDO gene expression. The ΔCT values for 
cytokine-stimulated samples were normalised to the CT values of reference genes 18S 
rRNA, Beta-Actin and UBC. The relative quantities of QPRT and IDO gene expression 
(RQ) in treated cells were compared to zero hour unstimulated control cells. All error 
bars depict the standard error of the mean (S.E.M). Kruskal-Wallis tests with Dunn’s 
multiple comparison post-test analyses were performed to determine the significance 
levels between treatment groups. **=P≤0.01. 
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6.3.5 MMP-1 and MMP-3 are upregulated by IL-1 β in RASFs 
Expression of MMPs -1 and -3 in response to cytokine stimulation was also 
analysed. In contrast to NAMPT gene expression (figure 6.3.2), MMP gene expression 
was generally induced at later time points (4 hours post-stimulation). IL-1β caused an 
overall significant induction of MMP-1 gene expression compared to the zero hour 
control, as determined by Kruskal-Wallis tests (P=0.049). In particular, MMP-1 
expression was significantly enhanced at 6 hours post stimulation compared with the 
unstimulated control (figure 6.3.5A). MMP-1 expression appeared enhanced in TNFα 
treated RASFs; however, there was no significant difference in RQ values between time 
points (P=0.08; figure 6.3.5B). Despite being a strong inducer of NAMPT, OSM had a 
comparably minimal effect on MMP-1 expression over time (P=0.69; figure 6.3.5C), with 
RQ values comparable to unstimulated (zero hour) control samples. MMP-3 was 
significantly induced by IL-1β stimulation in RASFs in a time-dependent manner 
(P=0.046; figure 6.3.5D). TNFα induced MMP-3 gene expression in two of the three cell 
lines, but due to the variability observed between the groups, there was no overall effect 
on MMP-3 expression by this cytokine (P=0.175; figure 6.3.5E). As with MMP-1, OSM 
had no stimulatory effect on MMP-3 gene expression (P=0.095; figure 6.3.5F).  
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Figure 6.3.5 The effect of pro-inflammatory cytokines on MMP gene expression 
Human RASFs (n=3 cell lines, one biological replicate per time point) were assayed for 
MMP-1 and MMP-3 gene expression in response to stimulation with 1 ng/ml of cytokines 
A) IL-1β, B) TNFα and C) OSM.  MMP-3 gene expression was also monitored in 
response to D) IL-1β, E) TNFα and D) OSM. The ΔCT values for cytokine-stimulated 
samples were normalised to the CT values of reference genes 18S rRNA, Beta-Actin and 
GAPDH. . The relative quantities of MMP gene expression (RQ) in treated cells were 
analysed in duplicate using real-time quantitative PCR, compared to washed zero hour 
unstimulated control cells. All data points are graphically presented with mean ± standard 
error of the mean (S.E.M). Kruskal-Wallis tests with Dunn’s multiple comparison post-
test analyses were performed to determine the significance levels between treatment 
groups. *=P≤0.05. 
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6.3.6 In-house NAD+ assay lacks sensitivity 
In order to confirm a role for iNAMPT in NAD+ metabolism in RASFs, resting 
(unstimulated) cells were cultured for up to 72 hours in the presence of 10 nM APO866, 
and intracellular NAD+ levels determined. Cells were cultured in complete medium and 
extracted at the point of established growth. Initially, an in-house NAD+ assay was 
developed, and cell extracts from untreated human RASFs were prepared as in section 
2.1.4.1 and tested. The addition of the cycling buffer led to a rapid colorimetric change; 
however, the colour of the test samples differed greatly from the standards, yielding a 
reddish-brown colour instead of the expected purple colour of the top standards (figure 
6.3.6A). The optical density (OD) values of NAD+ standard did not conform to standard 
linear or polynomial curves, therefore a standard curve was generated using a Michaelis-
Menton nonlinear regression and unknown test values were interpolated from the curve 
(figure 6.3.6B). From five of the six values initially tested, the mean value of NAD+ 
detected was 12.7 ± 0.71 μg/ml. However, one cell source contained a higher level of 
NAD+ (26.3 ± 1.53 μg/ml), despite an identical extraction procedure (figure 6.3.6C). The 
assay was repeated on samples from cells treated with 10 ng/ml IL-1β, 10 nM APO866, 
or a combination of both (section 6.2.3). Samples were extracted from proliferating cells 
at 24 and 48 hours post-stimulation. The purpose of this assay was to determine if 
APO866 could reduce cellular NAD+, and to find out if NAD+ depletion was more marked 
in activated cells. Although NAD+ appeared to be detected at both time points (figure 
6.3.7), the assay lacked the sensitivity and reproducibility required to accurately quantify 
differences over time. Therefore, a commercial NAD+ assay was used in further studies.  
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Figure 6.3.6 Testing and optimisation of in-house NAD+ assay  
Cell extracts from actively proliferating human RASFs (one cell line with six experimental 
replicates) were prepared and tested for levels of intracellular NAD+ (section 2.1.4.1). 
Samples were plated in duplicate alongside a NAD+ standard of known concentrations 
ranging from 0.9375-30 μg/ml, and a cycling buffer was added, resulting in a 
colourimetric change. A) Typical plate layout, showing the serially diluted NAD+ standard 
and samples. B) A Michaelis-Menton standard curve, showing OD readings of samples 
in triplicate. C) The NAD+ levels of the six individual samples, in triplicate. The mean ± 
standard error of the mean (S.E.M) of individual replicates are plotted. 
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Figure 6.3.7 Detection of NAD+ in treated samples using the in-house assay  
Human RASFs (n=3 cell lines, one biological replicate per condition) were stimulated 
with a combination of 10 ng/ml IL-1β and 10 nM APO866 (section 2.2.3), and cells taken 
from A) 24 and B) 48 hours post-stimulation were prepared for analysis of intracellular 
NAD+ (section 2.1.4.1). All data points are graphically presented with mean ± standard 
error of the mean (S.E.M). 
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6.3.7 APO866 reduces cellular NAD+ over time in RASFs 
Using a commercial NAD/NADH assay (section 2.1.4.2), cells extracted at zero 
hour with no APO866 treatment had the highest levels of total NAD (NADt; i.e. NADH 
and NAD+) with a mean value of 10.9 pmol/106 cells (figure 6.3.8). Although the assay is 
capable of discerning between NAD+ and NADH (section 2.1.4.2), NAD+ itself could not 
be accurately quantified; so only NADt data are presented (figure 6.3.8). The zero hour 
sample yielded a NADt value of 10.91 ± 1.58 pmol/106 cells, which was only just within 
the detection range of the assay. This suggests that the assay used lacks the sensitivity 
required in order to accurately quantify lower NADt values. However, APO866 treatment 
caused a significant time-dependent decrease in NADt levels in cell extracts over time, 
as determined by Pearson’s correlation coefficient analysis (P=0.0012; Figure 6.3.8A). 
By 72 hours, cell extracts had no detectable NADt, with OD values comparable to the 
negative (blank) control. Culture supernatants were analysed for LDH release, and it was 
shown that LDH release was significantly increased over time, peaking at an average of 
11.89 ± 2.18 of the percentage maximum of LDH release (P=0.012, figure 6.3.8B). This 
suggests a depletion in cellular NAD+ levels is causing a detrimental effect on cell 
viability.  
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Figure 6.3.8 Effect of APO866 on intracellular NAD+ and cell viability  
Human RASFs (n=3 cell lines, one experimental replicate per time point) in log phase 
growth were treated with 10 nM APO866, scraped and assayed in duplicate for 
intracellular NADt (total NAD and NADH). A) NADt levels quantified and normalised to 
cell number. Pearson’s correlation coefficient was used to determine the effect of 
APO866 treatment duration on NADt levels. All data points are graphically presented 
with mean ± standard error of the mean (S.E.M). B) Cell culture supernatants (n=3 cell 
lines) were analysed for LDH release. Fluorescence intensity values (in relative 
fluorescent units) were normalised to a maximum LDH release control sample, and are 
presented as percentage maximum LDH release in a cumulative plot.  
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6.3.8 SIRT1 is not induced by cytokine stimulation in RASFs 
Expression of the NAD+-dependent deacetylase SIRT1 was also studied in 
response to cytokine stimulation. Stimulation with IL-1β caused a slight but non-
significant induction of SIRT1 gene expression in RASFs (P=0.099; figure 6.3.9A). TNFα 
enhanced SIRT1 expression, peaking at 2 hours post-induction. However, there was no 
overall significant effect on SIRT1 expression (P=0.483; figure 6.3.9B). The IL-6 family 
cytokine OSM failed to induce SIRT1 expression in RASFs (P=0.47, figure 6.3.9C). SIRT 
expression was induced in two of the three cell lines used, resulting in considerable 
variability.  Therefore, further observations may be required to confirm whether or not IL-
1β and TNFα enhance SIRT1 expression. 
 
 
 
Figure 6.3.9 Cytokine-mediated expression of SIRT1 in RASFs  
Human RASFs (n=3 cell lines, one biological replicate per time point) stimulated for 0-6 
hours with 1 ng/ml of cytokines A) IL-1β, B) TNFα and C) OSM were analysed for SIRT1 
gene expression by qPCR. The relative quantity of SIRT1 gene expression (RQ) in 
treated cells was compared to washed zero hour unstimulated control cells. The ΔCT 
values for cytokine-stimulated samples were normalised to the CT values of reference 
gene Beta-Actin. Pearson’s correlation coefficient was performed to determine whether 
stimulation time was related to the relative quantity of SIRT1 mRNA. All data points are 
graphically presented with mean ± standard error of the mean (S.E.M). 
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6.3.9 Sirtuin inhibition enhanced IL-1 β induced MMP protein release 
As RASFs stimulated with IL-1β for 6 hours showed a time-dependent increase in gene 
expression of NAMPT (figure 6.3.1), as well as both MMP-1 and MMP-3 (figure 6.3.5), it 
was investigated how the induction of NAMPT may indirectly affect downstream 
expression of MMPs. Through the activity of NAD+ dependent cofactors (such as 
sirtuins). RASFs were stimulated with IL-1β alone or in combination with EX527 and 
PJ34, inhibitors of SIRT1 and PARP-1, respectively (section 6.2.4) IL-1β stimulation 
caused an upregulation of both MMP-1 (figure 6.3.10A) and MMP-3 (figure 6.3.10B) over 
time, although induction of the latter was less marked. Co-incubation with the SIRT1 
inhibitor (EX527) caused a significant induction of MMP-1 protein levels compared with 
IL-1β alone (figure 6.3.10A). In contrast, the addition of PARP-1 inhibitor PJ34 did not 
affect IL-1β induced MMP-1 release. Interestingly, EX527 did not significantly enhance 
IL-1-β MMP-3 release (figure 6.3.10B).  
 
 
Figure 6.3.10 Effect of SIRT1 and PARP-1 antagonists on IL-1β induced MMP 
release 
Human RASFs (n=3 cell lines) were cultured from 0-48 hours in the presence of 10 ng/ml 
IL-1β (IL-1), alone or100 μM EX527 (I/EX527) or PJ34 (I/PJ34). Culture supernatants 
were analysed for A) MMP-1 and B) MMP-3 protein levels by ELISA.  Differences in 
MMP levels between treatment groups were determined by two-way ANOVA with 
Bonferroni post-tests. *=P≤0.05, ***=P≤0.001. 
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6.4 Discussion 
Although circulating lymphocytes are thought to be a major source of NAMPT in 
conditions such as obesity (Friebe et al., 2011), NAMPT is also localised to the fibroblast-
like synoviocytes within the intimal lining in both experimental arthritis models (Nowell et 
al., 2006) and in patients with RA (Brentano et al., 2007). This chapter explored the 
regulation of NAMPT gene expression in RASFs activated by pro-inflammatory 
cytokines. In addition to this, inhibitors of NAD dependent cofactors were used to 
determine how the rate-limiting role of NAMPT in NAD+ biosynthesis might impact on the 
regulation and secretion of degradative MMPs by RASFs.  
6.4.1 NAMPT is upregulated by inflammatory cytokines in RASFs 
Firstly, the effect of pro-inflammatory cytokine stimulation on NAMPT gene 
expression was determined. NAMPT was strongly induced by the range of cytokines 
tested, supporting previous findings in RASFs (Nowell et al., 2006, Brentano et al., 2007). 
The cytokines IL-1β and TNFα are both potent inducers of NF-κB, a pivotal regulator of 
inflammation in RA (Firestein et al., 2009). In contrast, OSM operates mainly (although 
not exclusively) through the Janus kinase (JAK)/STAT signaling pathway (Kishimoto et 
al., 1995). The NAMPT gene promoters (both proximal and distal) are response-element 
rich, containing both NF-κB (Ognjanovic et al., 2001) and STAT (signal transducer and 
activator of transcription) (Nowell et al., 2006) binding sites, which facilitate rapid 
induction (summarised in section 1.3.3). The dampening effect of higher concentrations 
on NAMPT expression suggests control by a negative feedback mechanism. The 
possibility of a cytotoxic effect at these higher concentrations was ruled out, as samples 
were normalised prior to amplification by qPCR, to ensure they all contained equal 
amounts of cDNA; therefore, any differences in RQ value can be attributed to changes 
in levels of gene expression.  
6.4.2 Alternative NAD+ enzymes are not regulated by inflammatory cytokines 
These data have demonstrated the specific and preferential induction of NAMPT 
above all other rate-limiting NAD+ biosynthesis enzymes in RASFs stimulated with IL-1β, 
TNFα and OSM. This relates to previous findings by Iqbal and colleagues (2006), who 
showed that TNFα causes a time-dependent increase in NAMPT and IDO, but not QPRT, 
gene expression in murine macrophages (NAPRT expression was not analysed) (Iqbal 
and Zaidi, 2006).  In contrast to these findings, the studies in this current chapter failed 
to detect upregulation of IDO in response to TNFα stimulation. A possible explanation is 
that the tryptophan biosynthesis pathway may be less predominant in RASFs compared 
with macrophages. IDO expression is strongly induced by Interferon gamma (IFNγ) 
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(Yang et al., 2010). The effect of IFNγ on the expression of NAD+ enzymes was not 
investigated in this chapter; however, IFNγ is present at low levels in the synovial tissue 
of RA patients compared to patients with other forms of arthritis, and is undetectable in 
RA synovial fluid (Firestein and Zvaifler, 1987). Therefore, the tryptophan biosynthesis 
pathway is unlikely to contribute significantly to NAD+ biosynthesis in RASFs stimulated 
with RA-associated cytokines such as IL-1β and TNFα.  To my knowledge, the 
generation of NAD+ via the Preiss-Handler pathway has yet to be explored in active 
synoviocytes. However, our group has shown that compared with NAMPT, NAPRT is 
expressed at very low levels in RA tissue (Moideen and Nowell; unpublished), suggesting 
that activated cells may not readily utilise nicotinic acid. Taken together, these data 
suggest that the Nam salvage pathway is the predominant pathway for generation of 
NAD+ in activated RASFs.  
6.4.3 IL-1β and TNFα (but not OSM) upregulate MMP-1 and -3 gene expression 
IL-1β and TNFα both induced a time-dependent increase in MMP-1 and MMP-3 
gene expression. The stimulatory effect of these cytokines on MMP expression in RASFs 
has been reported in numerous studies (Langdon et al., 1997, Brentano et al., 2007, 
Niederer et al., 2011). NAMPT expression appeared to preclude the induction of MMPs, 
with almost immediate upregulation in response to cytokine stimulation. These data 
originally suggested that induction of NAMPT might somehow contribute to a subsequent 
induction of MMP gene expression. However, this was contradicted with the results of 
OSM stimulation. Despite being a strong inducer of NAMPT expression, OSM failed to 
induce expression of MMPs -1 and -3. This suggests that iNAMPT may not be directly 
involved in the induction of MMPs in RASFs.  
6.4.4 Activated cells have an increased requirement for NAD+ 
In inflammatory arthritis, synovial fibroblasts switch from normal mesenchymal 
cells to an aggressive rapidly proliferating phenotype (Müller-Ladner et al., 2007). 
Studies in mice with glucose-6-phosphate isomerase (G6PI)-induced arthritis showed 
that a metabolic tracer named 18F labelled fluorodeoxyglucose (18F-FDG) is rapidly taken 
up by activated cells compared with non-activated cells, as determined by positron 
emission tomography-computed tomography (PET/CT) (Irmler et al., 2010). It stands to 
reason that an increased metabolic requirement will mean that cells have an increased 
requirement for NAD+, as it is an essential cofactor involved in a broad range of biological 
functions (reviewed by Lin and Guarente, 2003). 
The effect of cytokine stimulation on cellular NAD+ levels appears to vary 
depending on cell type and cytokine involved. Iqbal and colleagues (2006) found that 
TNFα stimulation reduced cellular NAD+ levels in murine macrophages, as upregulation 
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of NAMPT was concurrent with an upregulation of CD38, a NAD+-degrading enzyme 
(Iqbal and Zaidi, 2006). This highlights the complexity of eukaryotic NAD+ metabolism, 
further complicated by the cellular changes associated with activation. Unfortunately in 
this current study NAD+ could not be detected in cytokine-stimulated cells. Quantifying 
NAD+ by enzymatic cycling, although accessible and relatively inexpensive, does not 
accurately determine the relative ratios of NAD+ and its reduced form NADH. 
Furthermore, enzymatic cycling techniques do not tell us the pathways involved in NAD+ 
biosynthesis. This information may be obtainable using a high-performance liquid 
chromatography (HPLC)-based assay (Sporty et al., 2008). It is possible to isotopically 
label the NAD+ precursor nicotinamide to quantify NAD+ synthesised via NAMPT. Such 
a technique has been successfully applied to yeast (Sporty et al., 2008), and may help 
determine the differences in NAD+ salvage pathway synthesis in both resting and 
activated cells. Despite the limitations of the assay used, APO866 was found to lower 
intracellular NAD/NADH levels in resting RASFs, reiterating findings from previous 
groups in a variety of cell types (Hasmann and Schemainda, 2003, Busso et al., 2008, 
Pittelli et al., 2010). 
6.4.5 Sirtuins downregulate MMP expression in RASFs 
To determine if NAD+ biosynthesis impacts upon MMP expression, attention was 
focused on NAD+-consuming factors.  Various pleiotropic factors which rely on NAD+ as 
a substrate have been identified, including ADP-ribose transferases, mono- and poly 
(ADP-ribose) polymerases, and sirtuins (Pittelli et al., 2010). Of particular interest are the 
sirtuins, a class of histone deacetylases that consume NAD+ and play a role in cell 
longevity and ageing. The sirtuin SIRT1 is constitutively upregulated in RA synovial 
tissue, and is induced by TNFα in synovial fibroblasts (Niederer et al., 2011). Therefore, 
it was originally speculated that increased levels of cellular NAD+ via iNAMPT might 
somehow positively regulate MMP gene transcription in a sirtuin-dependent manner. To 
test this hypothesis, EX527, a selective SIRT1 inhibitor, was added to RASFs in 
conjunction with IL-1β, and MMP protein levels were determined.  
The addition of EX527 significantly enhanced MMP-1 protein levels in activated 
RASFs, suggesting an anti-degradative role for SIRT1. A similar finding has also been 
reported in human dermal fibroblasts, where SIRT1 inhibition increases basal and IL-1β 
induced expression of MMP-1 and MMP-3 proteins (Ohguchi et al., 2010). The relatively 
low induction of SIRT1, compared with NAMPT, in cytokine-activated cells suggests that 
SIRT1 upregulation may be attributed to increased NAD+ availability. Induced SIRT1 may 
inhibit MMP gene expression, possibly through interactions with NF-κB; in lung cancer 
cell lines, SIRT1 was found to interact with and deacetylate the RelA/p65 subunit of NF-
κB, inhibiting its ability to interact with promoter regions of target genes to enhance 
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transcription (Yeung et al., 2004). Most MMP promoters contain binding sites for a 
number of transcription factors, including AP-1, STAT, and NF-κB (Yan and Boyd, 2007). 
The promoter region of MMP-1 contains an NF-κB binding site (Vincenti et al., 1998). 
Although MMP-3 does not contain a functional NF-κB binding site, it does contain binding 
sites for other transcription factors that may interact with NF-κB (Yan and Boyd, 2007). 
Studies in vascular smooth muscle cells have shown that NF-κB activity is essential for 
upregulation of MMP-1 and -3 (Bond et al., 2001). These data suggest a possible 
mechanism for SIRT1-mediated inhibition of cytokine-induced MMPs, which could be 
explored in future work.  
PARP-1 is an enzyme that modifies nuclear proteins by poly ADP-ribosylation, 
and is involved in cellular differentiation and DNA damage recovery (Masutani et al., 
2005). The addition of specific PARP-1 inhibitor, PJ34, did not affect IL-1β induced MMP-
1 and MMP-3 protein release. This is contrary to previous work, where inhibition has 
been shown to reduce arthritic symptoms in both mouse (Miesel et al., 1995) and rat 
(Kroger et al., 1996) models of arthritis. It is worth noting that work by previous groups 
has been carried out in various cell types/systems, and that NAD+-dependent 
deacetylases may exert different regulatory effects depending on stimulus and timing. 
The matter is also complicated by the fact that there are seven types of sirtuins in 
mammals, all with differing functions and sub-cellular localisation. An in-depth study into 
the full effects of NAMPT and sirtuins in RA-derived cells and tissues is beyond the scope 
of this current study, but may help elucidate the downstream effects of NAD+ metabolism 
in inflammation and possibly cartilage metabolism. 
6.4.6 Summary 
The findings of this chapter concerning the regulation and role of NAMPT in MMP 
expression are summarised in figure 6.4.1. NAMPT gene expression is upregulated in a 
time-dependent manner in response to cytokine stimulation in RASFs, and is the only 
rate-limiting NAD+ pathway enzyme upregulated by cytokine stimulation, with the 
exception of IDO upregulation by OSM. This suggests an important role in metabolism 
in activated cells. MMP gene expression is also upregulated. Finally, the SIRT1 inhibitor 
EX527 enhances IL-1β mediated MMP-1 protein expression, suggesting an anti-
degradative role for sirtuins such as SIRT1.  
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Figure 6.4.1 The regulation and role of NAMPT in MMP expression in vitro  
This schematic represents the possible role of NAMPT in RASFs. NAMPT mRNA 
expression is upregulated by OSM, TNFα and IL-1β. The product of the NAMPT gene 
has been reported to have a dual activity. It has an enzymatic rate-limiting role in the 
conversion of Nam to NMN in the Nam salvage NAD+ biosynthesis pathway [1]. Factors 
such as the protein deacetylase SIRT1 may subsequently consume NAD+ to exert 
various effects with the cell [2] NAMPT is also thought to be secreted from cells and 
exert autocrine regulation via an as yet unknown receptor (investigated in chapter 4). IL-
1β and TNFα (but not OSM) also induce expression of MMP-1, -3 and the NAD+ 
dependent deacetylase SIRT1. SIRT1 may inhibit MMP gene transcription, possibly 
through interactions with the transcription factor NF-κB. Dashed lines represent possible 
pathways/interactions. 
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Chapter 7: General discussion 
Previous studies have illustrated that NAMPT is a pleiotropic protein upregulated 
in inflammatory joint diseases such as RA (Otero et al., 2006, Nowell et al., 2006, 
Brentano et al., 2007). Busso and colleagues found that inhibition of NAMPT activity with 
the small-molecule inhibitor APO866 in a murine arthritis model decreased pro-
inflammatory cytokine secretion in affected joints (Busso et al., 2008). However, little is 
known of the role of NAMPT in the underlying processes of cartilage destruction, which 
are responsible for pain and decreased mobility in RA patients. The studies described in 
this thesis have attempted to answer some of these questions, by studying the role and 
regulation of NAMPT in a variety of model systems, from monolayer culture of synovial 
cells to longitudinal analyses of an animal disease model. These studies further illustrate 
the importance of NAMPT in cellular metabolism, and how its inhibition provides a 
promising strategy for treatment of inflammatory arthritis. The findings presented in this 
thesis confirm that NAMPT has an active role in cartilage destruction, with far reaching 
implications in health and disease. It is induced in the principle cells involved in the 
production of pro-inflammatory and pro-degradative factors in arthritis disease 
pathogenesis, and its inhibition affects MMP expression and release both in vitro and in 
vivo.  
7.1 eNAMPT may enhance expression of catabolic proteases in vitro 
NAMPT not only functions as an intracellular enzyme, but is also actively 
secreted from cells as an extracellular signalling ligand, eNAMPT. The data presented 
in chapter 3 demonstrated for the first time that eNAMPT upregulates MMP-3 protein 
release in a dose-dependent manner, with no significant effects on TIMP-1, thus possibly 
contributing to an imbalance towards cartilage catabolism in arthritis. These findings also 
provided further supporting evidence of a signalling role for eNAMPT. Cell stimulations 
were carried out for 18 hours only, which according to results presented in chapters 6 
would be insufficient for APO866 to affect cell viability or reduce intracellular NAD+ levels. 
If NAMPT-mediated induction of MMP-3 was solely attributed to its enzymatic role in 
NAD+ biosynthesis, then a longer period of incubation with APO866 would be required.  
A role for eNAMPT as a cytokine-like molecule was further supported by its ability 
to induce the release of the chemokines CCL2 and CXCL8. Li and colleagues (2008) 
provided evidence to suggest that the cytokine-like action of eNAMPT is independent of 
its enzymatic activity; NAMPT mutants lacking this capability were not impaired in their 
ability to induce IL-6 in macrophages (Li et al., 2008a). Although many groups suggest 
that NAMPT functions exclusively through its role in NAD+ biosynthesis (Yang et al., 
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2006, Revollo et al., 2007a), the data presented within this chapter suggest that NAMPT 
may indeed have dual activity.   
7.2 APO866 treatment caused a time and dose-dependent decrease in catabolic 
proteases in vivo 
In chapter 4, a murine arthritis model was used to explore the role of NAMPT in 
cartilage catabolism in vivo. For this purpose, the CIA model was chosen, as this 
systemic model of disease is the most widely-studied model of RA (Brand et al., 2007). 
As expected, disease severity increased over time, and cartilage and joint erosions was 
evident in post-sacrifice analyses of radiological and histological damage. All MMPs 
analysed by qPCR (MMP-1, -3, -9 and -13) were enhanced in CIA animals compared 
with naïve controls, confirming that upregulation of MMP gene expression in this model 
is associated with many pathological features of CIA, including inflammation, cartilage 
destruction, and bone erosion.  
Fluorescent imaging probes have been successfully used to monitor protease 
activity within the CIA model in previous studies (Wunder et al., 2004). Commercially-
available MMP probes are now available which fluoresce upon cleavage by MMP 
enzymes within tissues, resulting in a signal that can be detected in small animal imaging 
systems (Kossodo et al., 2010). Therefore, in vivo imaging protocols for the longitudinal 
assessment of MMP enzymatic activity in live mice were explored, using two separate 
NIRF probes called MMPSense680 and MMPSense750 FAST.  These imaging probes 
were shown to accurately determine both the extent and localisation of MMP activity in 
the live animal, providing novel insights into the process of cartilage degradation in 
animal disease models. MMP enzymatic activity (as determined from fluorescence 
intensity) increased in line with arthritis index scores, indicating their suitability as a 
marker of inflammation as well as cartilage catabolism. The fluorescent localisation of 
MMP activity in joints closely matched the areas of inflammatory infiltrate and cartilage 
erosion in corresponding histological sections. Although both MMP mRNA and protein 
levels were enhanced in CIA animals, there was a weak correlation between these two 
variables, suggesting that transcriptional regulation of MMP mRNA is not directly 
indicative of local MMP activity. Lack of association between these two variables may 
also be attributed to the low sample sizes (≤10 animals) used in CIA experiments. 
A combination of the techniques mentioned above was used to assess the 
efficacy and bioactivity of APO866 in vivo. Busso and colleagues (2008) had previously 
shown that APO866 administered intraperitoneally (i.p.) twice daily reduced clinical 
scores in CIA animals in a dose-dependent manner (Busso et al., 2008). Based on these 
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findings, APO866 was administered to CIA animals with established arthritis as a 
continuous infusion, and disease was monitored over time.  
Treatment with 0.08 mg/kg/h APO866 attenuated disease progression in 
animals, causing a significant reduction in arthritis index compared to the vehicle 
controls. APO866-treated animals had significantly lower levels of MMP enzymatic 
activity (as determined by in vivo imaging) compared with vehicle controls, but 
quantitative PCR analyses revealed that MMP gene expression was not attenuated in 
these tissues. Similarly, there were no significant effects on cartilage degradation, 
histology and radiology scores. The lack of observable effects is thought to be attributed 
to the short duration of the treatment. This is supported by analyses of archived samples 
(that had been subjected to longer and higher doses of APO866), which confirm that 
NAMPT has a time and dose-dependent effect on MMP gene expression. These latter 
results suggest that NAMPT plays an important role in the underlying processes involved 
in matrix destruction in inflammatory disease.  In the short-term APO866 treatment study, 
NAMPT inhibition did not cause a significant reduction in inflammatory infiltrate and 
synovial hyperplasia in affected paws of CIA animals. However, related studies 
performed in our group involving longer treatment regimens at higher dosages have 
shown an effect on these parameters, and are in concordance with other studies (Busso 
et al., 2008).  
Levels of the anti-collagen antibody IgG2a in plasma did not differ between 
animals treated with APO866 and those treated with the placebo, suggesting a true 
therapeutic response as opposed to a lack of antibody response. This is in contrast to 
anti-TNF receptor treatment, which elicits a therapeutic response in CIA animals by 
actively lowering levels of Th1 driven IgG2a antibodies (Mukherjee et al., 2003). NAMPT 
itself is highly induced in Th1/Th17 driven diseases such as RA (Ozgen et al., 2011), 
which may partly explain how APO866 intervention is so efficacious in the CIA model.  
From previous studies, it is apparent that rapidly proliferating synoviocytes and 
invading/peripheral leukocytes are the main sources of NAMPT in inflammatory arthritis 
(Nowell et al., 2006, Brentano et al., 2007). MMPSense fluorescence suggests that these 
cells may also be major sources of MMPs within the joint, as fluorescence was enhanced 
in areas of the hind foot associated with enhanced levels of synovial infiltrate and 
exudate, apparent in histological sections. The combined data of this thesis suggest the 
most abundant MMPs in these tissues are likely to be MMPs -1 and -3. Articular cartilage 
chondrocytes are likely to be another possible source of MMPs, particularly the 
gelatinase MMP-9 and the collagenase MMP-13, as all of these MMPs were significantly 
enhanced in CIA animals. This is supported by previous studies which show evidence of 
eNAMPT-induced upregulation of MMPs -3 and -13 in murine articular chondrocytes 
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(Gosset et al., 2008). Studies in chapter 3 indicate eNAMPT controls MMP expression 
in fibroblasts. However, it is as yet unclear how iNAMPT may influence MMP activity.    
7.3 Deprivation of iNAMPT in cartilage explants results in cell death  
The studies in RASFs (Chapter 6) suggest that enzymatic iNAMPT activity does 
not directly affect MMP expression, despite causing a reduction of intracellular NAD+ 
over time. This type of reduction in NAD+ has also been reported in studies on HepG2 
cells (Hasmann and Schemainda, 2003), HeLa cells (Pittelli et al., 2010), and human 
monocytes (Busso et al., 2008, Van Gool et al., 2009). In these studies, NAD+ reduction 
resulted in a decrease in TNFα levels in both murine peritoneal cells (Busso et al., 2008) 
and human monocytes (Van Gool et al., 2009). NAD+ reduction has also been associated 
with a down-regulation of cartilage-specific gene expression in human articular 
chondrocytes (Dvir-Ginzberg et al., 2008). The consequences of NAD+ reduction on 
MMP expression have yet to be explored. 
It is possible that APO866 might eventually cause a reduction in MMP expression 
and release through depletion of intracellular NAD+. However, as the in vitro experiments 
were relatively short-term studies (0-72 hours), it was important to address this scenario 
in a longer-term study. Therefore, a bovine cartilage ex vivo culture system was used to 
study the effects of APO866 on MMP activity and cartilage catabolism over a prolonged 
period of time (chapter 5) APO866 was added to explants alone or in combination with 
IL-1β in order to determine the role of long-term iNAMPT inhibition in catabolic 
processes. Within 6-8 days of explant culture, APO866 reduced cytokine-mediated s-
GAG and MMP release. However, upon microscopical examination, APO866 appeared 
to cause a reduction in the cellularity of cartilage explants, suggestive of cytotoxicity. An 
APO866 dose response experiment confirmed these microscopical observations, and 
analysis of cell viability by LDH assay showed a sudden peak of cellular toxicity in all 
APO866-treated explants at day 8 of culture. This cytotoxicity was attributed to a 
catastrophic depletion of intracellular NAD+, as the addition of NAD+ metabolites, NMN 
and NA, prevented this response, presumably through the replenishment of NAD+.   
 It is likely that APO866 treatment caused cell death due to interference of the 
NAD+ salvage ability of iNAMPT. This would result in a gradual depletion of NAD+ without 
any Nam cycling back into the pathway. Chondrocytes within explant culture may be 
unable to compensate through other pathways due to a paucity of cofactors such as NA 
or tryptophan (figure 7.1). Cell death occurred around 6-8 days into the culture period, 
prior to the enhancement of MMP activation seen around day 12 in cytokine-exposed 
explants (figure 5.3.16). Therefore, it was not possible to determine whether iNAMPT 
regulates cytokine-induced MMP expression in explants. It is noteworthy that 
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concentrations of APO866 used in this study may be well above those that may be 
considered physiologically relevant in an in vivo setting. Furthermore, the 
pharmacokinetic profile of APO866 means that bioavailability in vivo would be 
significantly less than the concentrations administered in this culture system 
Interestingly, both NMN and NA not only prevented APO866 induced cytotoxicity, 
they also enhanced s-GAG loss and MMP activity in activated explants. This suggests 
that increased NAD+ availability enhances the pro-degradative effects of cytokine 
stimulation in chondrocytes. The exact mechanism for this enhancement remains 
unclear, though it suggests that increased NAD+ availability may enhance the activity of 
a NAD-dependent cofactor involved in downstream regulation of MMP gene expression. 
The ‘rescue’ effect on cell viability caused by the addition of NA indicates the 
presence of the Preiss-Handler pathway enzymes NAPRT, NMNAT and NADSYN in 
chondrocytes. However, it is as yet to be determined whether these enzymes are 
upregulated like NAMPT in response to cytokine stimulation. Studies in RASFs in this 
thesis (chapter 6) and in previous published studies by Iqbal and colleagues suggest 
they are not (Iqbal and Zaidi, 2006).   
 
 
Figure 7.1 Cofactors involved in depletion and replenishment of NAD+ 
Schematic showing how addition of cofactors such as NMN or NA can counteract 
APO866-mediated intracellular NAD+ depletion 
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7.4 iNAMPT is the main rate-limiting NAD+ enzyme induced by pro-inflammatory 
cytokines in the resident cells of the joint  
NAMPT expression is greatly enhanced in chronically inflamed tissue, including 
within the structural cells of the synovial joint in RA (Nowell et al., 2006), implying active 
secretion by cells at sites of inflammation. In chapters 5 and 6, one of the aims was to 
determine the effect of pro-inflammatory cytokine stimulation on expression of 
intracellular (i)NAMPT in RA-derived chondrocytes and RASFs in vitro.  In addition, the 
expression of alternative rate-limiting NAD+ biosynthetic pathway enzymes was 
investigated. Using real-time quantitative PCR, it was shown that iNAMPT gene 
expression is upregulated in a time-dependent manner in response to cytokine 
stimulation in RASFs and human primary chondrocytes, and is the only rate-limiting 
NAD+ pathway enzyme upregulated by cytokine stimulation, with no discernible effect on 
gene expression of NAPRT, QPRT and IDO. The highly inducible nature of iNAMPT is 
possibly attributed to the myriad of response elements contained within its distal and 
proximal promoters (Ognjanovic et al., 2001). Although induction of iNAMPT in RASFs 
and chondrocytes has been shown in previous studies (Nowell et al., 2006, Brentano et 
al., 2007, Gosset et al., 2008), this is the first time that expression of genes encoding 
other NAD+ pathway enzymes has been explored in these cells, although similar findings 
have been observed in primary murine macrophages stimulated with TNFα (Iqbal and 
Zaidi, 2006). These data suggest an important role for iNAMPT in metabolism in 
activated or transformed cells.  
7.5 iNAMPT has little effect on MMP expression in synovial joint cells 
Real-time qPCR analyses showed that IL-1β upregulated both MMP-1 and MMP-
3 expression in a time-dependent manner in RASFs and human primary chondrocytes. 
TNFα also induced MMP-1 and -3 in RASF, whilst OSM failed to induce MMPs in RASFs. 
Although a potent inducer of NAMPT mRNA expression, OSM failed to induce both MMP 
expression, suggesting that OSM stimulation affects cells in a manner distinct from IL-
1β and TNFα.  
It was originally hypothesised that a depletion of intracellular NAD+ due to 
iNAMPT inhibition by APO866 might affect downstream MMP expression. This was 
thought to be due to the activity of NAD+ dependent sirtuins. As mentioned in section 
6.1, sirtuins are deacetylases that perform a wide variety of functions. Yeung et al (2004) 
demonstrated that SIRT1 interacts with and deacetylases the p65 subunit of NF-κB 
(Yeung et al., 2004), which may inhibit NF-κB mediated transcription of MMPs (Vincenti 
et al., 1998). In RASFs (chapter 6), qPCR analysis showed that SIRT1 expression was 
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not effected by cytokine stimulation suggesting SIRT1 expression is regulated 
independently of iNAMPT. Co-incubation with IL-1β and the SIRT1 antagonist, EX527, 
enhanced MMP-1 protein release in RASFs, suggesting that SIRT1 silences MMP 
expression. It is unclear whether sirtuin-mediated regulation of MMPs is NAMPT 
dependent or independent. Further investigations are needed to elucidate these 
processes. For example, assessment of NAD+ levels over time in cells treated with 
EX527 may show a gradual depletion of NAD+, as sirtuins actively degrade this cofactor 
back into Nam, the substrate for NAMPT in NAD+ salvage (figure 7.2). It is possible that 
blocking sirtuin activity allows a greater availability of NAD+ for other enzymes dependent 
on this cofactor, which may in turn positively regulate MMP expression.  
 
 
Figure 7.2 Possible effects of NAMPT and SIRT1 depletion on NAD+ salvage 
NAMPT, the rate-limiting enzyme for mammalian NAD+ biosynthesis, is inhibited by 
APO866. A subsequent drop in NAD+ availability may have a knock-on effect on activity 
of NAD+-dependent factors, such as SIRT1. NAD+ is further depleted, as SIRT1 bi-
product Nam is not available to cycle back into the salvage pathway. Inhibition of SIRT1 
(and other sirtuins) may initially lead to increased NAD+ availability for other NAD+ 
dependent processes, though lack of Nam salvage will also result in NAD+ depletion, 
unless Nam or NMN are replenished.  
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7.6 Future directions 
In a fibroblast cell line, addition of the eNAMPT protein was shown to enhance 
levels of MMP-3, CCL2 and CXCL8 protein release in a dose-dependent manner 
(chapter 3). Some studies suggest that the proposed signalling activities of eNAMPT 
may be mimicked by the addition of NMN to cells (Wang et al., 2009b, Romacho et al., 
2009, Fan et al., 2011, Jacques et al., 2012), thus it would be interesting to explore 
whether NMN has eNAMPT mimetic effects in fibroblasts in vitro. The eNAMPT receptor 
remains unknown; however attention is currently focused on the interaction of eNAMPT 
with growth hormone receptor (Jacques et al., 2012). Future studies might employ a 
growth hormone receptor antagonist in order to confirm whether or not eNAMPT 
mediated MMP activity is subsequently affected.  
The in vivo studies carried out in a murine arthritis model (chapter 4) suggest that 
synoviocytes and synovial lymphoid aggregates may be the major source of NAMPT and 
MMP production. There are commercially-available anti-NAMPT antibodies that could 
potentially be utilised to confirm this by immunohistochemistry (IHC). There are also IHC 
antibodies available that could show us the localisation and activity of pro-degradative 
enzymes such as MMPs and ADAMTSs. Optimising and performing these experiments 
is timely, but would provide key insights into the localisation and activity of NAMPT within 
the synovium. 
In cartilage ex vivo cultures, APO866 significantly attenuated cytokine-induced s-
GAG loss and MMP activity at the expense of cellular viability, an effect reversed by the 
addition of NMN or NA to explants. This experiment was only performed with APO866, 
NMN and NA in one dose combination (100 nM for APO866, and 100 μM for NMN and 
NA). A dose titration would be an interesting potential ex vivo study to determine if it is 
possible to protect articular cartilage without causing chondrocyte cytotoxicity.  
Cartilage catabolism ex vivo was determined through release of s-GAG from 
explants (chapter 5). However, whilst s-GAG loss is largely reversible, collagen 
breakdown is not (Karsdal et al., 2008). Unfortunately, collagenase activity was not fully 
explored in this thesis, as assays to measure this parameter can be costly. Exploring the 
effect of APO866 on collagen release, possibly by hydroxyproline assay, would add real 
value to the existing data of this thesis.  
Finally, the in vitro studies in RASFs (chapter 6) showed that iNAMPT is induced 
by the pro-inflammatory cytokines IL-1β, TNFα and OSM, and it was postulated that 
these cytokines might induce iNAMPT mRNA expression through activation of a myriad 
of key signalling pathways. It would be interesting to determine the principle pathways 
involved in induction of iNAMPT in response to cytokine stimulation, and this may 
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possibly be achieved with the use of specific inhibitors of these pathways, such as STAT 
and NF-κB inhibitors.  
Finally, a preliminary experiment in one RASF cell line (chapter 6) suggested that SIRT1 
inhibitor EX527 enhances MMP-1 (but not MMP-3) protein expression in a time-
dependent manner. Confirming and elucidating the proposed anti-degradative role of 
sirtuins would provide key insights into the role of Nam salvage in regulation of MMP 
gene expression. 
 
7.7 Concluding remarks 
Taken together, the results presented within this thesis and observations published in 
the literature suggest that NAMPT inhibition may reduce pro-inflammatory and pro-
degradative factors in affected limbs through depletion of intracellular NAD+ in iNAMPT-
sensitive cells. Activated cells appear to be more sensitive to this depletion, suggesting 
that high levels of NAMPT (induced as a result of cytokine-stimulation) may therefore 
ensure prolonged survival and enhanced proliferation at sites of inflammation.  
 Observations within the thesis have shown that APO866 may inhibit eNAMPT 
activation of MMPs in the structural cells of the joint. Targeting these cells with NAMPT-
specific inhibitors such as APO866, may also actively reduce lymphocyte infiltration, by 
reducing chemokine synthesis locally. This is supported by observations within this 
thesis, which suggest that APO866 may inhibit eNAMPT induced CCL2 and CXCL8 
release; subsequently preventing T-cell driven activation of the structural cells of the 
synovial joint. Although lymphocytes can produce MMPs such as MMP-9 (Owen et al., 
2003), they mainly induce MMPs through interactions with other cell types such as 
synoviocytes Interestingly, activated lymphocytes are particularly sensitive to iNAMPT 
and NAD+ depletion compared with resting lymphocytes (Bruzzone et al., 2009). 
Therefore, APO866 may well reduce MMP expression in activated lymphocytes as 
NAMPT inhibition was shown to impair proliferation and reduce IFNγ and TNFα 
production in these cells (Bruzzone et al., 2009). 
Upregulated NAMPT has also been shown to delay neutrophil apoptosis in 
response to inflammatory stimuli (Jia et al., 2004). As neutrophils are a source of MMP-
8; enhanced NAMPT and subsequent delayed neutrophil apoptosis will undoubtedly 
result in sustained MMP activity within the inflammatory exudate.  
The work presented in this thesis has confirmed that NAMPT has an important role in 
cell metabolism. It is highly induced in synovial joint cells which are involved in the 
production of pro-inflammatory and pro-degradative factors in arthritis disease 
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pathogenesis. Notably, its inhibition affects MMP expression in the principle cells of a 
synovial joint (figure 7.3). 
Many of the key findings of this thesis have been published in two peer-reviewed 
publications, with another expected to follow (Evans et al., 2011, Nowell et al., 2012)-
see Appendices). Further experiments are required to study the downstream effects of 
NAMPT.
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Figure 7.3 Role and regulation of NAMPT within the synovial joint  
A schematic of the synovial joint, showing the main cell types involved in disease 
pathogenesis in rheumatoid arthritis. Findings from this thesis are summarised in the 
pink-bordered boxes, in addition to findings by other groups in inflammatory cells that 
express NAMPT. 
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